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Summary 
Glycosphingolipids (GSLs) are amphiphatic molecules ubiquitiously expressed in eukaryotes and have 
been shown to play a crucial role in various (inherited) human disorders such as autoimmune diseases, 
ichthyoses and cancer. GSLs are one class of sphingolipids (SLs) and are constructed from ceramides 
(Cers), comprising a sphingoid base (typically sphingosine, a long-chain amino diol) which is amide-
linked to a fatty acid (FA) of variable chain length. GSLs are formed by the addition of mono- or 
oligosaccharides via a glycosidic linkage to sphingosine C1. Glucosylceramides (GlcCers) are 
precursors for most of the higher GSLs and major compounds of the stratified squamous epithelia. In 
particular, GlcCers comprise ca. 4% of the total lipid mass in the epidermis and ca. 16% in the 
esophageal epithelium. 
The lipophilic anchor of epidermal GlcCers contains a unique ultra-long-chain amide-linked fatty acid 
(ULC-FA) with up to 36 carbon atoms. The ULC-FAs are typically ω-hydroxylated to give the so-
called OS class of GlcCers, accounting for an essential part of the skin barrier. The ULC-GlcCers 
reside primarily in the outermost anucleated layers of the epidermis, i.e., the stratum corneum (SC), 
which is mainly composed of dead, flattened keratinocytes, the so-called corneocytes, embedded in a 
lipid-enriched extracellular matrix. This barrier protects the body from dehydration, mechanical insult 
and infection and derives from the interplay between proteins in the corneocyte membrane and the 
lipids. The lipid matrix surrounding the corneocytes is composed of Cers, cholesterol and free FAs in 
nearly equimolar ratios, which can be organized into lamellar sheets. 
The Cers found in the SC are believed to be derived from GlcCers which have been synthesized at the 
trans-Golgi network by the enzyme UDP-glucose:ceramide glucosyltransferase (UGCG). Thus, it has 
been suggested that GlcCers function as intracellular carriers of the hydrophobic Cers and are 
transferred via vesicular transport within lamellar bodies (LBs) to the apical plasma membrane (PM) 
of SC keratinocytes. LBs fuse with the PM in the upper stratum granulosum (SG) and at the SG/SC 
interface, where they exocytose their lamellar lipid content, together with structural proteins, enzymes 
and antimicrobial peptides, into the extracellular space. By the action of enzymes such as 
glucosylceramidase and ceramidase, Cers, glucose, FAs and free sphingoid bases are released from 
GlcCer precursors. 
The ω-hydroxy group of ULC-(Glc)Cers enables their esterification to an additional FA, 
predominantly linoleic acid (18:2, ω–6), to give the EOS subclass of (Glc)Cers. Trans-esterification to 
proteins of the corneocyte membrane then leads to the formation of protein-linked Cers (POS) and the 
cornified lipid envelope (CLE). EOS as well as POS species and their corresponding GlcCer-
precursors establish the extremely hydrophobic extracellular lipid lamellae of the SC and thereby the 
skin barrier.  
An earlier study using mice with constitutive Ugcg deletion in the epidermis (Ugcg f / f K14Cre mice) 
highlighted the importance of Cer glucosylation. Mutant mice lost the water permeability barrier 
(WPB) and died postnatally at day P5. However, the exact molecular and cellular contribution of OS 
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and specifically POS-Cers for the buildup and stability of the WPB could not be determined. In 
addition, the differentiation and function of UGCG-deficient epidermis and its function in clinically 
relevant pathophysiologic states, e.g. wound healing, could not be analyzed. 
Inducible Ugcg f / f K14CreERT2 mice were generated in our laboratory to circumvent the problem of early 
death experienced with Ugcg f / f K14Cre mice. Tamoxifen (TAM)-induced Ugcg gene deletion in keratin 
K14-positive basal cells resulted in a significant decrease in esophageal and epidermal GlcCers and, in 
contrast to newborn mice, to an almost complete loss of epidermal POS-Cers three weeks after 
initiation of TAM induction. Subsequent alterations in keratinocyte differentiation and epidermal 
barrier homeostasis were evidenced by an increase in transepidermal water loss (TEWL) and pH as 
well as by keratinocyte hyperproliferation to give a severe ichthyosiform skin phenotype. This skin 
phenotype was slightly reversed within three months following TAM induction, apparently due to the 
action of hair follicle stem cells. Furthermore, wound closure and reepithelialization was significantly 
delayed in mutant vs. control skin.  
Gene expression profiling of Ugcg mutant skin vs. control skin revealed a subset of differentially 
expressed genes which are involved in lipid signaling and epidermal differentiation/proliferation and 
which correlate with human skin diseases such as psoriasis and atopic dermatitis. Peroxisome 
proliferator-activated receptor β/δ (PPARβ/δ), a Cer-sensitive transcription factor, was identified as a 
potential mediator of the altered gene sets. Thus, we conclude that the combined increase in free 
epidermal Cers and the expression of PPARβ/δ and target genes serves as the driving mechanism for 
impaired epidermal homeostasis and barrier loss, thereby emphasizing the critical role of GlcCer in 
epithelial differentiation.  
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Zusammenfassung 
Glycophingolipide („Glycosphingolipids“, GSLs) sind ubiquitär vorkommende, amphipathische 
Lipidmoleküle in Eukaryoten denen eine entscheidende Rolle in verschiedenen humanen 
Erkrankungen wie z.B. Autoimmunerkrankungen, Ichthyosen und Krebs zugesprochen wird. GSLs 
bilden eine wichtige Klasse der Sphingolipide (SLs) und werden aus Ceramiden (Cers) gebildet. Ein 
Cer besteht in seiner Grundstruktur aus einer Sphingoid Base (i.d.R. Sphingosine), die über eine 
Amid-Bindung mit einer Fettsäure (N-Acyl), sowie im Falle von GSLs am C1 Atom mit einem oder 
mehreren Kohlenhydratmolekülen verestert ist. Glucosylceramid (GlcCer) ist Vorläuferlipid für alle 
höheren GSLs und stellt eine wichtige Komponenten von Plattenepithelien dar, wie z.B. in der 
Epidermis (mit ca. 4% der Gesamtlipidmasse) und im Esophagusepithel (mit ca. 16% der 
Gesamtlipidmasse). 
Der lipophile Anker der epidermalen GlcCers besteht aus ω-hydroxylierten (ωh) Ceramiden (Cers), 
OS-Cers, die ultra-langkettige („Ultra-Long-Chain“, ULC) N-Acylsubstituenten von bis zu 36 C-
Atomen besitzen und damit eine essentielle Komponente der Hautbarriere darstellen. Die eigentliche 
Permeabilitätsbarriere befindet sich in der äußersten, anukleären Epidermisschicht, im Stratum 
Corneum (SC), welches zum größten Teil aus abgeflachten, terminal-differenzierten Keratinocyten 
(sogenannten Corneozyten) besteht, die in einer lipidreichen extrazellulären Matrix eingebettet sind. 
Diese Barriere, die den Körper vor Austrocknung, mechanischen Verletzungen und Infektionen 
schützt, basiert auf der Interaktion von Proteinen der Corneozytenmembran mit Lipiden. Die 
äquimolare Zusammensetzung der Lipidmatrix aus Cers, Cholesterol und freien Fettsäuren bedingt 
ihre lamellare Struktur und damit ihre Funktion als Wasserpermeabilitäts-Barriere (WPB). 
Es wird angenommen, dass die Cers im SC aus GlcCer-Vorläufern entstehen, die im trans-Golgi-
Kompartiment der Keratinozyten in einer UDP-glucose ceramide glucosyltransferase (UGCG) 
katalysierten Reaktion gebildet werden. GlcCers gelten als intrazelluläre Trägerlipide der extrem 
hydrophoben Cers und gelangen via vesikulären Transport in sogenannten Lamellar Bodies (LBs) zur 
apikalen Plasmamembran (PM) der Keratinozyten. An der Grenze zwischen dem Stratum Granulosum 
(SG) und dem SC fusionieren die LBs mit der Keratinozytenmembran und extrudieren ihren Inhalt an 
SLs, Strukturproteinen, Enzymen und antimikrobiellen Peptiden in den Extrazellularraum.  
Die ω-hydroxy Gruppe der ULC (Glc)Cers ermöglicht die Veresterung entweder mit Fettsäuren, 
hauptsächlich mit Linolensäure, was zur Bildung von EOS (Esterified ωh-Spingosine) Cers führt, oder 
mit Proteinen der Corneozytenmembran, was zur Bildung von POS (Protein-linked ωh-Spingosine) 
führt. EOS und POS-Cers, sowie die korrespondierenden GlcCer Vorläufer, sind wichtige Bausteine 
der extrem hydrophoben extrazellulären Lipidlamellae des SC und damit der Hautbarriere.  
In einer früheren Studie, mit konstitutiv epidermal Ugcg-defizienten Mäusen (Ugcg f / f K14Cre), konnte 
die Bedeutung der Cer-Glucosylierung gezeigt werden. Die transgenen Tiere starben ca. fünf Tage 
postnatal aufgrund der Störung der epidermalen WPB. Aufgrund des frühen Todes der Tiere, konnte 
die genaue molekulare und zelluläre Funktion der OS, insbesondere der POS-Cers für den Aufbau und 
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Erhalt der WPB nicht untersucht werden. Darüber hinaus konnten Wundheilungsexperimente zur 
Untersuchung des Einflusses und der Funktion der UGCG-Depletion auf die Differenzierung der 
Keratinozyten nicht durchgeführt werden.  
Aus diesem Grund wurden induzierbar Ugcg-transgene Mäuse (Ugcg f / f K14CreERT2) generiert, in denen 
im adulten Stadium (im Alter von 8 Wochen) die Gendeletion mittels tamoxifen (TAM) initiiert 
wurde. Die Ugcg-Deletion in Keratin K14-positiven Basalzellen führte nach drei Wochen zu einem 
signifikanten Verlust an sowohl esophagealen als auch epidermalen GlcCers und, im Gegensatz zu den 
Neugeborenen Ugcg-defizienten Tieren, zu einem fast kompletten Verlust an POS-Cers. Nachfolgende 
Störungen der Kertinozytendifferenzierung und der WPB zeigten sich in erhöhtem transepidermalen 
Wasserverlust („Transepidermal Water Loss“, TEWL) und pH, sowie in der resultierenden 
Hyperproliferation der Keratinozyten, welche letztendlich zu Ichthyose-artigen Hautveränderungen in 
den transgenen Tieren führte. Nach drei Monaten wurde ein leichter Rückgang der Hautschuppung 
und des TEWL beobachtet, was wir auf die Aktivierung von Haarfollikel Stammzellen 
zurückgeführten. Darüber hinaus zeigten Wundheilungsexperimente in Kontrollen und UGCG-
defizienten Mäusen, sowie in Hauttransplantaten dieser Tiere, eine signifikant verzögerte 
Reepithelialisierung der Wunden. 
Die Evaluierung der Genexpressionsdaten von Kontroll- und Ugcg-transgenen Hautproben hob 
besonders differentiell exprimierte Gene des Lipidmetabolismus und der epidermalen 
Differenzierung/Proliferation hervor, die darüber hinaus in humanen Hauterkrankungen (z.B. 
Ichthyose, Psoriasis, Atopischer Dermatitis) eine Rolle spielen. Peroxisome proliferator-activated 
receptor β/δ(PPARβ/δ), ein Cer-sensitiver Transkriptionsfaktor, wurde als potentieller Mediator der 
Genveränderungen identifiziert. Die Ergebnisse deuten darauf hin, dass die Entwicklung der 
Ichthyose-artigen Hautveränderungen der GlcCer-defizienten Tiere auf Grund eines Anstieges freier 
Cers und aus einer Cer-getriggerten Aktivierung von PPARβ/δ (sowie dessen Zielgene) resultiert und 
unterstreicht damit die Bedeutung dieser SL Klasse für die epitheliale Differenzierung. 
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1.1 Sphingolipids 
Sphingolipids (SLs) were first described as components of the brain by the German physician Johann 
L. W. Thudichum (Thudichum, 1884), who named these enigmatic molecules after the sphinx, a 
Greek mythological creature. SLs are amphipathic molecules ubiquitously expressed in eukaryotic 
cells and are major constituents of the plasma membrane (PM), promoting its arrangement into a lipid 
bilayer. SL structure and metabolism have been intensively studied over the past decades, with 
complementary information coming more recently from the field of lipidomics, where the related 
networks and pathways involving SLs are explored. So far, SLs have been identified as 
multifunctional molecules involved in proliferation, differentiation and cell signaling. However, the 
function of only a minor fraction of the known GSLs has been elucidated so far. 
The key structural element of all SLs is a ceramide (Cer), composed of a sphingoid base and an amide-
linked fatty acid (FA) moiety (Figure 1). Cer is the precursor for more complex SL classes such as the 
sphingomyelins (SMs) and glycosphingolipids (GSLs), which exclusively differ in their type of 
substituent at carbon 1 of the sphingoid base (Figure 1). 
 
Figure 1. Major sphingolipid classes. 
Sphingolipids are biosynthesized via condensation of the amine group of a sphingoid molecule with an 
activated fatty acid (acyl CoA). The sphingoid base shown here corresponds to sphingosine (orange), 
designated d18:1 in the short-hand notation for a “standard” dihydroxy sphingoid with hydroxy groups 
at carbons 1 and 3 and a trans double bond at carbon 4. The amide-linked fatty acid at pos. 2 is 
represented here by a 16:0 palmitoyl moiety (yellow). The substituent (blue) at the sphingoid carbon 1 
determines the SL class and can be either the original hydroxy group (as in sphingosine), a 
phosphocholine moiety or a mono- or oligosaccharide group. Modified from (Rabionet 2011). 
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The amphipathic character of simple SLs (e.g. Cer) is determined by the amide linkage at C2 (NH as 
proton donor, C=O as proton acceptor) and the OH group at C3 (proton acceptor or donor), allowing 
for intermolecular hydrogen bonds (e.g., with cholesterol) (Uchida and Hamanaka, 2006). The 
amphipathic characteristics of more complex SLs can vary considerably and result from the combined 
properties of the hydrophobic sphingoid base, its amide-linked FA, and the hydrophilic region of the 
head group (i.e., phosphocholine (Cho-P) in SMs, mono- or oligosaccharide in GSLs). These three 
structural components: (1) the sphingoid base, (2) the FA, (3) the head group, are also the basis for the 
structural diversity of most SLs and their functional specialization in various tissues. 
The FA moiety may differ considerably in chain length, or in degree of saturation and hydroxylation 
in a tissue-specific manner. It can be attached to various sphingoid bases: most frequently sphingosine 
(4E-sphingenine, or in short-hand notation 4E-d18:1 or simply d18:1), as in the SLs in Figure 1, but 
also sphinganine (4,5-dihydrosphingosine; d18:0), 4E-6-hydroxy-sphingosine (6-t18:1) or 
phytosphingosine (4-hydroxysphinganine; 4-t18:0), (reviewed in (Kendall and Nicolaou, 2012; Pruett 
et al., 2008)). The short-hand notation for sphingoids used here and in the Figures is based on the 
scheme used for fatty acids: numbers x:y denote carbon chain length and number of double bonds; 
prefix m, d, or t denotes a mono-, di-, or trihydroxy molecule, where by default d = 1,3-dihydroxy; n-t 
denotes the position of a third hydroxyl group; for y = 1 the default is 4E while other double bonds are 
denoted by an appropriate prefix such as 8Z for 8-cis. This variety in SL structures is enhanced by the 
different possible head groups, e.g., phosphocholine in SMs or a carbohydrate in GSLs (e.g., 
monosaccharide in cerebrosides, oligosaccharide in globosides and gangliosides), whereby the 
oligosaccharides identified for GSLs include combinations of ca. 500 different sugar residues (Kolter 
et al., 2002). 
GSLs were initially studied in lipid storage diseases and brain tissue to investigate their role in the 
nervous system (Yates, 1986). More recently, mouse models lacking specific glycosyltransferases 
have faciliated the investigation of distinct GSL classes. Tissue-specific deletion of a key enzyme in 
GSL synthesis, glucosylceramide synthase (UGCG), in brain (Jennemann et al., 2005), epidermis 
(Jennemann et al., 2007) and intestine (Jennemann et al., 2012a) proved to be lethal in mice and 
evidenced the important role of GSLs in tissue development. Moreover, Nordström and coworkers 
have shown that inducible deletion of the Ugcg enzyme in the forebrain impairs energy homeostasis in 
mice (Nordström et al., 2013). In addition, glucosylceramide (GlcCer), the simplest GSL, has been 
observed to accumulate in kidneys of humans or mice afflicted with polycystic kidney disease (PKD) 
(Natoli et al., 2010) as well as in multidrug-resistant tumors expressing high levels of GlcCers (Lavie 
et al., 1996).  
A more complex GSL (GM3) was shown to influence cell-surface receptor function, e.g., the insulin 
receptor or epidermal growth factor (EGF) receptor, thereby regulating signal transduction (Aerts et 
al., 2007; Liu et al., 2008; Yamashita et al., 2003). Furthermore, GSLs can act as cell-specific 
recognition sites for bacterial toxins (e.g., tetanus or shiga toxin) or viruses (e.g., sendai virus), which 
can bind to specific carbohydrate moieties of these lipids and invade and infect the organism 
(Angstrom et al., 1994; Karlsson, 1989; Keusch et al., 1991; Markwell et al., 1981). Regarding the 
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immune system, glycolipid structures (e.g., GlcCer, GalCer) have been shown to activate T 
lymphocytes, and these findings launched the development of GSL-based therapies for auto-immune 
diseases such as diabetes or multiple sclerosis (De Libero et al., 2002; Van Kaer, 2005). 
The simpler SLs such as Cer, ceramide 1-phosphate (Cer-1-P) or sphingosine 1-phosphate (Sph-1-P) 
function as signaling molecules and regulate different cell fates such as proliferation, differentiation 
and apoptosis, either directly as a signaling lipid or via G-protein-coupled receptor cascades (Chalfant 
and Spiegel, 2005; Geilen et al., 1997).  
Cer is known as a potent inducer of apoptosis and is elevated following various external or internal 
stress signals. These signals lead to intracellular Cer synthesis and activation of Cer-responsive 
enzymes such as protein kinases (e.g., janus kinase (JNK), protein kinase C (PKC)), phosphatases 
(e.g., ceramides activated protein phosphatase (CAPP)), or phospholipase A2 (PLA2), phospholipase 
D (PLD)) (Bourbon et al., 2000; Huwiler et al., 2001; Perry and Hannun, 1998; Westwick et al., 
1995). Moreover, Cer may act via nuclear hormone receptors, as evidenced for the transcriptional 
regulator peroxisome proliferator-activated receptor beta/delta (PPARβδ), and induce the expression 
of the lipid transporter ABCA12 in keratinocytes (Jiang et al., 2009). 
Furthermore, signal transduction can be modified by so-called lipid raft microdomains in the PM. 
Such rafts are thought to be composed of Cers, GSLs and cholesterol; they trap and concentrate 
signaling molecules (e.g. FAS receptor) (Bollinger et al., 2005), thereby potentiating the signal. 
Much of the present research on SLs is certainly motivated by their recognized role in inherited and 
acquired human diseases such as sphingolipidoses (Doering et al., 1999b; McGovern and Schuchman, 
1993; Sandhoff, 1969), cancer progression (Kannagi et al., 2004; Raffaghello et al., 2003) and 
inflammatory skin diseases (Macheleidt et al., 2002). 
1.2 Sphingolipid Biosynthesis  
The cellular pathways involving SLs have been partially elucidated using synthetic as well as 
radiolabeled precursor lipids (Rosenwald and Pagano, 1993; van Echten-Deckert et al., 1997). 
SL biosynthesis begins at the cytosolic leaflet of the endoplasmic reticulum (ER) with the 
condensation of l-serine and palmitoyl-CoA (CoA = Coenzyme A) to form 3-keto-sphinganine (Figure 
2). This rate-limiting step of de novo Cer synthesis is catalyzed by the enzyme complex serine C-
palmitoyltransferase (SPT) and is crucial for Cer homeostasis in the skin (Hanada, 2003; Mizukoshi et 
al., 2011). The reduction of 3-keto-sphinganine to sphinganine (dihydrosphingosine) and the 
subsequent coupling to a particular FA by an acyl-CoA-specific ceramide synthase (CerS) results in 
dihydroceramide (Pewzner-Jung et al., 2006). A desaturase enzyme (DES1) introduces the 4,5-trans-
double bond to give Cer, which can enter the SL metabolic pathways, where it can be deacylated to 
give sphingosine, which, in turn, can be derivatized to Sph-1-P, for example, or where it can serve as a 
precursor for more complex SMs or GSLs (Figure 2).  
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Cer degradation via deacylation to give sphingosine and an FA is catalyzed by a family of 
ceramidases, which may have a neutral, alkaline or acidic pH optimum, depending on cellular 
localization (Lahiri and Futerman, 2007). Sphingosine or sphinganine derived from Cer can also be 
recycled for Cer synthesis via ceramide synthases (CerS) (Geilen et al., 1997). 
 
 
Figure 2. De novo ceramide synthesis, recycling and processing to higher SLs. 
(A) De novo ceramide synthesis begins with the condensation of L-serine and palmitoyl-CoA catalyzed 
by serine palmitoyltransferase (SPT). The product 3-keto-dihydrosphingosine is reduced to 
dihydrosphingosine (sphinganine) via 3-ketodihydrosphingosine reductase (KDSR) and acylated by a 
ceramide synthase (CerS) to give dihydroceramide and finally ceramide via a desaturase. Ceramide 
can be degraded by a ceramidase (B) to give sphingosine and a fatty acid. Sphingosine can be 
recycled (C) for ceramide formation in a CerS reaction. Ceramide serves as a precursor for more 
complex SLs such as sphingomyelin (D), glucosylceramide (E) or higher glycosphingolipids (GSLs). 
In contrast to the Cer processing described above, SM synthesis takes place at the luminal side of the 
Golgi (Jeckel et al., 1992) and requires that the ceramide transport protein (CERT) transfers Cer (with 
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acyl chain-lengths of C16-C20) from the ER to the Golgi (Hanada, 2006). Within the so-called SM 
cycle, Cer is converted into SM in a reaction catalyzed by SM synthase in which  phosphatidylcholine 
(PtdCho) is utilized to transfer phosphocholine (Cho-P) to the C1 position of the Cer backbone with 
release of a diacylglycerol (DAG) moiety. Cer can be recycled from SM by the action of a 
sphingomyelinase with release of Cho-P (Geilen et al., 1997). In response to extracellular stimuli (e.g., 
TNFα, IL-1, endotoxin), Cer can also be synthesized from PM-derived SM (Levade et al., 1999). 
In general, for GSL synthesis, Cer is shuttled from the ER by vesicle transport to the cytosolic face of 
the Golgi (Jeckel et al., 1992), except for galactosylceramide (GalCer) formation (Sprong et al., 1998). 
One of the key enzymes of GSL formation, glucosylceramide synthase (UDP-glucose:ceramide 
glucosyltransferase (UGCG); EC 2.4.1.80), is a transmembrane protein which transfers glucose from 
UDP-Glc to the sphingoid C1 of the Cer backbone, generating glucosylceramide (GlcCer) (Figure 2) 
(Jeckel et al., 1992). Higher GSLs are formed at the luminal side of the Golgi by enzymatic addition of 
further monosaccharides, sulfatides or neuraminic acid to give glucocerebrosides (e.g., Gb3, Gb4), 
sulfatides (e.g., SM4) or gangliosides (e.g., GM1, GM3), respectively. The majority of these GSLs 
contain GlcCer as a core structure. Only a few, the so-called galactocerebrosides, are derived from 
GalCer. Two major groups of GSLs can be distinguished by chromatography: neutral GSLs (nGSL) 
typically contain unsubstituted, uncharged carbohydrates (such as in Gb3 and Gb4); acidic GSLs 
(aGSL) contain carbohydrates with carboxyl, sulfate, or phosphate groups attached (such as in SM4, 
GM1 or GM3). After synthesis, complex GSLs either move via vesicular transport to the PM, where 
they are incorporated, or metabolized to give Cer and bioactive metabolites (Bartke and Hannun, 
2009). 
1.3 Epidermal Sphingolipids 
1.3.1 Distinction between LC-, VLC- and ULC- sphingolipids 
Whereas the mammalian PM primarily contains saturated long-chain (LC) and very-long-chain (VLC) 
FAs with 16 to 24 carbon atoms, the epidermis expresses not only LC- (C16-C20) and VLC-FAs 
(C22–C26) but also a unique diversity of Cers with ultra-long-chain (ULC) acyl FA moieties with 28 
to 36 carbon atoms (Figure 3). The lower epidermal layers contain higher amounts of LC and VLC 
Cers, localized in the nucleus, mitochondria, Golgi or PM (Uchida and Hamanaka, 2006). In contrast, 
barrier lipid synthesis becomes more important in the higher differentiated epidermis layers, whereby 
LC-, VLC-, or mainly ULC-FAs are incorporated into the Cers and localized in compartments such as 
trans-Golgi network, LBs, CE, or within corneocyte interstices (Vielhaber et al., 2001). The acylated 
FA chains in ULC-Cers may be saturated or mono-unsaturated and are essential for epidermal barrier 
function (Jennemann et al., 2012b). To a great extent, ULC-FA moieties are hydroxylated either at α 
or ω position. Furthermore, an ω-hydroxy group of a ULC-SL can be esterified to an additional FA, 
predominantly to linoleic acid (C18:2, ω–6) or to a protein sidechain on corneocytes to establish the 
CLE, a prerequisite for epidermal barrier formation (Figure 3) (Uchida and Hamanaka, 2006). 
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1.3.2 Major classes of epidermal ceramides 
In addition to cholesterol and free FAs, Cers are the major lipid class comprising almost half of the 
total SC lipid mass by weight (Hamanaka et al., 2002; Weerheim and Ponec, 2001). Twelve major Cer 
subclasses have been identified in human SC , which differ in the sphingoid backbone (i.e., 
sphingosine, phytosphingosine (4-hydroxysphinganine) or 6-hydroxysphingosine with C18 or C20 
chain length) as well as in the amide-linked FA moiety (Uchida and Hamanaka, 2006). Altogether, 
more than 340 different Cer species in the SC have been described (Masukawa et al., 2008). 
 
 
Figure 3. Acyl FA chain length in sphingolipids. 
Plasma membrane sphingolipids (SLs) typically contain FAs with chain lengths of C16 (palmitic) to 
C24 (nervonic) (red) amide-linked to the sphingoid base (blue) and are designated here as long-chain 
(LC-) and very-long-chain (VLC-) SLs. The sphingolipid class is determined by the head group R1. 
However, in the epidermis differentiated keratinocytes produce SLs with ultra-long-chain (ULC-) FAs 
with 32 to 36 carbons, which may be hydroxylated in the terminal ω position. The ω-hydroxyl group 
may be esterified to an additional FA, typically linoleic acid (C18:2, ω–6), designated here as R2. The 
ULC-SL depicted here contains C34:0 geddic acid, which is the most abundant ULC-FA in epidermal 
ω-hydroxylated Cers. Modified from (Rabionet 2011). 
SC Cers derived from sphingosine can be classified according to the characteristics of their FA 
residue. As shown in Figure 4, a commonly used scheme distinguishes between nonhydroxylated FAs 
(NS), α-hydroxy FAs (AS), and ω-hydroxy FAs (OS), which, in turn, may be esterified to a protein 
amino acid sidechain (POS) or to an FA (EOS), typially Lin.  
More than 62% of SC Cers are hydroxylated (subclasses AS, OS, EOS, POS) (Hamanaka et al., 2002). 
AS- and minor NS-Cers are typically linked to saturated FAs with 16 to 26 carbon atoms, but do not 
contain ULC-FAs (Coderch et al., 2003). Hydroxylated Cers with acyl FA moieties longer than C26 
are primarily ω-hydroxylated (OS) and can be esterified to FAs (EOS) or to proteins on corneocytes 
(POS), thereby establishing the CLE, a prerequisite for epidermal barrier function. In Gaucher’s 
disease and related mouse models, loss of OS-type Cers, particularly POS, coincides with severe 
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epidermal barrier defects (Doering et al., 1999b), indicating the significance of these Cers for barrier 
function (Jennemann et al., 2012b). 
 
 
Figure 4. Major epidermal ceramide subclasses distinguished by acyl FA chain length and 
hydroxylation. 
In keratinocyte-produced ceramides the amide-linked FA residues with chain lengths of C16 (palmitic) 
to C26 (cerotic) are typically nonhydroxylated (NS) or α-hydroxylated (AS). The ceramides with FA 
chain lengths of C32 (lacceroic) to C36 (hexatriacontylic)) generally carry an ω-hydroxy group (OS), 
which may be esterified to a protein sidechain (POS) or the unsaturated FA Lin (EOS). Modified from 
(Rabionet 2011). 
EOS-Cers are the most prominent Cer class in the epidermis. In human epidermis ca. 95% of the ω-
linked FAs are Lin, but only 45% in mouse epidermis (Uchida and Hamanaka, 2006). Altered 
epidermal lipid composition has been observed in essential fatty acid deficiency (EFAD), where Lin 
(C18:2, ω–6) in EOS-Cers was replaced by oleic acid (Ole: C18:1, ω–9), leading to abnormal lamellar 
formation and leakiness of the epidermal permeability barrier (Hou et al., 1991; Melton et al., 1987).  
Most epidermal Cers are believed to derive from the corresponding GlcCer classes, serving as 
essential precursors for epidermal barrier formation, except for Cer2 (NS) and Cer5 (AS), deriving 
from SMs (Hamanaka et al., 2002; Uchida et al., 2000). 
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1.4 The Epidermis 
The skin consists of an outer squamous epithelium (epidermis and hair follicles) and an insulating 
mesenchymal compartment (dermis and dermal papilla) connected via a basement membrane. The 
dermis is mainly composed of fibroblasts and fibroblast-derived proteins of the extracellular matrix 
(ECM) such as collagen, elastin and glycosaminoglycans, which confer the skin with tensile strength 
and elasticity. The dermis provides nourishment for the lower epidermal layers via dermal papillae. 
The primary function of the epidermis is to maintain the skin barrier and protect the body from 
environmental stressors such as pathogen invasion, mechanical insult and desiccation. The epidermis 
synthesizes a unique pattern of various long-chain FA-containing SLs, which, together with specific 
junction proteins (such as claudins), allow for the formation of a competent barrier confined to the 
outermost epidermal layer.  
1.4.1 Epidermis structure and keratinocyte differentiation 
The epidermis is a self-renewing, cornifying epithelium composed of different strata. Keratinocytes, 
which comprise ca. 95% of all epidermal cells, derive from stem cells in the lower basal layer (Watt, 
2002b). Minor components include melanocytes, Langerhan’s cells, Merkel cells and lymphocytes. In 
the stratum basale (SB), proliferating keratinocytes exit the cell cycle and undergo several stages of 
differentiation while migrating upwards through the epidermal strata, i.e., stratum spinosum (SS), 
stratum granulosum (SG) and stratum corneum (SC) (Figure 5). Upon terminal differentiation the cells 
become dead, flattened corneocytes of the SC and finally shed off during desquamation (Candi et al., 
2005), a repetitive process with a period of 6 to 7 weeks in humans (Halprin, 1972) and 8 to 10 days in 
mouse skin (Ghazizadeh and Taichman, 2001; Potten et al., 1987).  
At each stage of differentiation keratinocytes change their cytoskeletal structure and composition, 
expressing distinct sets of structural proteins, of which the most prominent are keratin intermediate 
filaments. In basal keratinocytes, the cytoskeleton is composed of keratin K5 and K14, as well as of 
microtubular and microfilamentous proteins. Via transmembrane receptors (e.g., integrins) basal 
keratinocytes are anchored to adhesive proteins of the underlying basement membrane (e.g., laminins), 
thereby regulating epidermal homeostasis (Watt, 2002a). When keratinocytes leave the SB, 
proliferation ceases and differentiation begins with the expression of keratins K1 and K10 in the SS. 
At this stage the keratinocytes are attached by stabilizing desmosomal junctions which serve as 
important adhesion sites for structural proteins. Late SS keratinocytes synthesize epidermal-specific 
lipids and early structural proteins such as involucrin (IVL) and transglutaminases (TG), as required 
for the cornified envelope (CE). With further keratinocyte maturation, a more granular-like pattern 
develops, and the cells become keratinocytes of the SG. These granular cells contain high amounts of 
keratohyalin granules (KG) storing profilaggrin (proFLG) and loricrin (LOR), important structural 
proteins for cornification. SG keratinocytes eventually enter terminal differentiation, initiated by 
filaggrin-assisted keratin condensation, and extrude their cellular contents, becoming anucleate 
corneocytes of the SC.  
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Figure 5. Epidermis structure: schematic view and microscopy of neonatal mouse skin. 
Left panel: schematic diagram of the epidermis, a squamous epithelium composed of different strata. 
Keratinocytes in the stratum basale proliferate and eventually enter several steps of differentiation, 
passing through the epidermal layers (stratum spinosum and stratum granulosum) to terminally 
differentiate into the dead flattened cells (corneocytes) of the stratum corneum. The corneocytes are 
surrounded by lipid lamellae (indicated in red) and finally shed off during desquamation. Right panel: 
light microscopy of cross section of neonatal mouse skin stained with PAS-methylene blue-Azure II. 
Taken from (Rabionet 2011). 
Upon onset of this cornification process, the corneocyte PM is gradually replaced by a scaffold of 
cross-linked structural proteins such as IVL and LOR with envoplakin (EVPL) and small proline-rich 
proteins (SPRRs) bound to lipids. The result is an insoluble, rigid CE, which is a prerequisite for 
epidermal barrier function (Candi et al., 2005). 
In parallel, lipid synthesis increases in SG keratinocytes, forming small secretory organelles, so-called 
lamellar bodies (LBs), which deliver lipids (SLs, phospholipids, cholesterolester), catalytic enzymes 
and antimicrobial peptides to the apical PM. The content of the LBs is externalized by exocytosis in 
the upper SG and at the SG/SC interface (Jennemann et al., 2012b). Extracellular lipids are 
enzymatically processed and form intercellular lipid lamellae or are covalently bound to proteins of 
the CE, forming the cornified lipid envelope (CLE) as the first barrier against epidermal water loss 
(Nemes et al., 1999; Sandhoff, 2009). This barrier demands permanent renewal of the outer cornified 
layer, which is achieved by steady, highly regulated corneocyte shedding (desquamation).  
The integrity of the epidermis is supported by cell-cell junctions, i.e., tight junctions, adherens 
junctions and desmosomes. Tight junctions (TJs, zonula occludens) are expressed in the more 
differentiated layers of the epidermis and have been shown to built up a potent barrier against 
epidermal water loss (Furuse et al., 2002). They form so-called “kissing-points” to neighboring cells, 
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sealing off the paracellular pathway. Typical epidermal TJ proteins are claudins (e.g., CLDN1) or 
tight-junction proteins (e.g., TJP1). 
Adherens junctions (AJs) are created by multifunctional adhesive proteins (e.g., AJAP1) which 
interconnect the cytoskeleton of neighboring cells, thereby ensuring keratinocyte cohesion. 
Furthermore, AJs create transcellular networks, thus regulating cytoskeletal remodeling and cell 
polarity (reviewed by (Brandner et al., 2010)). AJs are composed of cytoplasmic actin-associated 
plaque proteins called catenins (CTNNn), e.g., β-catenin (CTNNB1) and calcium-sensitive 
transmembrane proteins, the cadherins (CDHn), such as E-cadherin (CDH1) and P-cadherin (CDH3).  
The most characteristic epidermal junctions are desmosomes with a structure similar to that of the 
adherens junctions. Desmosomes function as “mechanical junctions” connecting the keratin 
cytoskeleton via catenins (e.g., plakoglobin (JUP), desmoplakin (DSP)) and transmembranous 
cadherins, such as the desmogleins (DSGn) and desmocollins (DSCn), to neighboring cells or to the 
ECM (in the form of hemidesmosomes). At the onset of terminal differentiation, desmosomes serve as 
templates for more specialized junctions in the SC, the corneodesmosomes. In the lower SC layers the 
latter are regularly expressed on corneocytes as integral compounds of the CE. In contrast to the 
desmosomes of the viable epidermal layers, corneodesmosomes contain a keratin-fused plaque protein 
on the inner cell side which is bound predominantly to the SC-unique corneodesmosin (CDSN) or to 
other cadherins (e.g., desmoglein 1 or desmocollin 1). Controlled proteolytic degradation of 
corneodesmosomes by LB-derived proteases (e.g., kallikreins of the KLK family) is a key factor for 
normal desquamation (Ishida-Yamamoto and Kishibe, 2011). Changes in protease (inhibitor) 
activities, calcium concentration, or SC pH and hydration can impair the regular desquamatory process 
and result in hyperkeratosis (ichthyosis) and other skin pathologies (Ishida-Yamamoto and Kishibe, 
2011).  
1.4.2 Epidermal barrier formation 
The epidermal (permeability) barrier (Figure 6, left panel) is confined to tight junctions in the granular 
layer, controlling paracellular transport (Furuse et al., 2002; Kirschner et al., 2010), and to the lipids 
and lipid-embedded corneocytes in the SC layer, providing a hydrophobic water-proof sheath (Elias, 
2005). The lipid matrix is composed of Cers, cholesterol and free FAs accounting, respectively, for 
50%, 25% and 15% of the total lipid mass in human SC (Wertz, 2006). Minor components of this 
barrier are cholesterol-sulfate (2-5% ww), which regulates protease activity during desquamation 
(Elias et al., 1984; Sato et al., 1998), and free sphingoid bases, important lipids for microbial defense 
(Bibel et al., 1992). Desquamation is a highly regulated process and ensures the sequential renewal of 
the outer epidermal layers. 
Lipid barrier formation begins with Cer formation at the ER in keratinocytes (Figure 6, right panel). 
Elongation of the FA moiety in Cers is carried out by a group of ELOVL enzymes (elongation of very-
long-chain fatty acyl-CoA), of which ELOVL4 is decisive for the synthesis of OS-type Cers. The 
significance of this enzyme for the epidermal water permeability barrier (WPB) is supported by the 
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observation that ELOVL4 –/– mice die shortly after birth due to barrier loss (Cameron et al., 2007; Li 
et al., 2007).  
Ceramide synthases (CerS), encoded by tissue-specific longevity assurance genes (Lass), catalyze the 
condensation of an FA with a sphingoid base. Among the CerS family (comprising CerS1 to CerS6), 
CerS3 has been identified to specifically use VLC/ULC-FAs to synthesize VLC/ULC-Cers in testes 
and epidermis (Jennemann et al., 2012b). Deletion of this enzyme caused premature death of newborn 
mice due to the lack of ULC-Cers and the deficiency in epidermal barrier formation. 
 
 
Figure 6. Epidermal glycosphingolipid synthesis and barrier formation. 
Barrier formation takes place at the interface of SG and SC (left panel, top). In the epidermis lipids 
accumulate with increasing differentiation. Much of the accumulating lipids is packed in lamellar bodies 
(LBs). The latter export their content by exocytosis near the apical boundary to the SG into the 
extracellular space, where hydrolytic enzymes act on the lipids to produce Cers, free FAs and 
cholesterol, the three major barrier lipids. Trans-esterification (T.E.) leads to protein-linked Cers and 
GlcCers. Unlinked Cers, cholesterol and free FAs form lipid lamellar sheets, thereby sealing the 
corneocyte interstices and completing lipid barrier formation. From (Sandhoff, 2009). 
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The next important step in barrier formation is the transient formation of glucosylated Cer precursors 
(GlcCers) by the action of glucosylceramide synthase (UGCG). Constitutive deletion of the Ugcg gene 
causes prenatal death of mice and implies an essential role for GSLs in embryonic development 
(Ichikawa et al., 1998). 
Further processing and transport of precursor lipids (GlcCers and SMs) to the apical PM involves 
small secretory granules, the LBs (Figure 6 right panel). These oval-shaped organelles consist of a 
unit-bounding membrane surrounding one or several stacks of lipid lamellar discs. Lamellar 
arrangement of OS/EOS-GlcCers within LBs is supported by the ATP-binding cassette transporter 
ABCA12. Loss-of-function mutations in the gene encoding for ABCA12 have been described for 
lamellar ichthyosis type II (LI2) as well as harlequin ichthyosis (HI), both severe autosomal recessive 
congenital ichthyoses (ARCI), characterized by hyperkeratosis and permeability barrier loss. 
Ichthyotic lesions revealed an accumulation of EOS-GlcCers, whereas EOS-Cers were significantly 
reduced (Zuo et al., 2008).  
Within the LBs, ULC-GlcCers are believed to become ω-O-acylated, predominantly with Lin, by the 
action of CGI-58, a lipid droplet-associated acyl transferase (Akiyama et al., 2008). Mutations in CGI-
58 are related to the neutral lipid storage disease called Dorfman-Chanarian syndrome. In addition to 
systemic accumulation of triglycerides, patients develop an ichthyosis-like skin phenotype, indicating 
the importance of regular lipid processing for epidermal barrier homeostasis (Akiyama et al., 2003; 
Demerjian et al., 2006).  
As barrier formation proceeds, LBs fuse with the apical PM in the upper SG and at the SG/SC 
interface to exocytose into the extracellular space their content: structural proteins (e.g., 
corneodesmosin), enzymes (e.g., TG, neutral lipase, GlcCerase, acid SMase), and antimicrobial 
peptides (e.g., cathelicidine, β-defensin) (Bouwstra et al., 2003; Elias et al., 2006; Madison, 2003). 
Upon transesterification, GlcCers and SMs are converted back into their corresponding Cers by the 
action of GlcCerase and acid SMase. Furthermore, FAs, glycerol and cholesterol are released (from 
phospholipids and cholesterol esters, respectively) by secretory phospholipase A2 (sPLA2) and 
cholesterol sulfatase. These components, together with Cers (OS, EOS), establish the extremely 
hydrophobic extracellular lipid lamellae of the skin barrier (Candi et al., 2005). Mutation or loss of 
function of the enzymes involved results in severe skin barrier defects (Doering et al., 1999b; Elias et 
al., 1984; McGovern and Schuchman, 1993). For instance, in Gaucher’s disease, depletion of 
GlcCerase or its activator protein prosaposin (PSAP) inhibits Cer formation from GlcCer precursors 
leading to impaired lipid lamellar membranes and subsequent WPB loss (Doering et al., 1999b).  
In the SC/SG interface, transglutaminase 1 (TG1) catalyzes the ω-esterification of ULC-Cers to 
glutamine-glutamate rich regions of CE proteins (e.g. involucrin, loricrin, envoplakin (EVPL), 
periplakin (PPL)), establishing the CLE (Nemes et al., 1999) (Doering et al., 1999a; Jennemann et al., 
2012b; Marekov and Steinert, 1998). Deletion of TG1 causes lamellar ichthyosis type I (LI1) , marked 
by clefts in the SC interstices and increased transepidermal water loss (TEWL) (Elias et al., 2002).  
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Specific SLs (e.g. sphingosine) also serve in antimicrobial defense. They are synthesized in the 
epidermis and carried to the surface as cells differentiate or are secreted from sebaceous glands onto 
the skin surface (Drake et al., 2008). 
1.4.3 Stratum corneum pH 
Under normal physiologic conditions, the SC pH of human epidermis ranges from pH 6.8 in the lower 
up to pH 4.5 in the uppermost SC layer, forming the so-called acid mantle of the skin. The pH gradient 
is maintained by acidic microdomains dispersed across the SC, which contain free FAs, protons 
(secreted from keratinocytes via the Na
+
/H
+
 antiporter SLC9A1 (formerly NHE1) and trans-urocanic 
acid (tUCA), the endproduct of the FLG metabolic pathway. Further contributors to the acidic pH can 
be lactate from sweat or microbial products (Fluhr and Elias, 2002).  
The SC pH is imperative for epidermal barrier homeostasis and regulates four key functions of the SC: 
(1) lipid processing (and thereby WPB formation), (2) antimicrobial defense, (3) cohesion and (4) 
desquamation. Whereas the extracellular ion concentration (Ca
2+
, K
+
) affects LB secretion, the pH 
determines the activity of LB-derived hydrolases and proteases such as GlcCerase and acid SMase 
(with its acidic pH optimum) as well as sPLA2, steroid sulfatase or the KLKs with neutral pH 
optimum.  
Elevation of the SC pH is fatal for skin barrier function since activated proteases such as KLKs 
accelerate CD degradation, thereby leading to impaired SC cohesion. A neutral pH has been observed 
in most skin disorders such as ichthyosis, psoriasis and atopic dermatitis (AD), and can aggravate their 
associated pathophysiologies (Fluhr and Elias, 2002).  
1.5 Loss of Barrier Function 
The important role of lipids, in particular of Cers, in skin barrier function has been determined from in 
vivo and in vitro studies of cutaneous disorders such as ichthyosis, lysosomal storage diseases, 
psoriasis and AD. These diseases may result from environmental factors such as allergens and irritants 
(UV radiation, detergents, carcinogenic agents, and stress) or are based on genetic defects affecting 
proteins of the lipid metabolic pathways.  
Ichthyosis (the so-called fish scale disorder) comprises a heterogeneous family of dry hyperkeratotic 
skin disorders but may also be a symptom of more systemic diseases such as lysosomal storage 
diseases (e.g., Gaucher’s disease or Niemann-Pick disease) (Doering et al., 1999b; McGovern and 
Schuchman, 1993). Niemann-Pick disease has been related to mutations in the SMPD1 gene for acid 
SMase, leading to loss of Cers and subsequent leakiness of the WPB and ichthyotic skin lesions 
(McGovern and Schuchman, 1993). Similar barrier disruption has been described in Gaucher’s 
disease, in which a defect in the GlcCerase enzyme eliminated the GlcCers degradation pathway, 
resulting in loss of Cers, in particular POS-Cers and permability barrier breakdown (Doering et al., 
1999b). 
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Congenital ichthyosis (CI) represents a heterogenous group of skin disorders with deficits in Cer and 
FA processing, leading to epidermal WPB loss. Mutation in the genes encoding for the ABCA12 
transporter or lipoxygenases (12R-LOX, eLOX3) were identified as further predisposing factors for 
the development of ichthyosis (Akiyama et al., 2005; Jobard et al., 2002). Moreover, deletion of the 
steroid sulfatase represents a putative risk factor for X-linked recessive ichthyosis (XRI), characterized 
by severe defects in desquamation (Elias et al., 1984).  
Psoriasis is a complex inflammatory skin disease of unknown etiology, which may derive from genetic 
(e.g., FLG gene mutation), infectious or environmental (e.g., stress) factors. Psoriatic lesions are 
characterized by a thickened dry scaling skin and basal inflammation. The overall reduction of Cers in 
some psoriatic patients has been related to a decrease in SPT activity and reduced de novo Cer 
synthesis (Hong et al., 2007). Moreover, AD is a chronic relapsing inflammatory skin disorder, also of 
unknown etiology. For long time, AD was regarded as an immune-mediated disease until FLG gene 
mutations leading to disturbed barrier function were shown to be associated with atopy in some 
populations (Palmer et al., 2006). Patients suffering from AD display dry, itchy skin with 
inflammatory rashes, and have a high risk for bacterial or viral infections, about fourfold higher than 
in psoriasis (Elias, 2005). In both diseases, depletion of POS-Cers and an impaired lamellar 
organization were considered to be responsible for the subsequent WPB breakdown (Macheleidt et al., 
2002). However, in skin, a potent regulator of lipid biosynthesis is the epidermis itself, as indicated by 
an increase in synthesis of major SC lipids (Cer, FA and cholesterol) upon barrier disruption (e.g., 
induced by wounding) (Holleran et al., 1991). 
The importance of (Glc)Cers in permeability barrier function has been demonstrated by the variety of 
cutaneous disorders which display alterations in (Glc)Cer composition (see above). Furthermore, the 
function of GlcCers in the esophageal permeability barrier has been recognized (Diaz-Del Consuelo et 
al., 2005). GlcCers comprise about 16% of the total esophageal lipid content (by weight) in contast to 
only 1% for Cers. The generally higher content in polar lipids (phospholipids, cholesterol, GlcCers) of 
nonkeratinized or partially keratinized epithelia confers a higher permeability to these tissues (Wertz et 
al., 1986). Most of what is known about the esophageal barrier properties has been determined in the 
context of gastroesophageal reflux disease (GERD) (Katz et al., 2013) and from whole-organ 
permeability studies in vitro (Diaz-Del Consuelo et al., 2005). In particular the distal (abdominal) part 
of the esophageal duct is prone to mucosal damage by gastric acids, as observed in clinical reflux 
esophagitis or Barrett esophagus (Yang et al., 2012). Therefore, the esophagus relies on a functional 
barrier comprising a layer of mucus and unstirred water, surface bicarbonate (HCO3
–
), junction 
proteins and, in particular, lipids (Diaz-Del Consuelo et al., 2005). 
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1.6 Wound Healing 
Cutaneous injury, specifically skin wounds, trigger a series of epidermal defense and homeostatic 
mechanisms to repair the skin barrier. These complex mechanisms can be divided into three 
overlapping phases: (1) inflammation, (2) tissue formation (granulation tissue formation and 
reepithelialization) and (3) tissue remodeling.  
Clot formation and a burst of proinflammatory cytokines released by platelets and polymorphonuclear 
leukocytes (PMNL) mark the onset of the inflammatory phase. In addition, injured keratinocytes 
release a preformed pool of cytokines (e.g., interleukins IL-1α, IL-1β, IL-6; TNFα), activating 
epidermis-specific Langerhan’s cells, dermal dendritic cells (DDCs) and fibroblasts (Eming et al., 
2007; Wang et al., 2004; Wood et al., 1992). Infiltration of peripheral leukocytes occurs a few hours 
after wounding. However, the mast cell and neutrophil response normally ceases within 48 h post 
injury.  
In addition to the resident cells, more macrophages migrate to the wound site within two days after 
injury, assisting in phagocytosis and promoting tissue formation via synthesis of growth factors, e.g., 
transforming growth factors (TGF-α, TGF-β), basic fibroblast growth factor (bFGF or FGF2). Cells of 
the adaptive immune system, in particular T-lymphocytes, arrive in the later tissue remodeling phase 
and modulate the inflammatory response. However, a subpopulation of T-lymphocytes, called γδT-
cells, has been identified as dendritic epidermal T-cells (DETCs), which enhance tissue repair 
(Jameson et al., 2002).  
Furthermore, barrier loss provokes enhanced LB secretion (triggered by Ca
2+
 efflux), and enhances 
lipid processing, as indicated by increased activity of enzymes such as SPT, GlcCerase, neutral 
SMase, cholesterol sulfatase, HMG-CoA reductase and FA synthase (reviewed by (Feingold, 2007)). 
The primary goal of the enhanced lipid trafficking is to restore the epidermal permeability barrier. 
Moreover, barrier disruption and the subsequent boost in lipid synthesis demand an increase in lipid 
transporters (e.g., fatty acid binding protein 5 (FABP5), cellular retinoic acid binding proteins 
(CRABP)) (Ogawa et al., 2011) and induces lipid-responsive transcriptions factors (e.g., PPARβ/δ), 
promoting keratinocyte proliferation, migration and advanced wound healing (Di-Poi et al., 2003; 
Schmuth et al., 2004; Tan et al., 2007).  
The decisive factors for final wound closure and restoration of a competent barrier are (1) 
reepithelialization and (2) keratinocyte differentiation (Raja et al., 2007). Reepithelialization depends 
critically on migration of keratinocytes, which, upon injury, are derived initially from hair follicle 
stem cells and at a later stage of wound healing from stem cells of the basal epidermal layer (Ito et al., 
2005).  
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1.7 Hypothesis and Aim 
Permeability barrier formation critically depends on epidermal Cers containing ULC-FAs (C28 to 
C36) with a unique ω-hydroxyl group. Cers are believed to derive from glucosylated intermediates, 
GlcCers, as surmised from human Gaucher’s disease and related mouse models. In turn, GlcCers are 
synthesized from Cers by the glucosylceramide synthase (UGCG) reaction and are major precursors 
for all higher GSLs. However, in the epidermis GSL synthesis stops at the level of GlcCer. Therefore, 
we chose the skin as an ideal tissue model to test the hypothesis that GlcCers are important regulators 
in epithelial differentiation. 
In an earlier study using mice with constitutive Ugcg gene deletion in the epidermis (Ugcg f / f K14Cre 
mice), we found that newborn mice died at postnatal day P5 due to dehydration upon WPB loss, thus 
demonstrating the importance of Cer-glucosylation in epidermal barrier development. Complete loss 
of GlcCers and accumulation of the corresponding Cers was observed together with distorted LBs. 
Surprisingly, POS-Cers were not altered, which might be explained by the early death of mice before 
the completion of one cycle of epidermal renewal (Jennemann et al., 2007). Therefore, inducible 
UGCG-deficient mice (Ugcg f / f K14CreERT2 mutants) have been generated in our department to 
circumvent early death.  
In the present thesis project, a TAM-inducible model of the endogenous Ugcg gene deletion in K14-
positive cells allowed for the investigation of the role of GlcCers in adult epidermis. This in vivo 
model provides insight into the specific function of GlcCers and Cers in keratinocyte differentiation 
and further highlights important steps of Cer-processing during epidermal barrier formation. In 
addition, the function of GlcCer-deficient epidermis in relation to clinically relevant pathophysiologic 
states, i.e., wound healing, will be examined.  
In the context of epithelial barrier function the Discussion will emphasize the relevance of the acquired 
data with regard to human skin diseases and propose a potential mechanism of Cer action in stages of 
impaired barrier homeostasis (e.g., dermatoses, gastroesophageal diseases). This work aims to 
further clarifiy the pathophysiology of such diseases. 
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2.1 Materials 
2.1.1 Chemicals 
Standard laboratory chemicals and reagents used for routine analyses in this study were purchased 
from Sigma-Aldrich (Deisenhofen), Merck (Darmstadt), Life Technologies (Darmstadt), Roche 
(Mannheim), Carl Roth (Karlsruhe), and Fluka (Neu-Ulm). Tamoxifen and sunflower seed oil were 
from Sigma-Aldrich (Deisenhofen).  
All other chemicals were obtained as indicated in the corresponding method section. 
2.1.2 Buffers and solutions 
All buffers and solutions were prepared with either Aqua ad injectabilia (Braun) or doubly distilled 
(dd) autoclaved water. Buffers and components are listed in the following Tables (see footnotes at end 
of Tables). 
Buffers for Genotyping 
TAE buffer (50x) 
2 M Tris/AcOH, pH 8.0 
0.1 M EDTA 
NID buffer  
10 mM Tris/HCl, pH 8.3 
50 mM KCl 
2.5 mM MgCl2 
0.01% w/v Gelatin 
0.45% v/v IGEPAL CA-630 
0.45% v/v Tween-20 
Xylene cyanol loading buffer (10x) 
20 mM Tris/HCl, pH 7.5 
0.001% xylene cyanol (w/v) 
50% glycerol (v/v) 
 
  
Buffers for Southern blot  
Denaturing solution 
1.5 M NaCl 
0.5 N NaOH 
0.25 N HCl 
Neutralization buffer 
0.5 M Tris-HCl, pH 7.0 
1.5 M NaCl 
SSC buffer (20x) 
0.3 M sodium citrate tri-basic, pH 7 
3 M NaCl 
Church (hybridization) buffer 
0.5 M sodium phosphate, pH 7.2 
7% SDS 
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MBS washing solution 
100 mM NaCl 
0.3% (v/v) Tween-20 
pH 7.5 
Blocking buffer 
100 mM maleic acid, pH 7.38 
10% blocking reagent (DIG Luminescent Detection 
Kit, Roche) 
150 mM NaCl 
Developing buffer 
100 mM Tris-HCl, pH 9.5 
100 mM NaCl 
DNA isolation buffer 
50 mM Tris-HCl, pH 8.0 
100 mM EDTA 
100 mM NaCl 
1% (v/v) SDS 
TE buffer 
10 mM Tris, pH 8 
1 mM EDTA 
 
Buffers for western blot  
 Digitonin lysis buffer 
1
 (1x) 
20 mM HEPES-NaOH buffer,  pH 7.4  
25 mM KCl  
250 mM sucrose  
2 mM MgCl2  
0.5 mM DTT  
1x protease inhibitors mixtures 
2
 
1% digitonin 
2, 3
 
LämmLi loading buffer 
1
 (4x) 
250 mM Tris, pH 6.8 
40% glycerol (v/v) 
0.02% bromophenol blue (w/v) 
8% SDS (w/v) 
0.4 M DTT 
Resolving gel buffer (8x) 
3 M Tris-HCl, pH 8.8 
0.1% SDS (w/v) 
Stacking gel buffer (4x) 
0.5 M Tris-HCl, pH 6.8 
0.1% SDS (w/v) 
Running buffer (10x) 
250 mM Tris, pH 8.3  
1.92 M glycine 
1% SDS (w/v) 
Transfer buffer (10x) 
250 mM Tris, pH 8 
1.92 M glycine 
 
PBS buffer (10x) 
0.1 M Na2HPO4, pH 6.8 
1.4 M NaCl 
27 mM KCl 
 
PBS-Tween® buffer (PBST) (1x) 
1x PBS buffer, pH 7.4 
0.1% Tween® 20 (v/v) 
Ponceau red 
0.5% Ponceau red (w/v) 
1% AcOH (v/v) 
Blocking buffer 
4, 5 
1x PBST, pH 7.5 
5% skimmed milk (w/v) 
 
Buffers for RNA isolation 
Citrate buffer (1x) 
25 mM sodium citrate, pH 7.5 
0.5% N-laurylsacrosine (w/v) 
Guanidine thiocyanate buffer 
5
 (10x) 
1x citrate buffer 
6
, pH 6.4 
4.23 M guanidine thiocyanate 
0.2 M 2-mercaptoethanol 
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Buffers and solutions for immunohistochemistry and immunofluorescence 
Citrate buffer (for antigen retrieval) 
2 mM citric acid, 0.9 M sodium citrate,  pH 6 
TBS (for antigen retrieval) 
0.01 M Tris base, pH 9 
0.15 M NaCl  
Tris-HCl (for washing) 
0.05 M Tris base + HCl,  pH 7.4 
TBS (for washing) 
0.05 M Tris base, pH 7.4 
0.15 M NaCl 
EdU staining buffer 
0.1 M TBS, pH 8.5 
0.1 M Vitamin C 
5 
0.001 M CuIISO4 
0.01 mM Alexa Azid antibody in H2O Braun 
2% PFA Fixative 
5
 
10x PBS, pH 7.4 
2% paraformaldehyde 
 
Buffers and solutions for β-galactosidase staining 
X-Gal staining solution 
5
 
1 mg/mL X-Gal* in N,N-dimethylformamide 
10 mM K3Fe(CN)6  
10 mM K4Fe(CN)6 
0.1% Triton X-100 
2 mM MgCl2 
*5-bromo-4-chloro-3-indolyl-D-galactosidase 
X-Gal washing buffer 
4
 
10x PBS, pH7.4 
0.1% Triton X-100 
2 mM MgCl2  
1% PFA Fixative 
10x PBS, pH7.4 
1% paraformaldehyde 
0.2% glutaraldehyde (w/v) 
0.02% Triton X-100 (v/v) 
 
Buffers and solutions for separating epidermis from dermis 
Thermolysin buffer 
1, 7
 (500 μg/mL) 
10 mM HEPES, pH 7.4 
142 mM NaCl 
6.7 mM KCl 
0.43 mM NaOH 
1 mM CaCl2 
Trypsin solution 
1, 8
  
0.25% Trypsin in 1x PBS, pH7.4 
Sodium thiocyanate buffer 
9
 (0.5 M) 
0.5 M Na2HPO4, pH 6.8 
0.1 M KSCN 
1 
Store at –20 °C. 
2 
Add freshly. 
3 
A 10% stock solution was prepared by dissolving the powder in boiling water and keeping the solution at 95 °C 
for 10 min.  
4 
Store at 4 °C. 
5
 Freshly prepared. 
6
 Freshly sterile filtered. 
7, 8, 9
 Buffers used to separate epidermis from dermis according to further analysis: lipid analysis
7
, Southern blot
8
, 
western blot
9
. 
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2.1.3 Primers 
All of the following primers were obtained from BioSpring GmbH (Frankfurt/M, Germany). 
2.1.3.1 Primers used for the genotyping of ES cells 
 
Name Primer sequence (forward; reverse) 
Ugcg 
5-TGATAGCCACTGTCTGCTCTGC-3 ; 
5’-CGAAGTTATGTTTAAACGCGGC-3 
Used to synthesize 
the Southern 
probe!! 
5-CAAAAAGGTTGGCATTAACCCTAAA-3 ;  
5’-TGTCATCTGATTCACCATGTCAGTT-3’ 
Ugcg flox/flox 
5-GATATCATGGTCTTCTTCATGTGCC-3 ; 
5-TTTCCTTCACGTCATTTTTCTGAAC-3 
 
2.1.3.2 Primers used for the amplification of K14-5- and 3-homology arms of the 
targeting construct  
 
Name Primer sequence (forward; reverse) 
5 probe 
5-ATAGGTACCCCGCGGCATTTGTTTGGGATCCTTGGC-3 ;  
5-TAGCTACCGGGAGATATCCATGGCTTTGAGAGAGGTGAG-3 
3 probe 
5-CACATTAATTAAGCCACCTGCAGCCGCCAGTTCA-3 ;  
5-TATGCTAGCAAACCGACCTGGGACCTGAGCCAAGC-3 
 
2.1.3.3 Primers used for the synthesis of the K14-DIG outside Southern probes 
 
Name Primer sequence (forward; reverse) 
5 probe 
5-TACTGCTGGGTCCTAGTCACCTG-3 ;  
5-CAACTTCTACAGCAAGGCTCCAA-3 
3 probe 
5-GTTCTCGATCCTGTCCCAGTTCT-3 ; 
5-CTAACCTTGGCCCTGCTCTGTAT-3 
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2.1.3.4 Primers used for the genotyping of mice 
 
Gene 
Primer sequence  
(forward; reverse) 
Ta (°C) Product size 
(bp) 
Ugcg
wt
 5-GATCTAAGAGGGTGAAGGCGCA-3 58 259 
Ugcg
wt/flox
 5-AAGCCAGTCCAGTCAAACCGAG-3 58 383 
K14–wt-F 5-AGGGATCTGATCGGGAGTTG-3  442 
K14–wt-R 5-ATCCATCAAATCGACCACCA-3  442 
K14CreERT2Δneo-F 5-CGCCAATTAACCCTCACTAAAGG-3;  55 357 
Rosa26R (1) 5-TCTGCTGCCTCCTGGCTTCTGA-3 63 
wt: 270 
mutant: 420 
Rosa26R (2) 5-CCAGATGACTACCTATCCTCCCA-3 63 
Rosa26R (3) 5-AAGCGCATGCTCCAGACTGCCT-3 63 
 
2.1.3.5 Primers used for qRT-PCR analysis 
 
Gene (gene ID) Primer sequence (forward; reverse) 
Smpd3 (ID 58994)  ATCCCTGACCACACAGGAAG; TTAGAGGTCCCAACCACAGG 
Sgpp2 (ID433323) CTCTGGGCCAAGTCATCAAT; ACCCAAGTTACCAGGCACAG 
Pparβ/δ (ID19015) 1 CTGAAGGGAAGGGGGTAGAG; CCAGTCTGGATGCTGCTACA 
Krt77 (ID406220) GTAGAGATCGCCACCTACCG; CCAATGGTCACCTGGCTACT 
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2.1.4 Antibodies 
2.1.4.1 Primary antibodies 
Antibody 
Gene 
name 
Hosta – 
clonalityb 
Applicationc 
(dilution) 
Supplier 
(clone) 
Order 
number 
β-Actin Actb rb – p WB (1:200) Santa Cruz d sc-1616-R 
Claudin 1 Cldn1 rb – p 
WB (1:1000) 
Cryo (1:10) 
Thermo Scientific e RB-9209 
Desmoglein 1/2  Dsg1/2 m – m 
WB (1:100) 
Paraffin (1:10) 
H. Heid f  (DG3.10) - 
Desmoplakin 1/2  Dsp1/2 m – m 
WB (1:50) 
Paraffin (pure) 
H. Heid f  (DP447) - 
Fatty acid binding protein 5  Fabp5 g – p WB (1:2000) R&D Systems g AF 1476 
(Pro-) Filaggrin Flg rb – p 
WB (1:1000) 
Paraffin (1:50) 
Covance h PRB-417P 
ER-HR3 - r – m Paraffin (1:50) Acris i  
Integrin α6 Itga6 r – m Cryo (1:50) Progen j (GoH3) 10709 
Integrin 4 Itgb4 r – m Cryo (1:100) BD k 553745 
Involucrin Ivl rb – p 
WB (1:100) 
Paraffin (1:100) 
Covance h PRB-140C 
Keratin 6 Krt6 gp – p Paraffin (1:100) L. Langbein l - 
Keratin 10 Krt10 gp – p Paraffin (1:100) L. Langbein l - 
Keratin 14 Krt14 gp – p Paraffin (1:2000) L. Langbein l - 
Ki-67 MKi67 r – m Paraffin (1:200) Dako m (TEC-3) M7249 
Laminin 5 Lama-5 rb – p Cryo (1:300) Abcam n ab14509 
Loricrin (LOR) Lor rb – p 
WB (1:1000) Paraffin 
(1:100) 
Covance h PRB-145P 
Peroxisome proliferation-
activated receptor δ 
Ppard rb – p WB (1:500) Thermo Scientific e PA1-823A 
a g, goat; gp, guinea pig; m, mouse; rb, rabbit; r, rat. 
b m, monoclonal; p, polyclonal. 
c Cryo: cryosections; IHC: immunohistochemistry; Paraffin: paraffin sections; WB: western blot. 
d Santa Cruz Biotechnology Inc., Heidelberg, Germany; e Thermo Scientific (Pierce Antibodies), Germany; 
f H. Heid, Dept. of Cell Biology , DKFZ, Heidelberg, Germany; g R&D Systems, Wiesbaden, Germany; 
h Covance, Munich, Germany; i Acris Antibodies, Hiddenhausen, Germany; j Progen Biotechnik, Heidelberg, Germany; 
k BD Biosciences, Heidelberg, Germany; l L. Langbein, Dept. of Genetics and Skin Carcinogenesis, DKFZ, Heidelberg, 
Germany; 
m Dako, Hamburg, Germany; n Abcam plc, Cambridge, UK. 
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2.1.4.2 Secondary antibodies 
Antibody
a
  Host
a 
Application
b
 
(dilution) 
Supplier (Clone) Order num. 
Alexa FluorR 488 anti-rb d  IHC (1:500) Invitrogen 
c 
A21206 
Alexa FluorR 546 anti-r g  IHC (1:500) Invitrogen 
c 
A11081 
Alexa Fluor® 594 azide - Click chemistry 
(1:1000) 
Invitrogen
 c 
A10270 
Cy3TM anti-gp g IHC (1:500) Abcam 
d 
ab102370 
Cy3TM anti-m d  IHC (1:500) dianova 
e 
715-165-150 
Cy3TM anti-rb d  IHC (1:500) dianova 
e 
715-165-152 
Biotinylated anti-r rb Paraffin (1:200) Vector Laboratories 
f 
BA-4001 
Goat-HRP d  WB (1:1000) Santa Cruz 
g 
sc-2020 
Mouse-HRP g WB (1:1000) Santa Cruz 
g 
sc-2005 
Rabbit-HRP g  WB (1:1000) Santa Cruz 
g 
sc-2004 
a
d, donkey; g, goat; gp, guinea pig; m, mouse; rb, rabbit; r, rat. 
b
IHC: immunohistochemistry; Paraffin: paraffin sections; WB: western blot. 
c 
Life Technologies (Invitrogen™), Darmstadt, Germany; d Abcam plc, Cambridge, UK; 
e
 dianova (Jackson ImmunoResearch), Hamburg, Germany; 
f
 Vector Laboratories, Burlingame, CA, USA. 
g
 Santa Cruz Biotechnology Inc., Heidelberg, Germany 
 
2.1.5 Enzymes 
Restriction Endonucleases Source 
BglII (50,000 U/mL) 
PacI,  SpeI 
New England Bio (NEB) Labs, Ipswich, UK 
ClaI,  EcoRV,  KpnI,  SstII Life Technologies (Invitrogen™), Darmstadt, 
Germany 
  
Other Enzymes Source 
alkaline phosphatase (AP, EC 3.1.3.1) Dako, Hamburg, Germany 
Proof reading polymerase (PFU) Promega, Mannheim, Germany 
Proteinase K (peptidase K, EC 3.4.21.64) Sigma-Aldrich, St. Louis, MS, USA 
Platinum® Taq DNA Polymerase, 
RNase A (bovine pancreatic, EC 3.1.27.5) 
SuperScript® II Reverse Transcriptase 
Life Technologies (Invitrogen™), Darmstadt, 
Germany 
Turbo DNA-free™ DNase treatment kit Life Technologies (Ambion®), Darmstadt, Germany 
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2.1.6 Kits, standards, stains, chromatography, electrophoresis 
Agilent RNA 600 nano reagents Agilent, Böblingen, Germany 
CSPD® solution (25 mM) 
DIG Probe Synthesis Kit 
DIG Luminescent Detection Kit, 
Light Cycler® FastStart DNA Master SYBR Green I 
Kit 
Roche Diagnostics Deutschland, Mannheim, Germany 
(Roche Applied Sciences) 
DNA ladder (1 kb), 
RNaseOUT™ (recombinant RNase inhibitor) 
Life Technologies (Invitrogen), Darmstadt, Germany 
ECL™ western blotting analysis system (Kit) Amersham GE Healthcare, München, Germany 
PageRuler™ SM0671, prestained protein ladder Fermentas, St. Leon-Rot, Germany 
Turbo DNA-free™ Kit: DNase treatment & removal, 
WT Expression Kit 
Life Technologies (Ambion), Darmstadt, Germany 
WT Terminal Labeling and Controls Kit Affymetrix, Santa Clara, CA, USA 
Nitrocellulose membrane Roche, Switzerland 
Hyperfilm
TM
 ECL, X-ray film Amersham Biosciences, UK 
C18 Porasil silica, 125 Ǻ,  55-105 µm Waters, Eschborn, Germany 
Acquity UPLC® BEH C18, 130 Å ,1.7 µm, 2.1 × 50 
mm column 
Waters, Eschborn, Germany 
DEAE Sephadex A-25 Pharmacia Biotech, Uppsala, Sweden   
HPTLC plates (Silicagel 60 F254) Merck Millipore, Darmstadt, Germany 
SL lipid standards for MS Avanti Polar Lipids, USA 
Bradford reagent for protein determination Sigma-Aldrich, Deisenhofen, Germany 
H&E stain (hematoxylin & eosin) Chroma, Köngen, Germany 
Streptavidin, alkaline phosphatase conjugated (SA-
5100)  
Vector Laboratories, Burlingame, CA, USA 
Giemsa stain Merck, Darmstadt, Germany 
Vitro-Clud® mounting media Langerbrink, Emmendingen, Germany 
DAPI stain  Sigma-Aldrich, Deisenhofen, Germany 
EdU reagent Invitrogen 
 
2.1.7 Cell lines 
Embryonic stem cells (ES), cell line E14 were obtained from the Transgen-Service of the German 
Cancer Research Center (DKFZ, Heidelberg, Germany). 
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2.1.8 Mouse lines  
Mouse Strain Origin 
C57/Bl6 Charles River, L’Arbresle, France 
K14CreERT2 
Ugcg
 f / f K14CreERT2
 
Generated by R. Jennemann 
1
 
FLP-deleter 
Rosa26 reporter 
Kindly provided by G. Schütz
 1
 
1
 DKFZ Heidelberg 
2.1.9 Instrumentation  
Instrument Company 
 
Instruments used for genotyping (PCR analysis) 
Agarose gel electrophoresis chamber Carl Roth, Karlsruhe, Germany 
Agarose gel chamber Carl Roth, Karlsruhe, Germany 
GelDoc
TM
 2000 Gel Documentation System Bio-Rad, München, Germany 
GeneAmp® PCR System 2400, 
2720 Thermal cycler – PCR 
Life Technology (Applied Biosystems), Darmstadt, 
Germany 
 
Instruments used for lipid extraction and analysis 
Alpha 1-2 Lyophilizer Christ, Osterode, Germany 
Evaporator Liebisch, Bielefeld, Germany 
Linomat IV Camag, Muttenz, Switzerland 
Sonorex Super RK 102H Sonicator Bandelin, Berlin, Germany 
Variofuge 3.0 R Heraeus Sepatech, Osterode, Germany 
Xevo® TQ-S Tandem MS 
Acquity UPLC® I-class 
Waters, Eschborn, Germany 
 
Instruments used for protein extraction, western & Southern blots 
Branson Sonifier® 250  G. Heinemann, Schwäbisch Gmünd, Germany 
Classic autoradiography film developing machine AGFA E.O.S., Bonn, Germany 
Electrophoresis blotting apparatus  Bio-Rad, Munich, Germany 
Mini-PROTEAN 3 Cell electrophoresis system Bio-Rad, Munich, Germany 
SM-30 Control rotary shaker Neolab, Heidelberg, Germany 
Ultrospec 2000 UV/visible spectrophotometer Pharmacia Biotech, Uppsala, Schweden 
UV Stratalinker 2400 Stratagene, USA 
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Instruments used for RNA analysis 
Agilent 2100 Bioanalyzer Agilent Technologies, Böblingen, Germany 
Avanti J-25 centrifuge Beckman Coulter, Krefeld, Germany 
GeneChip® Mouse Gene 1.0 ST Arrays 
GeneChip® Scanner 3000 
Affymetrix, Santa Clara, USA 
Light Cycler 2.0 system Roche Diagnostics, Mannheim, Germany 
Ultra-Turrax® T25 Basic homogenizer IKA Labortechnik, Staufen, Germany 
 
Instruments used for surgery and surgical dressing 
Biopsy punches (5-mm and 8-mm diameter) Stiefel GmbH, Waiblingen, Germany 
Cavilon semipermeable dressing 3M Health Care, Neuss, Germany 
Kinesiologic tape Care Integral, Bad Schwartau, Germany 
Narcotic evaporator Dräger, Lübeck, Germany 
Surgical instruments Geuder, Heidelberg, Germany 
Prolene 5-0 surgical thread Ethicon, Norderstedt, Germany 
 
Instruments used for histology, microscopy and physical measurements  
Almemo® 2390-1 rectal thermometer,  
Sensor: ZA 9040-FS 
Ahlborn Messtechnik, Holzkirchen, Germany 
Autoanalyzer Hitachi 9-17-E  Hitachi, Frankfurt am Main, Germany 
Biorevo BZ-9000 microscope Keyence, Neu-Isenburg, Germany 
Cryostat Leica CM 3050S Leica Biosystems, Nussloch, Germany 
Dako Autostainer Dako, Hamburg, Germany 
Skincheck pH Tester HI 98110 PCE Deutschland, Meschede, Germany 
Microtome Microm HM355S Thermo Scientific, USA 
Tewameter TM300 (for TEWL measurements) Courage-Khazaka Electronics, Cologne, Germany 
Ultramicrotom Leica Ultracut Leica Microsystems GmbH, Wetzlar, Germany 
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Additional Equipment  
Dewar, liquid nitrogen container KGW-Isotherm, Karlsruhe, Germany 
Eppendorf refrigerated table top centrifuge 5417R, 
Eppendorf table top centrifuge 5415C 
Eppendorf, Hamburg, Germany 
Heating furnace (56°C)  Heraeus, Hanau, Germany 
HP LaserJet 2410 PS Hewlett-Packard, Böblingen, Germany  
Laboratory scale  Ohaus, Pine Brook, USA 
Laboratory micro scale Sartorius, Göttingen, Germany 
Minifuge RF (refrigerated centrifuge)  Heraeus, Hanau, Germany 
pH Meter  Schott, Mainz, Germany 
ScanMaker i800 Microtek, Taiwan 
Thermomixer compfort (1.5mL) Eppendorf, Hamburg, Germany 
Vortexer  IKA Labortechnik, Staufen, Germany 
 
2.1.10 Software 
Adobe Illustrator CS2 Adobe Systems, USA 
Bioconductor, version 2.9 freeware 
Endnote X6 ISI Research Software  Berkeley, USA 
Genomatix ChipInspector 
Genomatix Pathway System (GePS) 
Genomatix Software GmbH, Munich, Germany 
GraphPad Prism® 5  GraphPad Software, San Diego, CA, USA 
MADMAX (Management and Analysis Database for 
Multi-platform microArray eXperiments) 
https://madmax.bioinformatics.nl 
University of Wageningen 
Microsoft Office 2007  Microsoft Corp., Redmont, USA 
Microsoft Windows Vista Microsoft Corp., Redmont, USA 
R Statistical Package, version 2.14.0 freeware 
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2.2 Methods 
For abbreviations and terminology used in the Methods section, see Appendix 7.3. The materials, 
enzymes, antibodies, reagents and equipment used and their sources are, for the most part, summarized 
in Section 2.1 
2.2.1 Cloning and generation of transgenic mice  
2.2.1.1 K14CreERT2 knock-in mice 
A ca. 4.5 kb fragment of the keratin K14 promoter region was amplified by PCR using proof-reading 
polymerase (PFU, Promega). The primers were designed to introduce target sites for the restriction 
endonucleases KpnI and SstII at the 5 end as well as an ATG start-codon and an EcoRV site at the 3 
end of the PCR product. A second PCR was performed to amplify a ca. 4.5 kb fragment which 
included the complete coding sequence of K14 as well as PacI and NheI sites needed for cloning of the 
PCR fragment. The correctness of both PCR products was proven by sequence analysis. The 5 
homology arm was inserted via KpnI/EcoRV in frame into a modified cloning vector containing 
regions encoding for iCre, ERT2 and an FRT-flanked neomycin selection cassette (Figure 7). The 3 
homology arm was inserted into Pac I/Nhe I sites at the 3 end of the neomycin cassette. The targeting 
construct was then ligated via SstII/ClaI into a cloning vector containing a PGK-DTA cassette (Figure 
7) in order to enhance the efficiency of the homologous recombination in embryonic stem (ES) cells. 
E14 ES cells were transfected in the presence of the SstII-linearized K14-targeting vector and 
cultivated and genotyped as described previously (Jennemann et al., 2005). Southern blot analysis 
using digoxigenin-labeled probes revealed that four out of 384 ES cell clones were correctly targeted 
(Figure 7 B,C). Positive stem cells were injected into blastocysts, and the resulting chimeras were 
mated with C57BL/6 mice. Germ line transmission was indicated by the agouti-like color of the fur 
from the offspring, which were additionally genotyped by Southern blot analysis (Figure 7 D) and 
PCR (Figure 7 E,F). The neomycin selection cassette of the targeted allele was removed by crossing 
K14CreERT2-neo mice with FLP-deleter mice (kindly provided by G. Schütz, DKFZ-Heidelberg) 
(Rodriguez et al., 2000). K14CreERT2 delta-neo animals were backcrossed for at least 5 generations 
until they were combined with Ugcg-floxed mice of pure C57BL/6 background. 
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Figure 7. Generation of K14CreERT2 knock-in mice. 
(A) A PCR product including the promoter of K14 and the ATG-start codon was cloned in frame into a 
vector containing an iCre/ERT2 sequence and an FRT-flanked neomycin cassette. Part of the K14 
genomic sequence was also inserted at the 3 end of the neomycin cassette. The construct was 
transferred into a vector containing the PGK-DTA cassette. Stem cells were targeted and mice 
successfully generated. The neomycin antibiotic-resistance cassette was finally removed by crossing 
K14CreERT2-neo with FLP-deleter mice. (B–D) Genotyping of ES cells and knock-in mice by 
Southern blot analysis. The correct 5 (B) and 3 (C, D) homologous recombination of the targeting 
construct into E14 ES cells (A, B) and targeted mice (C) was confirmed by Southern blot analysis after 
KpnI (B) and PacI digestion (C, D) of DNA isolated from ES cells or mouse tail. Mouse tail biopsies 
from mutant mice were characterized by PCR analysis, detecting wild-type Ugcg and floxed Ugcg 
alleles as well as the K14CreERT2 transgene (E, F). 
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2.2.1.2 Ugcg f / f K14CreERT2 mice  
Homozygous-floxed mice (Ugcg f / f ) were generated as described (Jennemann et al., 2005) and crossed 
with K14CreERT2 mice. In a second mating step heterozygous-floxed Ugcg f / + K14CreERT2 mice were 
bred with Ugcg f / f , resulting in tamoxifen-inducible Ugcg f / f K14CreERT2 mice, which were born at the 
expected Mendelian ratio. TAM induction of Ugcg f / f K14CreERT2 mice resulted in disruption of the Ugcg 
gene by the action of Cre-recombinase, which excised exons 6–8 (including the catalytic domain) of 
the Ugcg gene locus (Figure 8). 
PCR analysis was performed to confirm wild-type (+ / +), heterozygous-floxed (f / +) or homozygous-
floxed (f / f) alleles (Figure 7E, F). Heterozygous-floxed and Ugcg f / + littermates served as controls. 
The efficiency of gene deletion was validated via Southern blot analysis (Figure 10) and 
byquantification of UGCG enzyme products, GlcCers, in epidermis samples obtained in week 3 or 4 
after initiation of TAM induction (Figure 12 and Figure 13).  
 
Figure 8. The tamoxifen-inducible Ugcg transgene. 
Deletion of the Ugcg gene for glucosylceramide synthase in murine epidermis was achieved by TAM-
induced Cre-recombinase activation specifically in K14-expressing cells.  
2.2.1.3 Rosa26/K14CreERT2 mice 
Rosa26-LacZ reporter mice (kindly provided by G. Schütz, DKFZ-Heidelberg), bearing a β-
galactosidase gene (LacZ), were crossed with transgenic K14CreERT2 mice. The resulting offspring 
(Rosa26/K14CreERT2 mice) were used to investigate TAM-induced Cre-activity before and after 
injection of 1 mg TAM dissolved in 100 µL oil. 
2.2.2 Animal care 
Animals were kept under specific pathogen-free conditions in barrier facilities, where a 12 h light / 12 
h dark cycle was maintained. Mice were housed in groups of up to five animals at a controlled 
temperature of 22 °C. They were fed a diet of regular laboratory chow and water, supplied ad libitum. 
All animal experiments were approved by German federal law (Regierungspräsidium Karlsruhe, 
Germany). 
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2.2.3 Genotyping 
2.2.3.1 Genotyping of ES cells 
DNA genotyping of ES cells was performed by PCR analysis using an upstream primer located on the 
5 region of the targeted Ugcg gene outside the region encompassed by the targeting construct. A PCR 
product much larger than 1.7 kb was diagnostic for the homologous recombination of the 5-terminus 
of the targeting construct (Figure 7). The data obtained from PCR were further confirmed by Southern 
blot analysis after NdeI restriction digestion using the PCR DIG Probe Synthesis Kit and DIG 
Luminescent Detection Kit (DIG = digoxigenin) according to the manufacturer’s protocol. 
Confirmation of the insertion of the 3 single loxP site was performed through PCR by using a primer 
pair to amplify one part of the Ugcg gene (>> 100 bp) before and after the single loxP integration site.  
The 3 homologous recombination of the targeting construct was additionally verified by Southern blot 
analysis after SpeI digest of the DNA with a 3 outside DIG probe. Six out of 384 ES clones 
underwent homologous recombination of the Ugcg gene locus. 
2.2.3.2 Genotyping of mice 
Mice were genotyped as previously described (Jennemann et al., 2005). In brief, genomic DNA was 
isolated from tail biopsies. Tails were digested overnight at 56 °C with 8 µL of proteinase K (10 
mg/mL, Sigma) dissolved in 800 μL of NID buffer. Upon heat inactivation of the enzyme at 85 °C for 
45 min, 2 μL of DNA solution was used for PCR analysis. Primers used for amplification of specific 
products corresponding to wild-type or mutant alleles are listed in Section 2.1.3. The results of the 
PCR analysis were confirmed by Southern blot analysis. 
 
PCR conditions for amplification of the Krt14 and Ugcg transgenes 
 
PCR reaction (50 μL) μL PCR program T [°C] Time [s] 
H2O 34.75 1. Denaturation 95 300 
10x Buffer 5.00 2. Denaturation 95 45 
MgCl2 (50 mM) 3.00 3. Annealing 58 30 
dNTPs (10 mM) 1.00 4. Elongation 72 40 
Forward primer (7.5 pmol/µL) 2.00 5. Elongation 72 300 
Reverse primer (7.5 pmol/μL) 2.00 6. Cooling 4  
NID-DNA 2.00 
Steps 2 to 4 are repeated for 35 cycles. 
Platinum Taq Polymerase (5 U/μL) 0.25 
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PCR conditions for amplification of the Rosa26/LacZ gene 
 
PCR reaction (50 μL) μL PCR program T [°C] Time [s] 
H2O 17.50 1. Denaturation 95 300 
10x Buffer 2.50 2. Denaturation 95 30 
MgCl2 (50 mM) 0.75 3. Annealing 63 60 
dNTPs (10 mM) 0.50 4. Elongation 72 60 
Primer 1 0.50 5. Elongation 72 600 
Primer 2 0.50 6. Cooling 4  
Primer 3 0.50 
Steps 2 to 4 are repeated for 35 cycles. NID-DNA 2.00 
Platinum Taq Polymerase (5 U/μL) 0.25 
 
2.2.4 Preparation and administration of tamoxifen 
Ugcg gene deletion was initiated by intraperitoneal (i.p.) injection of 1 mg TAM once per week as 
indicated in Figure 9. TAM was first dissolved in 100% ethanol and then further diluted with 
sunflower seed oil. Both steps were performed under sonication for ca. 5 min at 37 °C. The TAM 
solution was always freshly prepared at a concentration of 1 mg TAM per 100 µL as an ethanol/oil 
(10:90) suspension. Controls and Ugcg f / f K14CreERT2 mice were treated in parallel. 
2.2.5 Southern blot  
TAM-induced recombination of the Ugcg gene was confirmed by Southern blot analysis. Biopsies 
were taken and snap frozen in liquid nitrogen. Epidermis and dermis were separated after 
trypsinization (0.25% in PBS) of skin for 16 h at 4 °C (Mertens et al., 2005). Subcutaneous fat tissue 
was removed from the dermis. 
2.2.5.1 DNA isolation 
Tissue samples were digested in 500 µL of DNA isolation buffer containing 5.6 mg/mL proteinase K 
(Sigma/USA) at 56 °C overnight. Then 214 µL of saturated NaCl were added, and samples were 
gently mixed and centrifuged at 15000×g for 20 min at 4 °C. Supernatants were transferred into new 
Eppendorf tubes and incubated with bovine pancreatic RNAse A (19.6 µL/mL) for 25 min at 37 °C. 
DNA was precipitated by adding one volume of 2-propanol and gently mixing. Centrifugation was 
repeated (15000×g, 20 min, 4 °C) and the resulting DNA pellet was washed with 500 µL of ice cold 
70% ethanol. Next, the DNA was air-dried and dissolved in 50-100 µL of doubly distilled H2O at 37 
°C for 1 h. The DNA concentration of each sample was calculated from its optical density 
(absorbance) at 260 nm (A260) measured with an Ultrospec 2000 UV/vis spectrophotometer.  
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2.2.5.2 Restriction digest, electrophoresis and denaturation 
DNA samples (5 µg) were digested with 50 units of the BglII restriction enzyme overnight at 37 °C. 
Resulting fragments and a 1 kb DNA ladder were separated by 1% agarose gel electrophoresis in 1x 
TAE buffer (120 V, 4 h). The lane with the DNA ladder was manually removed, stained with 
ethidiumbromide and visualized under UV light. To denature DNA fragments, the gel was incubated 
for 10 min in 250 mM HCl, subsequently washed with dd H2O and placed for 30 min in denaturing 
solution. After repeated washing with dd H2O, the gel was incubated in neutralization solution (2 
times, 15 min each).  
2.2.5.3 DNA transfer and hybridization with DIG-labeled probe 
Further analysis was performed using a digoxigenin-labeled 3 “outside” Southern probe amplified 
according to the protocol of the DIG Probe Synthesis Kit and DIG Luminescent Detection Kit 
according to the manufacturer’s instructions (Roche Applied Science). Primers used for the synthesis 
of the Southern probe are listed in section 2.1.3.3.  
The DNA was blotted onto a nitrocellulose membrane in 20x SSC buffer overnight. Upon transfer, the 
DNA was fixed covalently to the membrane by UV-cross linking in a UV Stratalinker. Thereafter, the 
membranes were pre-hybridized for 6 h with Church buffer at 65 °C. The DIG probe was diluted 1:10 
in TE buffer and subsequently denatured at 95 C for 6 min. The membrane was then incubated at 65 C 
with Church buffer containing the DIG-labeled probe overnight. The next day, the membrane was 
washed twice with 2x SSC/0.1% SDS and twice with 0.5x SSC/0.1% SDS (15 min for each wash) and 
equilibrated with MBS washing buffer for 30 min at RT. Upon blocking (30 min, RT), an anti-DIG 
solution containing alkaline phosphatase (AP) (1:1000 dilution, of AP stock (150 mU /ml)) in 
blocking buffer) was applied (30 min, RT). The membrane was washed again, equilibrated in 
developing buffer and incubated with the chemiluminescence substrate for alkaline phosphatase 
(CSPD® solution) for 20 min at 37 °C in the dark. Bands were visualized by exposure to an X-ray 
film (Hyperfilm
TM
) for 2 h at RT. 
2.2.6 Lipid analysis 
2.2.6.1 Tissue preparation  
Skins were incubated in thermolysin buffer (500 µg/mL) at 37 °C for 2 h and subsequently washed 
with PBS. Epidermis was separated from dermis using forceps. Epidermis samples were lyophilized 
and powdered; dry weight was determined. Samples were stored air tight at 4 °C until lipid extraction 
was performed.  
Whole esophagus tissue was collected, directly lyophilized and further processed as described for 
epidermis. 
2.2.6.2 Lipid extraction 
Lipid extraction of lyophilized epidermis and esophagus tissue was performed according to Doering et 
al. with slight modifications (Doering et al., 1999a; Jennemann et al., 2007). In brief, 10–50 mg of 
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epidermis were extracted with 2 mL of chloroform/methanol/distilled water (C/M/W) (30:60:8 v/v) 
under sonication at 50 °C for 15 min. Extracts were centrifuged at ca. 2000×g for 10 min and 
supernatants were collected. Pellets were extracted again as described above using C/M/W (10:10:1 
v/v) and then with C/M (2:1 v/v). The supernatants were pooled with previous fractions and dried 
under air flow at 37 °C. Crude extracts were stored at 4 °C until further extraction. 
Aliquots of crude extracts (2–10 mg) were purified by saponification under mild alkaline conditions 
(0.1 M methanolic KOH, 4 h, 50 °C) to remove phospholipids. Purified extracts were then desalted 
using reverse-phase chromatography (RP-18) columns, air-dried and stored at 4 °C.  
For the extraction of protein-linked sphingolipids (POS), pellets were first subjected to 3 cycles of 
methanol “washings” to remove remaining free lipids and then saponified under mild alkaline 
conditions (1 M methanolic KOH, 2 h, 60 °C) to cleave ester-bonds and to release POS. Supernatants 
were collected, neutralized with 1 M acetic acid, then dried and desalted as previously described 
(Jennemann et al., 2012a).  
2.2.6.3 DEAE-Sephadex A-25 chromatography 
Esophagus crude extracts were subjected to anion-exchange chromatography for the separation of 
neutral and acidic GSLs as previously described (Jennemann et al., 1990). In brief, pasteur pipettes 
were packed with 200 µL of diethylaminoethyl (DEAE-) Sephadex A-25 and equilibrated with 2 mL 
of C/M/W (30:60:8 v/v). Esophagus samples were dissolved in 2 mL of C/M/W (30:60:8 v/v) by 
sonification and loaded onto freshly prepared columns. The eluate was collected directly. Sample vials 
were rinsed twice with 1 mL of C/M/W (30:60:8 v/v) and loaded. After additional washing of the 
columns with 2 mL of C/M/W (30:60:8 v/v) and 2 mL of methanol, the total eluate containing 
unbound, neutral GSLs (fraction 1), which do not bind to the column material, was air-dried by 
evaporation. Acidic GSLs (fraction 2) were eluted with 4 mL of 0.5 M potassium acetate (KAc) in 
methanol, air-dried, and dissolved in H2O to a final salt concentration of 0.1–0.2 M KAc. The salt was 
then removed using RP-18 columns. 
2.2.6.4 High-performance thin-layer chromatography (HPTLC) analysis 
For analysis of GlcCers, aliquots of saponified and nonsaponified crude epidermal extracts and lipid 
standards were dissolved in C/M/W (10:10:1 v/v) prior to loading of 20–40 µL volumes, 
corresponding to 1 mg dw of tissue, on an HPTLC glass plate (10 cm × 20 cm × 0.1 mm; Silicagel 60 
F254 ) using a Linomat IV (CAMAG). After a pre-run with chloroform/acetone (1:1 v/v), GSLs were 
separated using C/M/W (65:25:4 v/v) as running solvents. Plates were sprayed with 0.2% orcinol in 
10% sulfuric acid and developed at 120 °C for ca. 10 min and scanned (ScanMaker i800). For the 
analysis of freely extractable and protein-linked sphingolipids, amounts corresponding to 1 mg of dry 
epidermis in nonsaponified extracts and 0.25 mg of saponified extracts were separated with 
chloroform/methanol/glacial acetic acid (190:9:1 v/v) as running solvent. The plates were then sprayed 
with copper reagent (10% CuSO4 in 8% H3PO4), developed at 180 °C for 5–10 min and scanned 
(ScanMaker i800). 
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2.2.6.5 Quantification by liquid chromatography-electrospray ionization tandem mass 
spectrometry (LC-ESI MS/MS) 
Sphingolipid quantification was performed by tandem mass spectrometry using a Xevo® TQ-S triple-
quadrupole instrument (Waters) equipped with ultra-performance liquid chromatography hardware 
(Acquity UPLC® I-class, Waters) and a nano-electrospray source.  
Lipid extract samples, equivalent to a dried weight of 12.5 µg, were dissolved in 95% methanol 
(1 mL) and mixed with nonendogenous lipid standards prior to analysis. Lipid standards included the 
ceramides (d18:1/14:0), (d18:1/19:0), (d18:1/25:0), (d18:1/31:0), 6.25 pmol each; the GlcCers 
(d18:1/14:0), (d18:1/19:0), (d18:1/25:0), (d18:1/31:0), 3.125 pmol each; and the SMs (d18:1/14:0), 
(d18:1/25:0), (d18:1/31:0), 3.125 pmol each. 
The samples (extract + standard) were injected (10 µL) and separated into the UPLC using a reverse-
phase column (Acquity UPLC® BEH C18, 130 Å 1.7 µm, 2.1 × 50 mm column) which was 
maintained at 40 °C during the analyses. The chromatographic eluent gradient at a constant flow rate 
of 0.45 mL/min is given in the following table. 
 
UPLC-gradient elution of sphingolipids for detection by tandem mass spectrometry.  
Time [min] 
a 
Solvent A [%] 
b 
Solvent B [%] 
c 
Slope 
0.0 100 0 Initial 
0.1 100 0 linear 
0.2 92 8 linear 
5.0 10 90 concave 
5.25 10 90 linear 
5.50 100 0 linear 
6.50 100 0 linear 
a 
Flow rate 0.45 mL/min. 
b
 Solvent A: 95% methanol, 5% water, 0.05% formic acid, 1 mM ammonium formate. 
c
 Solvent B: 99% isopropanol, 1% methanol, 0.05% formic acid, 1 mM ammonium formate. 
 
MS/MS analysis was performed using the positive-ion ESI mode with multiple reaction monitoring 
(MRM) of daughter-ion fragments specific to each lipid class. For quantification, chromatographic 
peak areas corresponding to each specific lipid species were normalized to the peak areas of the 
corresponding internal standards. 
2.2.7 Transepidermal water loss (TEWL) 
The TEWL was determined using a Tewameter TM300 (Courage-Khazaka Electronics) instrument 
according to the manufacturer’s instructions. Mice were shaved and the water evaporation gradient 
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was measured at the skin surface by placing a special probe for small sample areas onto a dry 
depilated area for at least 30 s. The instrument was calibrated before each measurement. 
2.2.8 Stratum corneum pH 
The stratum corneum pH was determined with a skincheck pH Tester (PCE) according to the 
manufacturer’s protocol. In brief, the pH meter was calibrated and the pH electrode was placed on a 
depilated, moisturized area of skin on the back of a mouse for at least 1 min. Measurements were 
performed in duplicates.  
2.2.9 Body temperature 
Body temperature was measured using a rectal thermometer with a special small sensor (Almemo® 
2390-1, sensor: ZA 9040-FS). The sensor was covered with Vaseline and inserted into the rectum of a 
mouse for at least 1 min directly after anesthesia. The core body temperature of Ugcg mutants and 
control mice was determined during weeks 1 and 4 of TAM induction (Figure 14). 
2.2.10 Water deprivation experiments 
Water deprivation experiments were performed before and during TAM induction (weeks 1, 2
 
, 3
 
, 4
 
and 12) to investigate the onset and impact of epidermal barrier perturbations on weight maintenance 
of Ugcg mutants as compared to controls. Once per week control and mutant mice were deprived of 
drinking water for 6 h while their body weight was monitored (Figure 17) 
2.2.11 Time course of Cre-expression 
Long-term Cre-recombinase activity in Rosa26/K14CreERT2 mice was investigated by β-
galactosidase staining (el Marjou et al., 2004; Soriano, 1999). Control mice (Rosa26-
pos./K14CreERT2-neg.) and double mutant mice (Rosa26-pos./K14CreERT2-pos.) were induced once 
with TAM and monitored over 3 months (as Ugcg f / f K14CreERT2 mice). Full thickness skin samples were 
resected and snap-frozen in isopentane pre-cooled with liquid nitrogen and stored at –80 °C. Skin 
cryosections (5 µm) were fixed in 1% PFA Fixative, rinsed twice in PBS, and stained overnight at 
37 °C in X-gal staining solution (see section 2.1.2). The next day, stained sections were washed twice 
with PBS and distilled water and then mounted and visualized with a Biorevo BZ-9000 microscope 
(Keyence).  
2.2.12 Western blotting 
2.2.12.1 Epidermis preparation 
Adult control and mutant mice were depilated in the first week of TAM induction. Two weeks later 
(day 21 of induction), hair-free back skin of mice was collected and incubated in sodium thiocyanate 
buffer [check conc. in Table] for 30 min on ice (Diaz et al., 1977). Skins were rinsed with ice-cold 
PBS and the epidermis was peeled off the dermis using forceps. 
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2.2.12.2 Protein lysate preparation 
Epidermis samples were placed in digitonin lysis buffer and homogenized by sonication (Branson 
Sonifier 250) using five pulses every 30 s for 5 min. Lysates containing epidermal proteins were 
cleared by centrifugation at 21000×g for 15 min. 
2.2.13 Determination of protein concentration using Bradford assay 
The protein concentration in total lysates was dermined by the Bradford method (Bradford, 1976), a 
colorimetric assay based on the dye Brilliant Blue G. The formation of a protein-dye complex causes a 
shift in the absorption maximum of the dye from 465 to 595 nm. Protein-dye mixtures were prepared 
by mixing either 2.5 or 5 µL of lysate with Bradford reagent (Sigma-Aldrich) up to 1 mL. A dilution 
series with BSA standards ranging from 0 to 10 µg/mL dissolved in Bradford reagent was prepared in 
parallel. The absorbance of the protein-dye complex at its maximum at 595 nm was measured for the 
BSA standards and the epidermal lysates. The protein content of each lysate sample was calculated by 
interpolation of their absorbance values on the BSA standard curve. 
2.2.13.1 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Equal amounts of epidermal proteins (50 µg) were separated on 10% polyacrylamide gels by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) according to their molecular weight. 
They were blotted onto nitrocellulose membranes (3-4 h, at 180 mA) and equal loading of protein 
samples was controlled by staining with Ponceau S red solution. Unspecific binding sites were 
blocked with blocking buffer containing 5% milk for 1 h at RT followed by incubation with primary 
antibodies overnight at 4 °C (see 2.1.4.1). As reference proteinβ-actin was used. The next day, 
membranes were washed with PBST buffer (3 times, 10 min each) and incubated with HRP-coupled 
secondary antibody (see 2.1.4.2) for 45–60 min at RT. After repeated washings (3 times, 10 min each), 
antibody binding was detected using the chemiluminescence substrate luminol of the Amersham 
ECL™ western blotting analysis system and exposure of X-ray film (Amersham Hyperfilm ECL). The 
films were scanned (Epson Stylus SX435W multifunctional scanner/printer) and protein bands were 
identified according to their molecular weight using a prestained protein ladder (PageRuler
TM
).  
2.2.14 mRNA isolation and analysis 
2.2.14.1 Sample preparation 
Full-thickness dorsal skin of Ugcg f / f K14CreERT2 mutants and control mice (n = 4, each) was excised 
using an 8-mm biopsy punch.  
2.2.14.2 RNA extraction and DNAse digest 
RNA was directly extracted from skin samples by phenol-chloroform extraction (Chomczynski and 
Sacchi, 2006). Tissue samples were homogenized on ice using an Ultra-Turrax® T25 Basic 
homogenizer. RNA was digested using the Turbo DNA-free™ DNase treatment kit (Ambion). The 
RNA integrity was validated with the Agilent Bioanalyzer 1000.  
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RNA was reverse transcribed into cDNA using SuperScript® II reverse transcriptase (Invitrogen) 
according to the manufacturer´s instructions.  
2.2.14.3 Quantitative reverse transcription PCR (qRT-PCR)  
Real-time qRT-PCR was performed using the Light Cycler® FastStart DNA Master SYBR Green I 
Kit (Roche) under the following conditions. 
 
qRT-PCR conditions 
PCR mix µL PCR program 
a 
T [°C] time [s] 
cDNA (1:10) 2.0 1. Denaturation 95 600 
LC® SYBR Green 2.0 2. Denaturation 95 5 
MgCl2 (25 mM) 1.6 3. Annealing 56 10 
Primers (5 µL each) 2.0 4. Elongation 72 10 
dd H2O 12.4 5. Elongation 72 300 
  6. Elongation 4  
a 
Steps 2 to 4 are repeated for 35 cycles 
 
2.2.14.4 Gene expression profiling 
RNA was isolated and treated with DNAse as described above. The RNA integrity was validated with 
the Agilent Bioanalyzer 1000 and 100 ng of total RNA were further processed using the Ambion WT 
Expression Kit (Ambion) in order to synthesize cDNA, cRNA and finally ss cDNA. The ss cDNA was 
fragmented and labeled with the WT Terminal Labeling and Controls Kit (Affymetrix) and hybridized 
onto GeneChip® Mouse Gene 1.0 ST Arrays according to the manufacturer’s instructions 
(Affymetrix). Experiments were performed as independent triplicates. The microarray chips were 
scanned with a GeneChip® Scanner 3000.  
Quality control and clustering analyses were carried out using the MADMAX (Management and 
Analysis Database for Multi-platform microArray eXperiments) platform of the University of 
Wageningen (https://madmax.bioinformatics.nl). For these steps the Affymetrix CEL files (containing 
the results of the intensity calculations on the pixel values of the original DAT files, including an 
intensity value, standard deviation of the intensity, the number of pixels used to calculate the intensity 
value) were normalized according to the Robust Multi-array Average (RMA) technique (Irizarry et al., 
2003), using the freeware programs R Statistical Package and Bioconductor.  
The data were analyzed using Genomatix ChipInspector (for calculating fold changes) and Genomatix 
Pathway System (GePS). These tools utilize a single probe approach which allows pre-selection of 
differentially expressed genes. A cut-off of 0% false discovery rate (FDR) was applied to identify 
significantly regulated genes. The p-values for analysis of GO enrichment (Table A2) were determined 
Materials und Methods 
 41 
using Genomatix software. All gene expression data will be deposited in NCBI’s Gene Expression 
Omnibus (Edgar et al., 2002) upon acceptance of a manuscript for publication.  
2.2.15 Wound healing experiments 
2.2.15.1 Induction protocol and anesthesia of mice 
After three weeks of TAM induction, mice were anesthetized with 2.5 vol.% isofluran (Abbott, 
Illinois, USA) and wound healing experiments were performed as shown in Figure 9. 
 
Figure 9. Experimental scheme for wound healing.  
TAM-induction and wound healing experiments. Adult mice (7–8 weeks old) or mice with grafted skin 
(5 weeks after grafting) were injected i.p. with TAM (1 mg/mL in sunflower oil) once a week for up to 
four weeks. The hair was removed by depilation in the second week. Three weeks after initiating 
induction, when the epidermal defect was fully established, wounds were applied on the upper back of 
mice and monitored for 9-10 days until wounds were closed in controls. Mice were then sacrificed and 
tissue was collected for further analysis. 
2.2.15.2 Wound application and sample collection 
Full-thickness skin wounds were applied on the upper back of mice using disposable 5-mm biopsy 
punches. Wound size, TEWL and body weight of animals were documented over 9–10 days until 
wounds in control litters were closed. Wounds were collected at 6 h, and on day 2, 6 and 9 following 
wounding using surgical instruments (scissor, forceps) and subsequently fixed in 4% formaldehyde or 
snap-frozen in isopentane precooled with liquid nitrogen.  
2.2.15.3 Wound healing in skin transplants 
Isografting was performed on 7–8 week-old male mice (20 to 25 g). They were anesthetized with 
tribromoethanol (Avertin, Sigma) and full thickness skin (4 × 4 cm) was excised from donor animals 
(control and Ugcg f / f K14CreERT2 mutants) and quickly placed in sterile ice-cold PBS. Skins from acceptor 
animals (control litters) were resected and disposed of. Grafts were sewn on the back of acceptor mice 
using a surgical thread, and edges were covered with a semi-permeable dressing (3M, Neuss, 
Germany). Upon transplantation, mice were single-housed and cages were kept on a heating plate 1-2 
days until recovery. Transplants were fully adapted within 2–3 weeks after grafting. The fur started 
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growing ca. 4 weeks after grafting and had to be shaved before wound healing experiments could be 
performed, as described above. 
2.2.16 Histology and microscopy 
2.2.16.1 Sample preparation 
Skin samples were collected and were either fixed in formalin (4%) overnight at 4 °C or frozen in 
isopentane pre-cooled with liquid nitrogen for cryosectioning. The next day, formalin fixed samples 
were dehydrated in aqueous ethanol solutions of decreasing concentrations (70%, 80%, 96%, 100%) 
and embedded in paraffin. Prior to staining, paraffin sections (ca. 3 µm) were deparaffinized by 
immersion in xylol followed by 100%, 96%, 80% and 70% ethanol and were finally rinsed with 
distilled water. 
2.2.16.2 Staining for light microscopy  
H&E staining 
For routine morphologic analysis, skin and esophagus tissue were stained with hematoxylin and eosin 
(H&E), which highlights basophilic structures (pink; e.g. DNA) and proteins (blue).  
Ki-67 staining 
Keratinocyte proliferation was investigated by Ki-67 staining (pink), which is based on the nuclear 
protein MKI67 associated with proliferation. The procedure was performed using a Dako Autostainer. 
After permeabilization, blocking and an application of primary antibody for MKI67, sections were 
incubated with a biotinylated anti-rat antibody and detected with streptavidin conjugated to alkaline 
phosphatase (dilution 1:200 = 5 µg/mL). 
HR3 & Giemsa staining 
Skin macrophages and dendritic cells were stained using an anti-hematopoiesis-related antibody (ER-
HR3) as described previously (Jennemann et al., 2007). Skin granulocytes and monocytes were stained 
with Giemsa solution (methylene blue-eosin-Azure B). Sections were rinsed with 1% acetic acid and 
sequentially immersed in 96% ethanol, 2-propanol (twice for 2 min) and xylol (ca. 1 min). 
TUNEL staining 
Apoptosis of keratinocytes was investigated by TUNEL staining according to the In Situ Cell 
DeathDetection kit’s instructions (Roche, Mannheim, Germany).  
All sections were mounted with Vitro-Clud® mounting media (Langerbrink) and evaluated by 
counting of respective positive cells in five high-power fields (400×) of each tissue sample (Ki-67, 
HR3, Giemsa staining).  
-Galactosidase (LacZ) staining 
Cryosections (ca. 5 µm) from skins of Rosa26/K14CreERT2 and control mice were subjected to β-
galactosidase staining as previously described (el Marjou et al., 2004). Prior to incubation with X-Gal 
staining buffer overnight at 37 °C, cryosections were fixed in 1% PFA buffer for 15 min and 
subsequently washed with X-Gal washing buffer. The next day, sections were washed, mounted with 
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Vitro-Clud® mounting media and directly visualized using a Biorevo BZ-9000 fluorescence 
microscope (Keyence). 
2.2.16.3 Immunofluorescence microscopy  
For indirect immunofluorescence microscopy, deparaffinized sections were subjected to antigen 
retrieval using 10 mM sodium citrate at pH 6 and 96 °C for 3–5 min and permeabilization with triton 
X-100 in 0.1% PBS at RT for 5 min prior to 1 h blocking with (a) 5% BSA, (b) 5% goat serum or (c) 
mouse blocking solution (Vector Laboratories). Following several washings with PBS (3 times for 5 
min) incubation with primary antibodies (see Materials 2.1.4) was performed for 1 h at RT.  
For the detection of CLDN1, LAMA5 and ITGA6 cryosections (5 µm) were fixed in acetone at RT for 
10 min followed by blocking with 5% BSA for 45 min and subsequent incubation with primary 
antibodies for 1 h at RT.  
Upon several washings with PBS (3 times for 5 min), incubation with secondary antibodies and DAPI 
stain (20 ng/mL, for A-T rich DNA regions) was performed for 30 min at RT. Afterwards, sections 
were washed twice with PBS and 5 min in distilled water. Samples were mounted with FluoroMount 
(Dako) and visualized.  
2.2.16.4 In vivo DNA labeling with EdU 
Mice were injected intraperitoneally with 200 µg of 5-ethynyl-2-deoxyuridine (EdU), a thymidine 
analogue which is incorporated into the DNA of dividing cells. After 24 h mice were sacrificed, and 
skin and esophagus were dissected and embedded in paraffin. Sections of 5 µm thickness were taken, 
and EdU-labeled cells were stained by Click chemistry as described by Salic and Mitchison (Salic and 
Mitchison, 2008). In brief, deparaffinized sections were washed with TBS and incubated with staining 
buffer, containing 10 µM of Alexa Fluor® azide antibody (Invitrogen), for 30 min at RT. The 6-
azidohexanyl group of this antibody reacts with the terminal alkyne of EdU via a copper-catalyzed 
Click reaction. Sections were then washed with TBS and distilled water and subsequently mounted 
with Dako Fluorescent Mounting Medium. 
2.2.16.5 Staining for neutral and phospholipids with Nile red 
Neutral and phospholipids were analyzed as previously reported (Greenspan et al., 1985). 
Cryosections (5 µm) were air-dried, embedded with freshly prepared Nile red (5 mg/mL in 75% 
glycerol) and visualized with a Biorevo BZ-9000 fluorescence microscope.  
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2.2.17 Statistics 
All experiments included a minimum of 3 animals. The results obtained are shown as mean ± SD. All 
statistical tests were performed using GraphPad Prism® 5 software, except for the analysis of the lipid 
data, which was performed with Microsoft Office Excel 2007. Measurements in control (heterozygous 
[Ugcg f / + K14CreERT2], wildtype [Ugcg f / + , Ugcg + / + ]) and Ugcg f / f K14CreERT2 mice were compared by the 
Student’s t-test. Differences between group means were considered significant for p < 0.05 (*), p < 
0.01 (**) and p < 0.001 (***). The statistical methods used for the evaluation of the gene array are 
described in section 2.2.14.4. 
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3.1 The Challenge of TAM Induction and Tissue-specific Ugcg 
Gene Deletion  
Constitutive Ugcg gene deletion (Exon 6-8 removal) in the epidermis and consequent loss of UGCG 
activity and GlcCers synthesis caused disruption of the WPB and premature death of newborn 
Ugcg f / f K14Cre mice (Jennemann et al., 2007). In order to further study the role of Cer glucosylation in 
epidermal differentiation, in particular the function of GlcCers in barrier homeostasis, TAM-inducible 
Ugcg f / f K14CreERT2 mice were generated and investigated after Ugcg gene deletion. 
Control and Ugcg f / f K14CreERT2 mice were initially induced using a generally approved TAM induction 
protocol (el Marjou et al., 2004), which recommends 1 mg TAM per day on five consecutive days in 
the first week and one single injection of 1 mg TAM every second week. With this protocol severe 
health problems developed in Ugcg mutants already in week 2 of induction, hindering the mice to eat 
or drink. Deletion of Ugcg in K14-positive epithelia other than skin (see 3.2.1) was assumed to be 
responsible for the overall weak condition of the mice. However, no alterations in skin morphology or 
epidermal barrier function were observed at this time (see Appendix Figure A2, cf. Figure 14 E). Due 
to the overall health condition of mutant mice, further experiments could not be performed until a 
much lower TAM dose (1 mg TAM injection/week) was chosen (Figure 7), allowing for normal food 
intake and viability of UGCG-deficient mice. 
3.2 Characterization of Inducible Ugcg
 f / f K14CreERT2
 Mice  
3.2.1 Ugcg gene deletion and lack of GlcCers in the esophageal epithelium 
Following TAM induction, Ugcg gene deletion was demonstrated by Southern blot analysis in the 
epidermis and other stratified epithelia, such as tongue, esophagus and forestomach (UGCG-null band; 
Figure 10) where K14-promotor activity had been previously detected (Huelsken et al., 2001). 
However, in newborn Ugcg f / f K14Cre mice activity of this promoter was not evident. The UGCG-null 
band detected in the dermis of adult mutant mice resulted from K14-positive recombinant cells of 
epidermal appendages (e.g., hair follicle outer root sheath keratinocytes) residing in the dermis (Figure 
10). 
Lipid analysis of whole esophagus tissue revealed that EOS-GlcCers were expressed in control 
samples, a result which has not been described previously (Figure 11 A,B). In contast, GlcCers were 
markedly reduced in the esophagus of mutants. No alterations were observed in the acidic GSLs 
(aGSLs), despite the upcoming band in samples from mutants (at the position of the GM1 standard 
band), which was lacking in controls (Figure 11 D). However, this band might derive from GM1-
expressing macrophages infiltrating the esophageal tissue of mutant mice. Furthermore, high amounts 
of GM3, a major ganglioside of muscle tissue, were found in whole tissue extracts of control and 
mutant esophagi (Figure 11 D). 
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Figure 10. Investigation of Ugcg gene recombination.  
Tissue specificity of Ugcg gene recombination was confirmed by Southern blot analysis. 
Recombinations were detected not only in skin but also in tongue, esophagus and forestomach. 
Positivity of dermis tissue was derived from recombinations in K14-positive hair follicle outer root 
sheath keratinocytes. 
Morphologic alterations in the esophageal epithelium of Ugcg-mutant mice were already detected in 
week 2 of TAM induction. The esophagus of mutant mice was dilated and displayed a marked 
decrease in cellular organization and cohesion as compared to controls (Appendix Figure A1 A–F). 
Hyperproliferation was evidenced in all parts of the esophageal tube (cervical, thoracic, abdominal) by 
EdU staining, 24 h after EdU injection. EdU-positive cells were present in the esophageal lumen of 
mutant mice, indicating that a complete epithelial turnover deriving from proliferating basal cells was 
accomplished within ca. 24 h (Appendix Figure A1 A–F). In comparison, only a few EdU-positive 
cells were detectable in epidermis samples of same animals (not shown). 
 
Results 
 48 
 
Figure 11. TLC analysis of esophageal lipid extracts: detection of EOS-GlcCers and evidence 
for the depletion of GlcCers in UGCG-deficient samples. 
To investigate differences in the glycosphingolipid (GSL) pattern of whole esophagus tissue, crude 
extracts (ca. 4 mg dw each) were subjected to anion exchange chromatography (DEAE-Sephadex A-
25) for the separation of neutral (n) and acidic (a) GSLs (Jennemann et al., 1990). (A) TLC of nGSLs 
and subsequent orcinol staining (1.5 mg dw each, crude extracts) revealed the presence in esophagus 
of esterifed EOS-GlcCers (mainly with linoleic acid). All GlcCer species (NS, AS, OS, EOS) were 
reduced by ca. 66% in mutant tissue compared to controls. (B) Further purification of nGSLs by 
saponification and subsequent TLC (1.5 mg dw each) showed that phospholipids, but also EOS, were 
removed. (C) To discriminate GlcCers from GalCers, peracetylation and subsequent perborate 
separation of nGSLs (2 mg dw each) was performed (Jennemann et al., 1990). (D) TLC analysis of 
aGSLs (1.5 mg dw each) showed differences between control and mutant extracts (i.e., at the position 
of GM1 standard), but the exact GSL species could not be identified by TLC. Standards were: human 
spleen extract (St.1); GalCer (St.2); GlcCer (St.3); GM3 (St.4); ganglioside mixture (St.5). 
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3.2.2 Ugcg f / f K14CreERT2 mice exhibit reduced epidermal GlcCers and lack 
protein-linked sphingolipids 
The efficiency of Ugcg deletion was addressed by analysis of the UGCG enzyme products, the 
GlcCers, via 1D-TLC, which separates SL species according to their polarity (Figure 12 A,A). 
Orcinol-staining showed a significant reduction of all free extractable GlcCers (NS, AS, OS, EOS) in 
UGCG-deficient epidermis as compared to controls (Figure 12 A,A). In the epidermis EOS-GlcCers, 
in which the GlcCers are ω-linked predominantly with linoleic acid (Doering et al., 1999a), occur in 
relatively small amounts compared to EOS-Cers. However, EOS-GlcCers were detectable in 
nonsaponified crude extracts of controls and appear as an orcinol-positive band in the GlcCer fraction. 
In contrast, in UGCG-deficient tissue EOS-GlcCers were not detectable, marking a substantial loss of 
barrier lipids. 
A more complex chromatographic pattern was obtained for free extractable Cers (Figure 12 B,B). In 
crude extracts of mutants, most Cers seemed to be reduced (Figure 12 B), whereas in saponified 
extracts (containing nonesterified Cers) compounds running at the positions of the Cer-C16 and -C24 
standards and below were clearly elevated (Figure 12 B).  
Most strikingly, protein-linked POS-SLs, key material for the CLE, were drastically reduced (Figure 
12 C). More specific information concerning individual SL species could not be obtained from the 
TLC results, but was available from MS analyses (Figure 13). 
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Figure 12. Analysis of epidermal lipids via 1D-TLC for control vs. UGCG-deficient mouse 
epidermis. 
Epidermal sphingolipid composition with regard to freely extractable (A, A, B, B) and protein-linked 
sphingolipids (POS-SLs) (C) was investigated by separating the lipids according to their polarity. 
Orcinol staining of GSLs in crude extracts (A) and after alkaline treatment (A) revealed a significant 
reduction of all GlcCers species (NS, AS, OS, EOS) in mutant epidermis. Copper staining of 
extractable Cers (B, B) showed quantitative differences in the Cer profiles for Ugcg
 f / f K14CreERT2
 vs. 
controls. POS-SLs (C) were drastically reduced in epidermal extracts of Ugcg mutants. 
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Figure 13. Mass spectrometric analysis of epidermal sphingolipids and comparison of the 
lamellar lipid structure of the SC for control vs. UGCG-deficient mouse epidermis. 
Epidermal sphingolipids were quantified by LC-ESI MS/MS, showing that free GlcCers (A) as well as 
protein-linked species (POS-GlcCers) (B) were significantly reduced in the epidermis of 
Ugcg
 f / f K14CreERT2
 mutants. The corresponding Cers (C) were significantly increased in mutants 
compared to controls. Among the sphingomyelins (D) the levels of C16 to C36 nonhydroxylated 
species (NS) were the same in mutants and controls, whereas the low levels of ω-hydroxylated ULC-
SMs (OS) significantly increased in mutants. Surprisingly, C16 α-hydroxylated SMs (AS) significantly 
decreased. Under LM (E) Nile Red-stained cryosections alterations in the lipid constitution resulted in 
an abnormal lamellar lipid structure in mutant stratum corneum (SC). Lentil-like lipid aggregates within 
the lamellae of corneocytes were seen by Nile red staining (black arrows). Mean values ± SD are 
shown for n = 4; differences in group means are significant with p < 0.05 (*), p < 0.01 (**), or p < 0.001 
(***). 
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3.2.3 GlcCer depletion leads to a significant loss of protein-linked Cers and 
irregular lipid lamellae in the stratum corneum 
Quantification of sphingolipids by mass spectrometry (LC-ESI MS/MS) corroborated the results 
obtained by TLC. Free extractable GlcCers (NS, AS, OS, EOS) were significantly reduced by ca. 80% 
(Figure 13 A.). The largest reduction (by weight) of ω-hydroxylated (ωh) GlcCers was observed for 
EOS species with hC32:0, hC34:0 or hC36:1 FAs (see Appendix Figure A3), which are generally the 
most abundant ωh-GlcCer species in healthy skin (Doering et al., 1999a). Here the prefix h is used to 
denote a hydroxylated FA, whereby MS can normally only distinguish the number of hydroxyl groups 
(by mass) but not their positions. Generally, the FAs for epidermis SLs will be hydroxylated in 
position α for chain lengths C16 to C26 or in the terminal position ω for > C26.  
An even larger reduction (by 82%) was observed for POS-Cers and the few POS-GlcCers containing 
hC32:0 and hC34:1 FAs, essential barrier lipids (Figure 13 B and Appendix Figure A4 B). The POS-
Cers containing hC32:0 and hC34:1 FAs were the most prominent in control skin but showed the 
highest reduction in mutants (Figure A3 B). Loss of POS-Cers has been observed in several human 
skin diseases such as HI and AD (Akiyama et al., 2005; Macheleidt et al., 2002; Zuo et al., 2008), 
underlining the importance of these species for epidermal barrier function.  
GlcCer-deficient skin showed a significant increase (by 200%) in all free extractable Cers (NS, AS, 
OS, EOS) (Figure 13 C) with FA composition similar to that of the lost GlcCers. Among the ωh-Cers, 
EOS with FAs hC34:1, hC32:0, and hC36:1 were the most abundant in control skin (Figure A3). For 
EOS-Cers in mutant epidermis, the order of decreasing FA abundance was hC34:1, hC32:1, hC36:1, 
hC32:0, hC34:2. For the NS- and AS-Cers in mutant skin, the most abundant FAs were C24:0, 
hC16:0, C16:0, C26:0 and C22:0, in decreasing order (Figure A4).  
The SMs in mutant vs. control mice showed less uniform trends. Total NS-SMs did not change 
significantly (Figure 13 D), while the reduction of NS-SMs containing C17:0, C23:0 or C30:1 FAs 
and AS-SMs with hC16:0 was statistically significant (Figure A4 C). In contrast, the minor amounts of 
OS- and EOS-SMs were significantly elevated in mutants (Figure 13 C, Figure A3 D). The 
quantitative mass spectrometry data for the NS-, AS-, OS- and EOS-SLs are listed in Table A1.  
The observed alterations in epidermal SLs, in particular in barrier lipids (OS, EOS, POS), led us to the 
investigation of the SC lamellar lipid organization. Nile Red staining on cryosections displayed 
orderly structured lipid lamellae in controls, whereas mutant SC was interspersed with granular-like 
lipid aggregates within disordered lamellar sheets (Figure 13 E). 
3.2.4 Ugcg mutants develop an ichthyosiform skin phenotype marked by 
hyperkeratosis and leakiness of the water permeability barrier 
Ugcg f / f K14CreERT2 mice were easily distinguishable from controls in week 3 of TAM induction. The 
mutants exhibited sticky fur, dark tails and pruritus (data not shown). Dry, flaky skin became visible at 
the end of week 3 (Figure 14 A). Ugcg mutants displayed a hyperstratified and hyperkeratotic 
epidermis (Figure 14 B and Appendix Figure A2) with a fivefold increase in epidermal thickness 
(Figure 14 C).  
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Significant weight loss of mutants was observed parallel to increasing TEWL in week 3 (Figure 
14 D,E), indicating the onset of WPB disruption. Mutant mice sufficiently compensated the high water 
loss by increased water uptake (Figure 14 F). As a consequence of high water evaporation via the skin, 
the core body temperature (Figure 14 H) as well as the surface temperature (Appendix Figure A5) of 
mutant mice was reduced in week 4. In addition, impaired barrier function was demonstrated by a 
significant increase in SC pH, (pH 6.1 in mutant versus pH 5.1 in control mice) (Figure 14 G), which 
explains in part the visible loss in SC cohesion and obvious desquamation defect of mutant epidermis. 
3.2.5 Barrier loss provokes keratinocyte hyperproliferation and chronic 
inflammation 
Hyperkeratosis in UGCG-deficient skin was associated with an increase, relative to controls, in the 
number of Ki-67-positive cells in basal, para- and lower suprabasal layers of the epidermis as well as 
in hair follicles (Figure 15 A–C). Furthermore, immune cell activation upon epidermal barrier 
disruption resulted in an increase of ER-HR3-positive dendritic cells/macrophages in mutant skin 
(Figure 15 C–F). No significant difference in granulocytes and mast cells was observed between 
control and mutant mice (Figure 15 G–I). TUNEL staining revealed apoptotic nuclei in the lower and 
upper SC (Appendix Figure A6) indicating a delay in corneocyte maturation but not an increase in 
apoptosis. Control samples were TUNEL-negative. 
 
Results 
 54 
 
Figure 14. Phenotype analysis of control and Ugcg
 f / f K14CreERT2
 mice.  
(A) Ugcg mutants showed dry, scaling skin, greasy fur and impaired hair growth at week 3 of TAM 
induction; scale bar = 0.5 cm. (B) LM with H&E staining revealed a hyperstratifed epidermis in mutants 
(scale bar = 50 µm) with a fivefold increase in epidermal thickness (C) in week 4 of induction. The 
body weight of mutants began to decrease by week 2 (D). In week 3 the epidermal barrier failed, as 
reflected by significant increase of the TEWL (E), water uptake (F) and stratum corneum (SC) pH (G). 
The body temperature of mutants decreased in week 4 (H). In the micrographs dashed lines indicate 
the dermal/epidermal junction zone; the arrow indicates a sebaceous gland; e = epidermis; d = dermis; 
inf = infundibulum; sc = stratum corneum; mean values ± SD are shown with significance of 
differences p < 0.05 (*); p < 0.01 (**); p < 0.001 (***). 
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Figure 15. Ugcg
 f / f K14CreERT2
 mouse skin is hyperproliferative and exhibits increased apoptosis 
and chronic inflammation. 
(A–C) Keratinocyte proliferation, as judged by the number of Ki-67-positive cells, was markedly 
enhanced in mutant skin. (D–F) In addition, macrophages and dendritic cells (ER-HR3 staining) were 
significantly increased, whereas no differences were observed for granulocytes and mast cells (G–I; 
Giemsa staining). Dashed lines indicate the dermal/epidermal junction zone; arrows indicate 
sebaceous glands; e = epidermis; d = dermis; inf = infundibulum; sc = stratum corneum; scale bars = 
50 μm; mean values ± SD are shown; significance of difference, p < 0.001 (***). 
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3.2.6 Partial recovery of epidermal barrier dysfunction implies the action of 
hair follicle stem cells  
Long-term Cre-recombinase (Cre) activity was analyzed in Rosa26/CreERT2 mice in order to 
investigate the enzyme’s persistence after TAM induction by injection on day 1 and day 8 (Figure 
16 A). Cre activity was observed in the epidermis of Rosa26 mutants at all investigated time points but 
not in control skin. The highest activity was observed in weeks 2 and 4 after TAM induction. 
Thereafter, Cre-activity decreased in the epidermis, but persisted even after 12 weeks. However, the 
infundibulum lost positivity approximately 8 to 10 weeks after TAM induction. 
Based on these observations, we decided to investigate whether or not Ugcg f / f K14CreERT2 mice recover 
from the WPB defect over time after TAM induction. Hence, TAM-induced mutants were monitored 
over three months, and the TEWL, water uptake and body weight were documented (Figure 16 B–D).  
Barrier disruption occurred in the end of week 3 (Figure 16 B), indicated by a constantly increasing 
TEWL until week 6. From day 38 onward, water loss and water uptake regressed but remained 
significantly elevated even three months after TAM induction. In contrast, TEWL and water uptake 
values for controls remained at baseline. Body weight gain was slightly lower for mutants vs. controls 
but not significantly different (Figure 16 D). 
In line with the observed decline of Cre-activity in Ros26 reporter mice (in particular within the 
infundibulum), we observed a recovery of the skin phenotype of Ugcg mutants. Dry, scaling skin 
persisted mostly at locations with low hair follicle density, e.g., ear, paw and tail, implying the action 
of K14-negative hair follicle stem cells in epidermal barrier restoration. Nevertheless, the permeability 
barrier did not fully recover, as evidenced by sustained TEWL and water uptake. Furthermore, weight 
loss of mutant mice during 6-h water deprivation experiments was documented once a week for one 
month and at the end of the long-term monitoring period (Figure 17 A–E). In Ugcg-mutants, weight 
loss increased significantly from the third week onwards as compared to controls. These results 
demonstrated the lack of epidermal permeability barrier restoration in GlcCer-depleted skin.  
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Figure 16. Continuous Cre-activity sustains leakiness of the WPB.  
(A) X-gal staining was performed to investigate long-term Cre-recombinase activity in K14CreERT2 
mice by crossing K14CreERT2
–
 with Rosa26 reporter mice (Rosa26/K14CreERT2). Cre-activity was 
strongest in epidermis and hair follicles from week 1 to 4. The staining intensity decreased slightly until 
week 12, and hair follicles stained negative approximately 8 to 10 weeks beyond TAM induction. Ugcg 
mutants and control mice were induced with TAM (two injections) and monitored over the same time 
period as reporter mice. From the onset of barrier pertubations (week 3), transepidermal water loss 
(TEWL; B) and water consumption (C) were significantly higher in mutants. Body weight gain (D) was 
similar in mutant and control mice. Scale bars = 50 μm; mean values ± SD are shown for n ≥ 4; 
significance levels are p < 0.05 (*); p < 0.01 (**); p < 0.001 (***). 
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Figure 17. Body weight loss is significantly higher for UGCG-deficient mice vs. controls during 
6-h water deprivation. 
Water deprivation experiments for one 6-h period in weeks 1-4 and 12 revealed that weight loss for 
mutants vs. controls was initially the same (A, B) but increased significantly following the onset of 
WPB loss in week 3 of TAM induction (C–E). Data for individual mice and mean values ± SD are 
shown; significance of differences: p < 0.05 (*); p < 0.01 (**). 
3.2.7 Early keratinocyte differentiation and epidermal cohesion is disturbed 
Epidermal differentiation is a complex signaling and remodeling process in which proliferating basal 
keratinocytes exit the cell cycle to move upwards and continuously differentiate until they become 
keratin-filled anucleate corneocytes, which finally shed off during desquamation (Candi et al., 2005). 
Immunofluorescence (IF) microscopy was used to characterize keratinocyte maturation by means of 
the keratin expression pattern (red fluorescence). Keratin K14 was normally expressed in the basal 
layer keratinocytes in control skin but was additionally present in all suprabasal layers in the GlcCer-
deficient skin of UGCG-deficient mice, indicating abnormal keratinocyte differentiation (Figure 
18 A,B). Keratin K10 is expressed in the differentiated layers of the SS and SG in control skin. In 
mutants K10 was distributed in the normal manner, including the fivefold multilayered epidermis 
(Figure 18 C,D). Keratin K6, a stress-induced intermediate filament, was present in all nonapoptotic 
epidermal layers in the mutant, reflecting the hyperproliferative state of GlcCer-deficient epidermis, 
but was absent in control skin (Figure 18 E,F). Abnormal keratinocyte differentiation was further 
demonstrated by the presence of numerous nuclear remnants in SC layers of mutant skin, indicating 
not only the inability of GlcCer-deficient keratinocytes to terminally differentiate and shed off during 
desquamation but also an inability to transit into a state of “full apoptosis” (Figure 18 B,F). In 
summary, the epidermis of Ugcg mutants appeared as a disorganized hyperproliferative layer. 
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Figure 18. Early keratinocyte differentiation is delayed in Ugcg
 f / f K14CreERT2
 mice vs. controls. 
Immunofluorescence (IF) microscopy of mouse skin sections (red = a specific keratin antibody, blue = 
nuclear staining with DAPI). In control epidermis (A) keratin K14 was restricted to the basal layer, 
whereas in UGCG-deficient mutants (B) K14 was expressed in all epidermal layers. Keratin K10 
distribution in the SS was normal (C), but a larger number of cell layers was evident in mutant 
epidermis (D). Concomitant with the observed hyperkeratosis, stress-induced keratin K6 was detected 
in mutant epidermis (F) but not in controls (E). Note the nuclear remnants present in stratum corneum 
layers of UGCG-deficient skin, reflecting the delay in terminal keratinocyte differentiation (B, F; 
arrows). e = epidermis; d = dermis; inf = infundibulum; sc = stratum corneum; scale bars = 50 μm. 
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Anchorage of the basal epidermal layer to the underlying basement membrane (BM) is imperative for 
normal keratinocyte maturation and epidermal renewal. Such anchorage is ensured by heterodimeric 
transmembrane receptors, so-called integrins, located in the PM of basal (and outer root sheet) 
keratinocytes. They are composed of an α- and β-subunit connecting the keratin cytoskeleton with 
adhesive proteins of the BM. Integrin-α6β4 (ITGA6B4) is one of the most abundant integrins in basal 
keratinocytes, connecting the keratin cytoskeleton with adhesive proteins in the BM such as laminin-5 
(LAMA5), thereby regulating cell adhesion, proliferation and differentiation (Watt, 2002a). 
Deletion or a loss-of-function mutation (in either subunit) of the integrin has been related to the 
autosomal recessive skin disorder epidermolysis bullosa, causing severe epidermal blistering in 
humans and mice (Ashton et al., 2001). Furthermore, overexpression of ITGA6B4 is a known feature 
of several papillomas and squamous cell carcinomas (Owens et al., 2003). 
IF microscopy of ITGA6 and its binding partner LAMA5 indicated that their expression patterns were 
the same in skin from UGCG-deficient mice and controls (Figure 19) and that these proteins are not 
significantly involved in the observed differentiation defect in mutant skin. Nevertheless, 
determination of the exact cellular localization of these proteins was difficult with IF microscopic 
analysis alone; techniques with higher resolution, such as electon microscopy (EM), should be 
employed.  
To closer examine the epidermal integrity of mutant skin, tight junctions (TJs) and desmosomes were 
investigated with IF microscopy. The expression of TJ protein claudin 1 (CLDN1) (Figure 20 A,B) 
and the desmosomal cadherins desmoglein 1 and desmoglein 2 (DSG1, DSG2) (Figure 20 C,D) were 
detectable in all vital epidermal layers in controls – with DSG2 in the basal and DSG1 in the 
suprabasal strata. Note, the employed desmoglein antibody labeled both isoforms; (Simpson et al., 
2011). Compared to controls, mutant skin showed a slightly weaker punctuate staining which was 
more concentrated at the cell margins of the large hyperproliferative cells and was practically absent in 
the basal layer (Figure 20 D), indicating a reduction of DSG2. Quantitative differences of CLDN1 and 
DSG1/2 in GlcCer-depleted epidermis vs. controls were corroborated by western blotting (Figure 21 
A) and correlate with the leakiness of the epidermal junction barrier in mutants. Furthermore, the 
desmosomal catenin desmoplakin (DSP), was strongly expressed in all viable strata in mutant 
epidermis, as demonstrated by its typical diffuse punctuate staining pattern in the basal and spinous 
layers, and was more concentrated at cell membranes in the upper layers (Figure 20 E,F). These results 
suggest that deficient junction formation (regarding CLDN1 and DSG2) contributes to the epidermal 
barrier loss as well as the leakiness of the SC lipid barrier. 
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Figure 19. Anchorage of basal layer keratinocytes to the underlying basement membrane via 
integrin and laminin is not altered in Ugcg
 f / f K14CreERT2
 mutants vs. controls. 
IF microscopy of mouse skin sections from UGCG-deficient mutants vs. controls. Single IF staining of 
basal cell-specific integrin-6 (red; A, B) or its basement membrane binding partner laminin-5 (green; 
C, D) were performed. Overlays of the two types of protein stainings are shown in E, F to demonstrate 
co-localization. Nuclear staining with DAPI is shown in blue. No differences in the protein staining 
pattern between control and UGCG-deficient skin were observed; e = epidermis; d = dermis; sc = 
stratum corneum; scale bars = 50 μm. 
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Figure 20. Malformation of the junction protein barrier in Ugcg
 f / f K14CreERT2
 mutants vs. 
controls. 
IF microscopy of mouse skin sections from UGCG-deficient mutants and controls (red = a specific 
junction protein antibody; blue = nuclear staining with DAPI). Claudin 1 (A, B) and desmoglein 1 and 
desmoglein 2 (C, D) in SS/SG layers show weaker expression in Ugcg mutant epidermis. 
Desmoplakin (E, F) was detected as a diffuse cytosolic staining in the lower SS of mutant epidermis. 
Note the nuclear remnants present in SC layers of UGCG-deficient skin, reflecting the delay in 
terminal keratinocyte differentiation (D, F; arrows); e = epidermis; d = dermis; sc = stratum corneum; 
scale bars = 50 μm. 
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3.2.8 Corneocyte maturation and cornified envelope formation is impaired 
The CE is formed early during corneocyte maturation. Its formation relies on intracellular synthesis of 
structural proteins which are stored in so-called keratohyalin granules (KGs) in granulocytes, which 
contain large F-granules (profilaggrin) and small L-granules (loricrin). During cornification, polymeric 
profilaggrin is processed into monomeric filaggrin (FLG) units, thus regulating the condensation of 
keratin intermediate filaments in the developing corneocyte. Monomeric FLG is then further processed 
into hydrophilic free amino acids (AA), which function as natural moisturizing factors (NMFs) and 
retain water in the SC (Brown and McLean, 2012).  
In control skin, profilaggrin (proFLG) and FLG were normally located in the outer SG and SC 
whereas in mutant epidermis F-granules were present in almost all suprabasal layers, with highest 
accumulation in the SC (Figure 21 B,C). KGs were more numerous and larger in size throughout SS 
and SG layers of mutant epidermis vs. controls, suggesting a defect in proFLG synthesis and 
processing. Immunoblots (Figure 21 A) supported these results: mono-, di- and trimeric FLG (1 FLG, 
2 FLG, 3 FLG) as well as polymeric FLG (FLG2) were detected in controls but were strongly reduced 
in mutants, where other proFLG peptides of abnormal chain lengths accumulated, giving a diffusive 
staining pattern (Figure 21 A).  
During early CE assembly, involucrin (IVL) shifts from the cytosol to become aligned along the PM 
of granulocytes. At the SG/SC interface, this membrane is gradually replaced by a CE, indicated in 
control epidermis by the polarized staining pattern of IVL (Figure 21 D). In mutants IVL was strongly 
expressed in the cytosol of late SS and SG keratinocytes (Figure 21 E), indicating a delay in IVL 
processing in comparison with controls. Western blotting supported these results by revealing a 
reduced level of IVL in mutants (Figure 21 A).  
Loricrin (LOR) is the major component of the CE (80-85% of total CE weight) and is initially 
expressed late during CE formation. In control skin, LOR expression appeared late at the SG/SC 
interface, whereas mutants displayed an earlier strong cytosolic staining for LOR as well as diffuse 
nuclear staining (Figure 21 F, G), indicating a delay in LOR processing. Western blot results 
demonstrated a large reduction of LOR expression in mutant epidermis (Figure 21 A). The delay in 
terminal keratinocyte differentiation (into anucleate corneocytes) was also apparent in the detection of 
nuclei (blue DAPI staining) in SC keratinocytes (Figure 21 C,G). 
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Figure 21. Impaired cornification and CE formation in Ugcg
 f / f K14CreERT2
 mutants vs. controls. 
Western blot analysis (A) confirmed a deficit in protein expression or impaired processing in mutant 
epidermis. IF microscopy for the terminal differentiation marker (pro)filaggrin (B, C; red) revealed a 
strong dotted-like pattern in the upper epidermal layers of mutant skin. Involucrin (IVL) was expressed 
early in the late stratum spinosum cells in mutants and showed a more cytosolic staining pattern as 
compared to controls (D, E; red). Cornified envelope marker loricrin (LOR) (F, G; red) was strongly 
expressed in the stratum granulosum and stratum corneum (SC) of mutants. Its staining alternated 
throughout the granular layer, but clearly encircled the rim of F-granules in control and mutant skin (G, 
yellow arrows). Note the nuclear remnants (blue DAPI stain) in mutant SC (C, G; white arrows). 
Dashed lines indicate the dermal/epidermal junction zone and the apical margin of the SC, 
respectively; e = epidermis; d = dermis; scale bars = 50 μm. 
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3.2.9 Wound healing of full-thickness skin wounds is delayed in GlcCer-
depleted skin and skin grafts 
An in vivo wound healing model was chosen to investigate the function of GlcCers in epithelial 
differentiation. Wound healing experiments were performed in control and UGCG-deficient skin and 
skin grafts to investigate whether GlcCer-depletion affects reepithelialization. Transplantation 
experiments were conducted to exclude effects of a systemic factor on the outcome of wound healing. 
Control mice with grafted skin from either wild type or Ugcg f / f K14CreERT2 litters were TAM-induced 
five weeks after transplantation, when grafts were fully adapted and hair growth was observed (Figure 
22 A). Skin grafts were shaved previous to initiation of TAM induction (Figure 22B). After three 
weeks of induction, UGCG-deficient grafts were marked by dry scaly patches and pruritus (Figure 22), 
as observed in non-transplanted mutant mice (Figure 14 A). The same TAM induction and wound 
healing protocol was used for grafted and non-grafted mice (see Figure 9). 
Full thickness skin wounds (5 mm in diameter) were applied on the lower back of control and mutant 
mice. Closure of wounds was significantly delayed at all investigated time points in Ugcg mutants vs. 
controls (Figure 23 A-J). Proliferation was investigated by Ki-67 staining and was significantly higher 
in mutant skin vs. controls in the early (6 h) and late (day 6) wound healing phase (Figure 23 K). 
Proliferation in controls at day two of wound healing increased as a normal response to injury.  
To investigate the inflammatory response to wounding, HR3 and Giemsa stainings were performed 
(Figure 23 L,M). HR3-positive dendritic cells and macrophages were significantly increased in wound 
sites of mutant skin at all time points (Figure 23 L). In contrast, Giemsa-positive cells were not 
significantly different between the two groups, at least not during the early wound healing phase, but 
seemed to be slightly elevated in UGCG-deficient skin (Figure 23 M). At day 2, granulocyte numbers 
in control skin increased as a normal response to wounding, and also regressed in the late healing 
phase (at day 6). However, Giemsa-positive cells did not increase in mutant skin during the early 
wound healing phase (at day 2), indicating a delayed or impaired response to wounding. At day 6, 
mainly Giemsa-positive mast cells (not granulocytes) remained slightly elevated in mutant skin as a 
significant effect (Figure 23 M). In sum, dendritic cells and macrophages seemed to be the driving 
cells of an altered inflammatory response to wounding in Ugcg mutants, resulting in a delay in wound 
closure. 
IF staining for the early differentiation markers keratin K14 and K10 revealed reepithelialization of the 
wounds to be completed in controls (Figure 24 A,C) and corresponding grafts (Figure 24 E,G) at day 9 
post wounding. In contrast, wounds of GlcCer-deficient skin (Figure 24 B,D) and skin grafts (Figure 
24 F,H) were not closed, as indicated by the lack of keratin K14- and K10-positive cells in the former 
wound center. 
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Figure 22. Skin grafts before and during TAM induction. 
(A) Grafted skins were fully adapted five weeks post transplantation as indicated by hair growth in both 
control and mutant isografts. (B) Mice were shaved before TAM injection in week 6 after grafting. (C) 
Three weeks later, control grafts appeared normal, whereas UGCG-mutant grafts displayed dry, scaly 
patches and impaired hair growth. Due to pruritus, scratching led to sporadic crusts in lesional skin 
(C). Scale bars = 0.5 cm. 
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Figure 23. Wound healing is delayed in Ugcg
 f / f K14CreERT2
 mice. 
H&E stainings were performed to investigate wound morphology at 6 h (A, B), day 2 (C, D), day 6 (E, 
F) and day 9 (G, H) after wounding. In contrast to controls, wounds of mutant mice were not fully 
reepithelialized by day 9. Wounds were monitored (I) and wound area (J) measured at different time 
points during wound healing, showing a significant delay in wound closure in mutants. Epidermal 
proliferation (K) was significantly enhanced in wound sites of mutants, except for day 2, when 
proliferation increased in controls in response to wounding. HR3-positive macrophages and dendritic 
cells (L) were the predominant immune cells in wound sites of mutant mice. (M) Granulocytes were 
slightly increased in mutant wound sites at 6 h and in controls at day 2 of healing. Cell numbers 
decreased until day 6, but mast cells remained significantly higher in mutant wound sites. d = dermis; 
e = epidermis; m = muscle; wc = wound center; dashed lines = dermal/epidermal junction zone;  = 
hair follicles; scale bars = 600 µm (A-H) or 0.5 cm (I); mean values ± SD are shown for n ≥ 3; 
significance levels for differences:  p < 0.05 (*); p < 0.01 (**); p < 0.001 (***). 
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Figure 24. Reepithelialization is delayed in Ugcg
 f / f K14CreERT2
 mutant skin and skin grafts vs. 
controls. 
At day nine of wound healing, control wounds were fully reepithelialized as demonstrated by IF 
microscopy and staining (red) for keratin K14 (A) and keratin K10 (C) of controls. In contrast, 
reepithelialization was significantly delayed in wounds of mutants stained for K14 (B) and K10 (D). 
Wound healing in skin grafts (E–H) three weeks after TAM induction was also delayed for mutants vs. 
control grafts, as judged by expression of K14 (E,F) and K10 (G,H); d = dermis; e = epidermis; wc = 
wound center; dashed lines indicate dermal/epidermal junction zone;  = infundibulum; scale bars = 
200 μm.  
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3.2.10 Gene expression profiling reveals genes involved in lipid metabolism 
and epidermal development 
In order to identify differentially expressed genes and enriched molecular networks resulting from 
epidermal Ugcg gene deletion, we conducted gene expression profiling and subsequent gene ontology 
(GO) enrichment analyses. Using the Genomatix single-probe approach, a total set of 362 
differentially regulated transcripts was found from which 168 were induced and 194 were suppressed 
in the knockout epidermis (FDR = 0).  
As described above, UGCG-deficient mice showed alterations in epidermal lipid composition and KC 
differentiation. GO enrichment analysis of the altered genes revealed the involvement of biological 
processes related to lipid metabolism (GO:0006629, GO:0008610, GO:0044255) and epidermal 
differentiation/proliferation (GO:0008544, GO:0031424, GO:0009611, GO:050678) (Appendix Table 
A2). The genes corresponding to these specific GO terms are shown in the differential expression plots 
in Figure 25. Selected genes in this collection were further validated by qRT-PCR (Appendix Figure 
A7) and western blot (Figure 25). 
Regarding lipid metabolism, we found in particular upregulated genes which encode for enzymes of 
the Cer synthesis pathway such as (1) desaturase 2 (Degs2, FC 3.5), which catalyzes Cer formation 
from dihydroceramide, (2) neutral sphingomyelinase (Smpd3, FC 2.5), which catalyzes Cer formation 
from plasma-membrane derived SM, (3) sphingosine-1-phosphate phosphatase 2 (Sgpp2, FC 2.6), 
which generates Sph from Sph-1-P, and (4) CerS3 (encoded by the gene Lass3, FC 1.7), which 
converts dihydroceramide into Cer (Figure 25 and Figure 26). 
Furthermore, two genes of the lipoxygenase (LOX) family were significantly altered: the epidermis-
type Alox12b (encoding for 12R-LOX, FC 2.7) and Alox12e (encoding for eLOX-3, FC -4.1) (Figure 
25). LOX enzymes are involved in the arachidonic acid (C20:4, ω–6) metabolism and thereby in 
eicosanoid biosynthesis. The enzymes 12R-LOX and eLOX-3 have been shown to act in concert, and 
lack of one or both of these has been related to SC hyperthickening and epidermal hyperplasia in 
patients with congenital ichthyosis (CI) (reviewed in (Furstenberger et al., 2007)).  
Moreover, the gene encoding for bone morphogenic protein 6 (BMP6), a member of the TGF-β 
family, was downregulated (FC -1.4) in Ugcg-mutant skin (Figure 25). Among the 14 known BMP 
proteins, which are important for normal tissue function ((Schulz and Tseng, 2009)), BMP6 is 
normally expressed in the regenerating epidermis, repressing keratinocyte proliferation and inducing 
differentiation (Werner and Grose, 2003). The lack of Bmp6 mRNA in Ugcg-mutant skin matches the 
phenotype of epidermal hyperplasia and impaired keratinocyte maturation.  
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Figure 25. Evaluation of differentially expressed genes. 
Enrichment analysis of differentially expressed genes (mutant vs. controls) in GSL-depleted skin 
revealed a significant induction of proteins involved in lipid metabolism and signaling (A) as well as in 
epidermal differentiation (B). Numbers in parentheses indicate gene IDs. Arrows indicate the genes for 
the potential regulators PPARβ/δ and FABP5. Induction of these two proteins in mutant epidermis was 
demonstrated by Western blotting (C). () indicates EDC genes; (+) indicates proliferation-related 
genes, i.e., K6 keratins, epigen (Epgn) and heparin-binding EGF-like growth factor (Hbegf); (^) 
indicates kallikreins (Klk14, Klk8). 
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Figure 26. Induction of gene expression for proteins involved in Cer synthesis. 
Gene expression profiling evidenced the upregulation (red arrows) of major Cer-synthesizing enzymes 
in Ugcg mutant skin. Gene names are: CerS3, ceramides synthase 3; Degs2, desaturase 2; Smpd3, 
neutral sphingomyelinase, Sgpp2, sphingosine phosphatase 2; Ugcg, glucosylceramide synthase. 
Numbers in parentheses indicate the fold change (FC) parameter used to quantify changes in 
expression.  
The biggest group of differentially expressed genes was assigned to epidermal 
differentiation/proliferation. For example, we found that the transcriptional activators peroxisome 
proliferator-activated receptor β/δ (Pparβ/δ) and grainyhead-like 3 (Grlh3) were significantly 
upregulated (FC 1.8 and FC 1.5, respectively) (Figure 25). PPARβ/δ has been reported as a regulator 
of lipid transport, lipid signaling and differentiation in KCs (Jiang et al., 2009; Kannan-Thulasiraman 
et al., 2010; Tan et al., 2002). Furthermore, mRNA levels of potential PPARβ/δ target genes involved 
in proliferation and cell survival were significantly enhanced, e.g., members of the EGF family such as 
epigen (Epgn, FC 3.3) and heparin-binding EGF-like growth factor (Hbegf, FC 2.5) as well as lipid 
chaperones such as retinol binding protein 2 (Rbp2, FC 3.1), fatty acid binding protein 5 (Fabp5, FC 
2.1) and cellular retinoic acid-binding protein 2 (Crabp2, FC 1.7).  
Moreover, GRHL3 has been shown to play a pivotal role in differentiation of stratified epithelia, by 
regulating genes of the epidermal differentiation complex (EDC) (Kypriotou et al., 2012). This group 
of genes is altered in various human skin diseases such as lamellar ichthyosis, psoriasis or AD. EDC 
genes can be clustered into three distinct families encoding for (1) CE proteins such as involucrin 
(IVL), loricrin (LOR), small proline rich proteins (SPRR family) and late cornified envelope (LCE) 
proteins; (2) calcium-binding S100 proteins such as S100A8 (calgranulin A), S100A9 (calgranulin B); 
and (3) S100-fused proteins such as filaggrin (FLG), filaggrin-2 (FLG2) and repetin (RPTN), as 
reviewed in (Kypriotou et al., 2012).  
Gene expression profiling uncovered major alterations in the expression of EDC gene members in 
Ugcg mutant skin. For example, Sprr genes (FC 3.2–5.7), Rptn (FC 3.0) (shown in Figure 25) and 
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Lce’s (FC 4.0-5.8, not shown) were upregulated, while Flg2 was downregulated (FC 2.8, not shown). 
Additionally, significant induction was found for the hyperproliferation markers keratin K6 (Krt6b 
(FC 3.9) and Krt6a (FC 5.5)) and the tissue kallikreins Klk14 (FC 3.9) and Klk8 (FC 2.8) (Figure 25). 
The KLKs belong to the group of secretory serine proteases, which are important for regular 
desquamation and/or protein shedding. Upregulation of the EDC genes, keratins K6 and KLKs, has 
been associated with hyperproliferative/inflammatory skin diseases such as psoriasis and AD 
(Bergboer et al., 2011; Iizuka et al., 2004; Komatsu et al., 2007).  
To summarize, the identified gene subsets corroborate the observed phenotypes resulting from Ugcg 
gene deletion at the molecular level. Furthermore, the results obtained by gene expression profiling 
and western blotting suggest PPARβ/δ and FABP5 as potential transcriptional regulators of epidermal 
development. Thus, we propose that alterations in Cer homeostasis affect a PPARβ/δ-mediated 
signaling cascade as a likely mechanism for hyperproliferation in UGCG-deficient epidermis (see 
Discussion 4.4). 
Additionally, analysis with the Genomatix software allowed for the correlation of differentially 
expressed genes to human diseases based on the Medical Subject Headings (MeSH) database 
(http://www.nlm.nih.gov/mesh). In line with the above results, the generated gene sets show the highest 
correlation to cancer and skin diseases such as psoriasis (Appendix Table A3).  
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4.1 Glucosylceramides are Essential Barrier Lipids in Oral 
Stratified Epithelia 
TAM induction of Ugcg f / f K14CreERT2 mice led to Ugcg gene deletion in the epidermis and in other K14-
positive epithelia such as tongue, esophagus and forestomach, representing stratified squamous 
epithelia of the alimentary tract and an oral barrier against noxious luminal contents. The esophageal 
epithelium is rapidly renewed due to the high passage rate of food and mucus (Tobey, 1995).  
In contrast to the epidermis, the esophagus is nonkeratinized and contains a (para)keratotic stratified 
squamous epithelium with typically more polar (GlcCers, cholesterol, phospholipids) than non-polar 
lipids (e.g., Cers) (Diaz-Del Consuelo et al., 2005). However, intercellular lipid lamellae and LB 
structures similar to those in the SC of the epidermis have been described (Elias et al., 1977). In our 
study, lipid analysis of control esophagus demonstrated the presence of GlcCers (NS, AS, OS) and 
most strikingly of linoleic acid-containing EOS-GlcCers, which so far have not been described in 
esophageal tissue. In contrast, the esophagus of Ugcg mutants was almost devoid of GlcCers, in 
particular of EOS-GlcCers, explaining the observed alterations of the epithelial barrier which occurred 
by day 10 of TAM induction. Damage to the esophageal barrier resulted in epithelial 
hyperproliferation, most probably as a compensatory mechanism to rapidly repair the injured tissue. In 
addition to the role of GlcCers in the skin barrier, these results suggest a potential role of EOS-
GlcCers in oral barrier homeostasis, which is to our knowledge a new finding. Investigations of the 
esophageal lipid barrier could be the subject of further studies, in particular with regard to improved 
treatment of human gastroesophageal reflux diseases (GERD).  
4.2 Glucosylceramides are Unique Precursors for Epidermal 
Protein-linked Ceramides  
Based on pathologies of human diseases such as Gaucher’s disease and Harlequin ichthyosis, it has 
been concluded that Cers in the SC derive from glucosylated intermediates delivered by LBs from the 
underlying SG layer (Doering et al., 1999b; Zuo et al., 2008). Results from UGCG-deficient newborn 
mice (Ugcg f / f K14Cre) only partially corroborated this “precursor concept”, since epidermal POS-Cers 
were still present despite the loss of POS-GlcCers (Jennemann et al., 2007).  
In the present study, induction of Ugcg deletion in adult Ugcg f / f K14CreERT2 mice resolved the apparent 
discrepancy by demonstrating that GlcCer-derived POS-Cers are significantly reduced in the mutant 
mice. These data support the hypothesis that the major portion of SC Cers derive from glucosylated 
intermediates (GlcCers) and suggest that Cer glucosylation, a prerequisite for lipid barrier formation, 
precedes the formation of POS-Cers by ω-esterification of Cers to proteins of the CE. Nevertheless, 
EOS-Cers were not lost in GlcCer-deficient skin, but instead accumulated, indicating no direct 
involvement of UGCG in the ω-esterification of FAs to Cers.  
In GlcCer-deficient mice vs. controls the depletion of POS-Cers was accompanied by a significant 
increase in ωh-Cers and SMs. However, the increase in Cers (by ca. 4500 pmol/mg dry epidermis 
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weight) in UGCG-deficient epidermis cannot be accounted for alone by the concomitant loss of 
GlcCers (ca. 670 pmol/mg epidermal dry weight) in these mice. Instead, Cer accumulation might 
result from enhanced de novo Cer synthesis at the ER and/or to a lesser extend from Cer recycling in 
the salvage pathway, as compensation for barrier loss (Geilen et al., 1997; Grubauer et al., 1987). 
Recycling would explain the unchanged and even reduced levels of non-hydroxylated (NS) and α-
hydroxylated (AS) SMs.  
Moreover, long-chain (LC) and very-long-chain (VLC) Cers (C16–C24) are potential regulators of 
various cell fates, as evidenced from studies of human cancers and cancer cell lines. Increased levels 
of specific NS-Cers (C16, C24, C24:1), promote apoptosis and tumor progression (Eto et al., 2006; 
Hartmann et al., 2012; Koybasi et al., 2004; Schiffmann et al., 2009). In Ugcg mutants loss of NS-
GlcCers and a significant increase of the corresponding NS-Cers did not lead to enhanced apoptosis in 
the epidermis (Figure A6), but may be responsible for the observed hyperproliferation and de-
differentiation of GlcCer-deficient keratinocytes, as mediated by the nuclear transcription factor 
PPARβ/δ (see section 4.4). 
4.3 Ceramide Glucosylation is Required for the Formation of a 
Competent Epidermal Permeability Barrier and for Barrier 
Restoration 
GlcCer-deficient mice displayed severe ichthyosiform skin abnormalities within 3 to 4 weeks of 
induction. Hyperkeratosis with elevated TEWL and pH resulted in WPB loss. Morphologic alterations 
appeared to result from the early onset differentiation defect in K14-positive cells of the basal layer. 
UGCG-deficient keratinocytes lost their ability for normal maturation and expressed basal keratin K14 
throughout all epidermal layers. This differentiation defect occurred together with a reduction of the 
junction barrier (involving the tight junction protein CLDN1 and the desmosomal junction proteins 
DSG1, DSG2 and DSP), potentiating the leakiness of the WPB. In patients suffering from congenital 
HI, dehydration becomes a lethal risk factor and results from accumulation of epidermal GlcCers, Cer 
loss and barrier loss. In comparison, GlcCer deficiency in Ugcg f / f K14CreERT2 mice caused similar 
alterations, highlighting Cer glucosylation as a requirement for Cer processing and barrier formation. 
Nevertheless, Ugcg mutants sufficiently compensated the water loss by increasing their water uptake. 
The SC of Ugcg mutants appeared as a thick rigid layer of partially undifferentiated corneocytes. The 
disorder in corneocyte maturation was further associated with altered processing of the terminal 
differentiation markers LOR, and (pro)FLG. Strong cytosolic and nuclear localization of LOR was 
observed in mutant skin and is a feature of loricrin keratoderma, e.g., Vohwinkel’s syndrome (Ishida-
Yamamoto et al., 2000). Furthermore, FLG depletion is characteristic for atopic skin of patients with 
FLG gene mutations (Palmer et al., 2006; Weidinger et al., 2006). Deficient proteolytic cleavage of 
proFLG in mutant skin was demonstrated by western blots which showed diffusive bands of FLG-like 
intermediates, and reduced levels of dimeric, trimeric and polymeric FLG (FLG2). FLG2 is a 250 kDa 
FLG polymer, which was found to be reduced in skin of atopic patients and in mice fed with an 
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essential FA-deficient diet (Hansmann et al., 2012) and displaying a skin phenotype similar to that of 
TAM-induced Ugcg f / f K14CreERT2 mice. Loss of monomeric FLG might not only hinder keratin 
condensation in corneocytes (Sandilands et al., 2009), but also its degradation into water-retaining 
amino acids (e.g., histidine, glutamine, arginine) and their derivatives (e.g., trans-urocanic acid) within 
the SC, thus promoting further dehydration. Loss of the ability to retain water directly affects an 
increase in SC pH, which was indeed higher in mutants than in controls. Many enzymes secreted 
together with the lipids at the upper SG and SG/SC interface are typically found in the 
endosomal/lysosomal compartments and have an acidic activity optimum. Elevation of the SC pH in 
mutants implies reduced activity of such enzymes involved in lipid metabolism (e.g., 
glucosylceramidase, sphingomyelinases, phospholipases) (Fluhr et al., 2001; Holleran et al., 1992; 
Schmuth et al., 2000) and protein shedding (e.g., kallikreins) (Lin et al.; Ohman and Vahlquist, 1998), 
thereby contributing to hypercornification, impaired lamellar membrane formation and loss of barrier 
function.  
Hyperproliferation and hyperkeratosis of UGCG-deficient skin was evidenced by K6-expression and 
increased numbers of Ki-67-positive keratinocytes, including the lower suprabasal layers. In addition, 
enhanced signs of inflammation, i.e., infiltration of HR3-positive macrophages and dendritic cells into 
dermis and epidermis, were observed for mutants vs. controls. Dendritic cells are normally recruited 
by chemotactic stimuli synthesized by keratinocytes (e.g., IL-1, TGFα) (Wang et al., 2004; Werner 
and Grose, 2003). Accordingly, GlcCer-depleted keratinocytes themselves may have activated 
epidermal dendritic cells (e.g., Langerhans cells), dermal-resident cells (e.g., macrophages) or 
peripheral immune-competent cells (e.g., neutrophils) as a stress response to barrier loss.  
During wound healing, a tight regulation of the inflammatory phases is important for efficient 
cutaneous tissue repair, whereas excessive or chronic inflammation can lead to impaired wound 
healing (e.g., diabetic wounds) (Eming et al., 2007). Although, at the onset of wounding, mutant skin 
contained significantly more HR3-positive cells than control skin, the immune response upon 
wounding was similar in mutants and controls and did not alter granulation tissue formation. The lack 
of K14- and K10-positive cells in wound tissue suggested rather a defect in reepithelialization as the 
cause for delayed wound closure. To exclude the possibility of a systemic effect of factors such as 
water and electrolyte loss as well as low body temperature (Figure A5) on delayed wound closure, 
wound healing experiments were performed on skin isografts of control and Ugcg f / f K14CreERT2 mice 
upon TAM induction. These experiments corroborated the delay in keratinization in Ugcg mutants and 
excluded a relevant role for systemic effects. In summary, the pronounced defect in differentiation of 
GlcCer-depleted keratinocytes can explain the delay in wound closure (reepithelialization) and provide 
evidence for a pivotal role of GlcCers in keratinocyte differentiation and barrier restoration.  
4.4 Ceramide Potentially Regulates Keratinocyte Differentiation 
Mediated by Epidermis-type PPARβ/δ 
The molecular events induced upon Ugcg gene deletion in the epidermis were addressed by 
performing gene expression profiling and GO enrichment analysis. The clustering of differentially 
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expressed genes disclosed pathways specifically related to lipid metabolism and epidermal 
development. Genes of the lipid metabolic pathway are involved in (1) Cer synthesis (CerS3, Degs2, 
Smpd3, Sgpp2) (Figure 26), (2) Cer signaling (Pparβ/δ) and (3) lipid transport (Rbp2, Fabp5, Crabp2).  
The upregulation of genes promoting Cer synthesis (Figure 26) clearly supports the lipid results 
obtained from TLC and quantitative MS analysis, demonstrating a significant increase in epidermal 
Cers in Ugcg mutants. The major increase in ωh-ULC-Cers can be accounted for by the blockage of 
Cer processing (Cer glucosylation) in the suprabasal living epidermal layers upon Ugcg gene deletion. 
Additionally, accumulation of LC- and VLC-Cers may result from the upregulation of CerS3 and 
Degs2 genes, thus promoting Cer de novo synthesis as a compensatory mechanism for barrier loss. 
Moreover, induction of Smpd3 and Sgpp2 implies the activation of the salvage pathway (SM 
recycling) in favor of Cer synthesis. Cers (with LC- and VLC-FA moieties) are known for their crucial 
function in cell signaling with the activation of a variety of key enzymes involved in protein 
phosphorylation (e.g., CAPP, PKC, JNK) and phospholipid hydrolysis (e.g., PLA, PLD) (Geilen et al., 
1997; Perry and Hannun, 1998). However, gene expression profiling did not reveal significant 
alterations in expression of the described Cer targets.  
Instead, induction of the Cer-responsive gene Pparβ/δ was conclusive. PPARβ/δis not expressed in 
normal adult skin but is activated by proliferative stimuli such as injury or inflammation, exerting a 
protective effect on keratinocytes and promoting efficient wound healing (Di-Poi et al., 2003). A 
conformational change in PPARβ/δ, as induced by cognate ligands, e.g., C2-ceramide (N-acetyl-D-
sphingosine) and C6-ceramide (N-hexanoyl-D-sphingosine), linoleic acid derivatives, saturated and 
polyunsaturated fatty acids (PUFAs) (Coll et al., 2010; Jiang et al., 2009; Naruhn et al., 2010), leads to 
its activation via heterodimerization with nuclear retinoic X receptors (RXR; in particular RXRα) and 
binding to peroxisome proliferator responsive elements (PPRE) in the promoter region of target genes 
(e.g., Fabp5, Vegf) (Schachtrup et al., 2004; Wang et al., 2006). Both, FABP5 and PPARβ/δ, have 
been suggested as (cooperative) lipid-responsive regulators of transcription in skin. In this context, 
FABP5 may act as either a coactivator of PPARβ/δ, delivering lipophilic ligands to Pparβ/δ in the 
nucleus (Tan et al., 2002), or its gene may act as a target, mediating PPARβ/δ function (Schachtrup et 
al., 2004). As coactivator, FABP5 may be induced by epidermal growth factors (e.g., EPGN, HBEGF) 
in an NF-B-mediated manner (Kannan-Thulasiraman et al., 2010), as observed in hyperproliferative 
settings such as psoriasis, wound healing or cancer (Di-Poi et al., 2003; Kannan-Thulasiraman et al., 
2010; Ogawa et al., 2011). However, in Ugcg mutants mRNA transcription levels of Nf-κb were not 
significantly altered. 
Furthermore, we analyzed PPARβ/δ and FABP5 protein expression in control and mutant epidermis. 
Our results showed a strong induction in GlcCer-deficient skin as compared to controls. The 
expression of both proteins may explain the hyperproliferative state of keratinocytes in Ugcg mutants, 
directed by the alterations in Cer composition. This conclusion was corroborated by the observation of 
enhanced mRNA levels from potential PPARβ/δ target genes such as the lipid transporters (Fabp5, 
Crapb2, Rbp2) and EGF family members (Epgn, Hbegf) (Figure 25) (Han et al., 2009; Morgan et al., 
2010). 
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A proposed mechanism of Cer function inducing keratinocyte proliferation and de-differentiation is 
summarized in Figure 27. However, further evidence is needed to confirm this hypothesis which could 
be the subject of future investigations, e.g., in vitro using a 3D culture system (“skin equivalents”) of 
primary keratinocytes. The cells have been successfully isolated from control and Ugcg-mutant skin, 
and could provide substantial information for elucidating the underlying mechanism of GlcCer-
dependent epithelial cell differentiation.  
 
 
Figure 27. Schematic representation of processes induced upon Ugcg deletion and subsequent 
Cer accumulation in mouse epidermis. 
Elimination of GlcCer synthesis in mutant epidermis leads to Cer accumulation and induction of 
proliferation and de-differentiation processes mediated by the peroxisome proliferator-activated 
receptor β/δ (PPARβ/δ), fatty acid binding protein 5 (FABP5) and potential target genes encoding for 
proteins such as heparin-binding EGF-like growth factor (HBEGF), epigen (EPGN) and fatty acid 
binding protein 5 (FABP5). 
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Intensive investigations over the last two decades led to major advances in SL research and confirmed 
the roles of distinct SLs and GSLs in human skin diseases such as ichthyosis, psoriasis, AD and 
xerosis (Coderch et al., 2003). GlcCer has long been identified as the major GSL in the epidermis, 
comprising ca. 4% of the total epidermal lipid mass (Madison et al., 1986). Its synthesis is known to 
depend on the enzyme UGCG, which catalyzes Cer glucosylation as the initial step in GSL 
biosynthesis. GlcCer itself is thought to function as an intracellular precursor and carrier for 
extracellular Cers. The aim of this thesis project was to prove this hypothesis and, furthermore, to 
investigate the potential role of GlcCer in epithelial cell differentiation using a TAM-inducible tissue-
specific Ugcg knockout mouse model. 
Although no human skin disorder has been directly related to mutations of the Ugcg gene, the UGCG 
enzyme catalyzes the key metabolic step in Cer processing (i.e., glucosylation), and resolution of these 
key steps are important for fully understanding the metabolic functions of Cers, in particular in 
relation to human pathologies such as skin diseases and cancer.  
Previously, UGCG has been shown to be of vital importance during embryogenesis and for the 
epidermal WPB in newborn mice. TAM-inducible Ugcg deletion in adult mice allowed for a longer 
and more detailed investigation of lipid barrier formation. UGCG depletion resulted in a significant 
decrease (by 80%) of epidermal GlcCers and an increase in free extractable Cers and ωh SMs. More 
importantly, protein-linked POS-Cers were significantly reduced, indicating that sequential Cer 
processing was blocked. Hence, we conclude that Cer glucosylation is pivotal for transport and ω-
esterification of Cers into the CE – a prerequisite for barrier formation in the skin and esophagus.  
GlcCer depletion in basal cells directly affected keratinocyte maturation and hampered cornification as 
well as wound reepithelialization.  
Gene expression data were conclusive and pointed to alterations in Cer composition and induction of a 
PPARβ/δ-mediated signaling cascade as a likely mechanism for de-differentiation and 
hyperproliferation in UGCG-deficient epidermis (Figure 27).  
In conclusion, the results of the present thesis work provide important evidence concerning the 
function of GlcCers in epithelial differentiation and barrier homeostasis in the epidermal and 
esophageal epithelium. The underlying mechanism of the observed ichthyosiform defects may be 
regulated by Cers via activation of the nuclear receptor PPARβ/δ and target genes involved in 
epidermal differentiation. In addition, modulation of the inflammatory signaling cascade and 
epidermal healing does occur with a deficiency in UGCG (and in GlcCers) and with an increase in 
epidermal Cers. 
 
 
References 
 81 
 
 
 
 
 
 
6. References 
 
References 
 82 
 
Aerts, J.M., R. Ottenhoff, A.S. Powlson, A. Grefhorst, M. van Eijk, P.F. Dubbelhuis, J. Aten, F. Kuipers, M.J. 
Serlie, T. Wennekes, J.K. Sethi, S. O'Rahilly, and H.S. Overkleeft. 2007. Pharmacological inhibition of 
glucosylceramide synthase enhances insulin sensitivity. Diabetes. 56:1341-1349. 
Akiyama, M., K. Sakai, C. Takayama, T. Yanagi, Y. Yamanaka, J.R. McMillan, and H. Shimizu. 2008. CGI-58 
is an alpha/beta-hydrolase within lipid transporting lamellar granules of differentiated keratinocytes. Am J 
Pathol. 173:1349-1360. 
Akiyama, M., D. Sawamura, Y. Nomura, M. Sugawara, and H. Shimizu. 2003. Truncation of CGI-58 protein 
causes malformation of lamellar granules resulting in ichthyosis in Dorfman-Chanarin syndrome. J Invest 
Dermatol. 121:1029-1034. 
Akiyama, M., Y. Sugiyama-Nakagiri, K. Sakai, J.R. McMillan, M. Goto, K. Arita, Y. Tsuji-Abe, N. Tabata, K. 
Matsuoka, R. Sasaki, D. Sawamura, and H. Shimizu. 2005. Mutations in lipid transporter ABCA12 in 
harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest. 115:1777-1784. 
Angstrom, J., S. Teneberg, and K.A. Karlsson. 1994. Delineation and comparison of ganglioside-binding 
epitopes for the toxins of Vibrio cholerae, Escherichia coli, and Clostridium tetani: evidence for 
overlapping epitopes. Proc Natl Acad Sci U S A. 91:11859-11863. 
Ashton, G.H., P. Sorelli, J.E. Mellerio, F.M. Keane, R.A. Eady, and J.A. McGrath. 2001. Alpha 6 beta 4 integrin 
abnormalities in junctional epidermolysis bullosa with pyloric atresia. Br J Dermatol. 144:408-414. 
Bartke, N., and Y.A. Hannun. 2009. Bioactive sphingolipids: metabolism and function. J Lipid Res. 50 
Suppl:S91-96. 
Bergboer, J.G., G.S. Tjabringa, M. Kamsteeg, I.M. van Vlijmen-Willems, D. Rodijk-Olthuis, P.A. Jansen, J.Y. 
Thuret, M. Narita, A. Ishida-Yamamoto, P.L. Zeeuwen, and J. Schalkwijk. 2011. Psoriasis risk genes of 
the late cornified envelope-3 group are distinctly expressed compared with genes of other LCE groups. 
Am J Pathol. 178:1470-1477. 
Bibel, D.J., R. Aly, and H.R. Shinefield. 1992. Antimicrobial activity of sphingosines. J Invest Dermatol. 
98:269-273. 
Bollinger, C.R., V. Teichgraber, and E. Gulbins. 2005. Ceramide-enriched membrane domains. Biochim Biophys 
Acta. 1746:284-294. 
Bourbon, N.A., J. Yun, and M. Kester. 2000. Ceramide directly activates protein kinase C zeta to regulate a 
stress-activated protein kinase signaling complex. J Biol Chem. 275:35617-35623. 
Bouwstra, J.A., P.L. Honeywell-Nguyen, G.S. Gooris, and M. Ponec. 2003. Structure of the skin barrier and its 
modulation by vesicular formulations. Prog Lipid Res. 42:1-36. 
Brandner, J.M., M. Haftek, and C.M. Niessen. 2010. Adherens junctions, desmosomes and tight junctions in 
epidermal barrier function. The Open Dermatology Journal. 4:14-20. 
Brown, S.J., and W.H. McLean. 2012. One remarkable molecule: filaggrin. J Invest Dermatol. 132:751-762. 
Cameron, D.J., Z. Tong, Z. Yang, J. Kaminoh, S. Kamiyah, H. Chen, J. Zeng, Y. Chen, L. Luo, and K. Zhang. 
2007. Essential role of Elovl4 in very long chain fatty acid synthesis, skin permeability barrier function, 
and neonatal survival. Int J Biol Sci. 3:111-119. 
Candi, E., R. Schmidt, and G. Melino. 2005. The cornified envelope: a model of cell death in the skin. Nat. Rev. 
Mol. Cell Biol. 6:328-340. 
Chalfant, C.E., and S. Spiegel. 2005. Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in 
cell signaling. J Cell Sci. 118:4605-4612. 
Chomczynski, P., and N. Sacchi. 2006. The single-step method of RNA isolation by acid guanidinium 
thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protoc. 1:581-585. 
Coderch, L., O. Lopez, A. de la Maza, and J.L. Parra. 2003. Ceramides and skin function. Am J Clin Dermatol. 
4:107-129. 
Coll, T., E. Barroso, D. Alvarez-Guardia, L. Serrano, L. Salvado, M. Merlos, X. Palomer, and M. Vazquez-
Carrera. 2010. The Role of Peroxisome Proliferator-Activated Receptor beta/delta on the Inflammatory 
Basis of Metabolic Disease. PPAR Res. 2010. 
References 
 83 
De Libero, G., A. Donda, H.J. Gober, V. Manolova, Z. Mazorra, A. Shamshiev, and L. Mori. 2002. A new 
aspect in glycolipid biology: glycosphingolipids as antigens recognized by T lymphocytes. Neurochem 
Res. 27:675-685. 
Demerjian, M., D.A. Crumrine, L.M. Milstone, M.L. Williams, and P.M. Elias. 2006. Barrier dysfunction and 
pathogenesis of neutral lipid storage disease with ichthyosis (Chanarin-Dorfman syndrome). J Invest 
Dermatol. 126:2032-2038. 
Di-Poi, N., L. Michalik, N.S. Tan, B. Desvergne, and W. Wahli. 2003. The anti-apoptotic role of PPARbeta 
contributes to efficient skin wound healing. The Journal of steroid biochemistry and molecular biology. 
85:257-265. 
Diaz-Del Consuelo, I., Y. Jacques, G.P. Pizzolato, R.H. Guy, and F. Falson. 2005. Comparison of the lipid 
composition of porcine buccal and esophageal permeability barriers. Arch Oral Biol. 50:981-987. 
Diaz, L.A., M.R. Heaphy, N.J. Calvanico, T.B. Tomasi, and R.E. Jordon. 1977. Separation of epidermis from 
dermis with sodium thiocyanate. J Invest Dermatol. 68:36-38. 
Doering, T., W.M. Holleran, A. Potratz, G. Vielhaber, P.M. Elias, K. Suzuki, and K. Sandhoff. 1999a. 
Sphingolipid activator proteins are required for epidermal permeability barrier formation. J Biol Chem. 
274:11038-11045. 
Doering, T., R.L. Proia, and K. Sandhoff. 1999b. Accumulation of protein-bound epidermal glucosylceramides 
in beta-glucocerebrosidase deficient type 2 Gaucher mice. FEBS Lett. 447:167-170. 
Drake, D.R., K.A. Brogden, D.V. Dawson, and P.W. Wertz. 2008. Thematic review series: skin lipids. 
Antimicrobial lipids at the skin surface. J Lipid Res. 49:4-11. 
Edgar, R., M. Domrachev, and A.E. Lash. 2002. Gene Expression Omnibus: NCBI gene expression and 
hybridization array data repository. Nucleic Acids Res. 30:207-210. 
el Marjou, F., K.P. Janssen, B.H. Chang, M. Li, V. Hindie, L. Chan, D. Louvard, P. Chambon, D. Metzger, and 
S. Robine. 2004. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. 
Genesis. 39:186-193. 
Elias, P., K.R. Feingold, and M. Fartasch. 2006. The epidermal lamellar body as a multifunctional secretory 
organelle. Skin Barrier:261-272. 
Elias, P.M. 2005. Stratum corneum defensive functions: an integrated view. J Invest Dermatol. 125:183-200. 
Elias, P.M., N.S. McNutt, and D.S. Friend. 1977. Membrane alterations during cornification of mammalian 
squamous epithelia: a freeze-fracture, tracer, and thin-section study. The Anatomical record. 189:577-
594. 
Elias, P.M., M. Schmuth, Y. Uchida, R.H. Rice, M. Behne, D. Crumrine, K.R. Feingold, W.M. Holleran, and D. 
Pharm. 2002. Basis for the permeability barrier abnormality in lamellar ichthyosis. Exp Dermatol. 
11:248-256. 
Elias, P.M., M.L. Williams, M.E. Maloney, J.A. Bonifas, B.E. Brown, S. Grayson, and E.H. Epstein, Jr. 1984. 
Stratum corneum lipids in disorders of cornification. Steroid sulfatase and cholesterol sulfate in normal 
desquamation and the pathogenesis of recessive X-linked ichthyosis. J Clin Invest. 74:1414-1421. 
Eming, S.A., T. Krieg, and J.M. Davidson. 2007. Inflammation in wound repair: molecular and cellular 
mechanisms. J Invest Dermatol. 127:514-525. 
Eto, M., J. Bennouna, O.C. Hunter, M.T. Lotze, and A.A. Amoscato. 2006. Importance of C16 ceramide 
accumulation during apoptosis in prostate cancer cells. Int J Urol. 13:148-156. 
Feingold, K.R. 2007. Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability 
barrier homeostasis. J Lipid Res. 48:2531-2546. 
Fluhr, J.W., and P. Elias. 2002. Stratum corneum pH: Formation and function of the Acid Mantle. Exog. 
Dermatol. 1:163–175. 
Fluhr, J.W., J. Kao, M. Jain, S.K. Ahn, K.R. Feingold, and P.M. Elias. 2001. Generation of free fatty acids from 
phospholipids regulates stratum corneum acidification and integrity. J Invest Dermatol. 117:44-51. 
Furstenberger, G., N. Epp, K.M. Eckl, H.C. Hennies, C. Jorgensen, P. Hallenborg, K. Kristiansen, and P. Krieg. 
2007. Role of epidermis-type lipoxygenases for skin barrier function and adipocyte differentiation. 
Prostaglandins & other lipid mediators. 82:128-134. 
References 
 84 
Furuse, M., M. Hata, K. Furuse, Y. Yoshida, A. Haratake, Y. Sugitani, T. Noda, A. Kubo, and S. Tsukita. 2002. 
Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-
deficient mice. J Cell Biol. 156:1099-1111. 
Geilen, C.C., T. Wieder, and C.E. Orfanos. 1997. Ceramide signalling: regulatory role in cell proliferation, 
differentiation and apoptosis in human epidermis. Arch Dermatol Res. 289:559-566. 
Ghazizadeh, S., and L.B. Taichman. 2001. Multiple classes of stem cells in cutaneous epithelium: a lineage 
analysis of adult mouse skin. EMBO J. 20:1215-1222. 
Greenspan, P., E.P. Mayer, and S.D. Fowler. 1985. Nile red: a selective fluorescent stain for intracellular lipid 
droplets. J Cell Biol. 100:965-973. 
Grubauer, G., K.R. Feingold, and P.M. Elias. 1987. Relationship of epidermal lipogenesis to cutaneous barrier 
function. J Lipid Res. 28:746-752. 
Halprin, K.M. 1972. Epidermal "turnover time"--a re-examination. Br J Dermatol. 86:14-19. 
Hamanaka, S., M. Hara, H. Nishio, F. Otsuka, A. Suzuki, and Y. Uchida. 2002. Human epidermal 
glucosylceramides are major precursors of stratum corneum ceramides. J Invest Dermatol. 119:416-423. 
Han, J., M. Kioi, W.S. Chu, J.L. Kasperbauer, S.E. Strome, and R.K. Puri. 2009. Identification of potential 
therapeutic targets in human head & neck squamous cell carcinoma. Head Neck Oncol. 1:27. 
Hanada, K. 2003. Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim Biophys Acta. 
1632:16-30. 
Hanada, K. 2006. Discovery of the molecular machinery CERT for endoplasmic reticulum-to-Golgi trafficking 
of ceramide. Mol Cell Biochem. 286:23-31. 
Hansmann, B., K. Ahrens, Z. Wu, E. Proksch, U. Meyer-Hoffert, and J.M. Schroder. 2012. Murine filaggrin-2 is 
involved in epithelial barrier function and down-regulated in metabolically induced skin barrier 
dysfunction. Exp Dermatol. 21:271-276. 
Hartmann, D., J. Lucks, S. Fuchs, S. Schiffmann, Y. Schreiber, N. Ferreiros, J. Merkens, R. Marschalek, G. 
Geisslinger, and S. Grosch. 2012. Long chain ceramides and very long chain ceramides have opposite 
effects on human breast and colon cancer cell growth. Int J Biochem Cell Biol. 44:620-628. 
Holleran, W.M., K.R. Feingold, M.Q. Man, W.N. Gao, J.M. Lee, and P.M. Elias. 1991. Regulation of epidermal 
sphingolipid synthesis by permeability barrier function. J Lipid Res. 32:1151-1158. 
Holleran, W.M., Y. Takagi, G. Imokawa, S. Jackson, J.M. Lee, and P.M. Elias. 1992. beta-Glucocerebrosidase 
activity in murine epidermis: characterization and localization in relation to differentiation. J Lipid Res. 
33:1201-1209. 
Hong, K.K., H.R. Cho, W.C. Ju, Y. Cho, and N.I. Kim. 2007. A study on altered expression of serine 
palmitoyltransferase and ceramidase in psoriatic skin lesion. J Korean Med Sci. 22:862-867. 
Hou, S.Y., A.K. Mitra, S.H. White, G.K. Menon, R. Ghadially, and P.M. Elias. 1991. Membrane structures in 
normal and essential fatty acid-deficient stratum corneum: characterization by ruthenium tetroxide 
staining and x-ray diffraction. J Invest Dermatol. 96:215-223. 
Huelsken, J., R. Vogel, B. Erdmann, G. Cotsarelis, and W. Birchmeier. 2001. beta-Catenin controls hair follicle 
morphogenesis and stem cell differentiation in the skin. Cell. 105:533-545. 
Huwiler, A., B. Johansen, A. Skarstad, and J. Pfeilschifter. 2001. Ceramide binds to the CaLB domain of 
cytosolic phospholipase A2 and facilitates its membrane docking and arachidonic acid release. FASEB J. 
15:7-9. 
Ichikawa, S., K. Ozawa, and Y. Hirabayashi. 1998. Molecular cloning and characterization of the mouse 
ceramide glucosyltransferase gene. Biochem Biophys Res Commun. 253:707-711. 
Iizuka, H., H. Takahashi, M. Honma, and A. Ishida-Yamamoto. 2004. Unique keratinization process in psoriasis: 
late differentiation markers are abolished because of the premature cell death. J Dermatol. 31:271-276. 
Irizarry, R.A., B. Hobbs, F. Collin, Y.D. Beazer-Barclay, K.J. Antonellis, U. Scherf, and T.P. Speed. 2003. 
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. 
Biostatistics. 4:249-264. 
Ishida-Yamamoto, A., H. Kato, H. Kiyama, D.K. Armstrong, C.S. Munro, R.A. Eady, S. Nakamura, M. 
Kinouchi, H. Takahashi, and H. Iizuka. 2000. Mutant loricrin is not crosslinked into the cornified cell 
envelope but is translocated into the nucleus in loricrin keratoderma. J Invest Dermatol. 115:1088-1094. 
References 
 85 
Ishida-Yamamoto, A., and M. Kishibe. 2011. Involvement of corneodesmosome degradation and lamellar 
granule transportation in the desquamation process. Med Mol Morphol. 44:1-6. 
Ito, M., Y. Liu, Z. Yang, J. Nguyen, F. Liang, R.J. Morris, and G. Cotsarelis. 2005. Stem cells in the hair follicle 
bulge contribute to wound repair but not to homeostasis of the epidermis. Nat Med. 11:1351-1354. 
Jameson, J., K. Ugarte, N. Chen, P. Yachi, E. Fuchs, R. Boismenu, and W.L. Havran. 2002. A role for skin 
gammadelta T cells in wound repair. Science. 296:747-749. 
Jeckel, D., A. Karrenbauer, K.N. Burger, G. van Meer, and F. Wieland. 1992. Glucosylceramide is synthesized 
at the cytosolic surface of various Golgi subfractions. J Cell Biol. 117:259-267. 
Jennemann, R., S. Kaden, R. Sandhoff, V. Nordstrom, S. Wang, M. Volz, S. Robine, N. Amen, U. Rothermel, H. 
Wiegandt, and H.J. Grone. 2012a. Glycosphingolipids are essential for intestinal endocytic function. J 
Biol Chem. 287:32598-32616. 
Jennemann, R., M. Rabionet, K. Gorgas, S. Epstein, A. Dalpke, U. Rothermel, A. Bayerle, F. van der Hoeven, S. 
Imgrund, J. Kirsch, W. Nickel, K. Willecke, H. Riezman, H.J. Grone, and R. Sandhoff. 2012b. Loss of 
ceramide synthase 3 causes lethal skin barrier disruption. Human molecular genetics. 21:586-608. 
Jennemann, R., A. Rodden, B.L. Bauer, H.D. Mennel, and H. Wiegandt. 1990. Glycosphingolipids of human 
gliomas. Cancer Res. 50:7444-7449. 
Jennemann, R., R. Sandhoff, L. Langbein, S. Kaden, U. Rothermel, H. Gallala, K. Sandhoff, H. Wiegandt, and 
H.J. Grone. 2007. Integrity and barrier function of the epidermis critically depend on glucosylceramide 
synthesis. J Biol Chem. 282:3083-3094. 
Jennemann, R., R. Sandhoff, S. Wang, E. Kiss, N. Gretz, C. Zuliani, A. Martin-Villalba, R. Jager, H. Schorle, M. 
Kenzelmann, M. Bonrouhi, H. Wiegandt, and H.J. Grone. 2005. Cell-specific deletion of 
glucosylceramide synthase in brain leads to severe neural defects after birth. Proc Natl Acad Sci U S A. 
102:12459-12464. 
Jiang, Y.J., Y. Uchida, B. Lu, P. Kim, C. Mao, M. Akiyama, P.M. Elias, W.M. Holleran, C. Grunfeld, and K.R. 
Feingold. 2009. Ceramide stimulates ABCA12 expression via peroxisome proliferator-activated receptor 
{delta} in human keratinocytes. J Biol Chem. 284:18942-18952. 
Jobard, F., C. Lefevre, A. Karaduman, C. Blanchet-Bardon, S. Emre, J. Weissenbach, M. Ozguc, M. Lathrop, 
J.F. Prud'homme, and J. Fischer. 2002. Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) 
are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 
17p13.1. Human molecular genetics. 11:107-113. 
Kannagi, R., M. Izawa, T. Koike, K. Miyazaki, and N. Kimura. 2004. Carbohydrate-mediated cell adhesion in 
cancer metastasis and angiogenesis. Cancer Sci. 95:377-384. 
Kannan-Thulasiraman, P., D.D. Seachrist, G.H. Mahabeleshwar, M.K. Jain, and N. Noy. 2010. Fatty acid-
binding protein 5 and PPARbeta/delta are critical mediators of epidermal growth factor receptor-induced 
carcinoma cell growth. J Biol Chem. 285:19106-19115. 
Karlsson, K.A. 1989. Animal glycosphingolipids as membrane attachment sites for bacteria. Annu Rev Biochem. 
58:309-350. 
Katz, P.O., L.B. Gerson, and M.F. Vela. 2013. Guidelines for the Diagnosis and Management of 
Gastroesophageal Reflux Disease. Am J Gastroenterol. 
Kendall, A.C., and A. Nicolaou. 2012. Bioactive lipid mediators in skin inflammation and immunity. Prog Lipid 
Res. 52:141-164. 
Keusch, G.T., M. Jacewicz, M. Mobassaleh, and A. Donohue-Rolfe. 1991. Shiga toxin: intestinal cell receptors 
and pathophysiology of enterotoxic effects. Rev Infect Dis. 13 Suppl 4:S304-310. 
Kirschner, N., P. Houdek, M. Fromm, I. Moll, and J.M. Brandner. 2010. Tight junctions form a barrier in human 
epidermis. Eur J Cell Biol. 89:839-842. 
Kolter, T., R.L. Proia, and K. Sandhoff. 2002. Combinatorial ganglioside biosynthesis. J Biol Chem. 277:25859-
25862. 
Komatsu, N., K. Saijoh, C. Kuk, A.C. Liu, S. Khan, F. Shirasaki, K. Takehara, and E.P. Diamandis. 2007. 
Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. Exp 
Dermatol. 16:513-519. 
References 
 86 
Koybasi, S., C.E. Senkal, K. Sundararaj, S. Spassieva, J. Bielawski, W. Osta, T.A. Day, J.C. Jiang, S.M. 
Jazwinski, Y.A. Hannun, L.M. Obeid, and B. Ogretmen. 2004. Defects in cell growth regulation by 
C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J 
Biol Chem. 279:44311-44319. 
Kypriotou, M., M. Huber, and D. Hohl. 2012. The human epidermal differentiation complex: cornified envelope 
precursors, S100 proteins and the 'fused genes' family. Exp Dermatol. 21:643-649. 
Lahiri, S., and A.H. Futerman. 2007. The metabolism and function of sphingolipids and glycosphingolipids. Cell 
Mol Life Sci. 64:2270-2284. 
Lavie, Y., H. Cao, S.L. Bursten, A.E. Giuliano, and M.C. Cabot. 1996. Accumulation of glucosylceramides in 
multidrug-resistant cancer cells. J Biol Chem. 271:19530-19536. 
Levade, T., N. Andrieu-Abadie, B. Segui, N. Auge, M. Chatelut, J.P. Jaffrezou, and R. Salvayre. 1999. 
Sphingomyelin-degrading pathways in human cells role in cell signalling. Chem Phys Lipids. 102:167-
178. 
Li, W., R. Sandhoff, M. Kono, P. Zerfas, V. Hoffmann, B.C. Ding, R.L. Proia, and C.X. Deng. 2007. Depletion 
of ceramides with very long chain fatty acids causes defective skin permeability barrier function, and 
neonatal lethality in ELOVL4 deficient mice. Int J Biol Sci. 3:120-128. 
Lin, T.K., D. Crumrine, L.D. Ackerman, J.L. Santiago, T. Roelandt, Y. Uchida, M. Hupe, G. Fabrias, J.L. Abad, 
R.H. Rice, and P.M. Elias. Cellular changes that accompany shedding of human corneocytes. J Invest 
Dermatol. 132:2430-2439. 
Liu, Y., Y. Su, M. Wiznitzer, O. Epifano, and S. Ladisch. 2008. Ganglioside depletion and EGF responses of 
human GM3 synthase-deficient fibroblasts. Glycobiology. 18:593-601. 
Macheleidt, O., H.W. Kaiser, and K. Sandhoff. 2002. Deficiency of epidermal protein-bound omega-
hydroxyceramides in atopic dermatitis. J Invest Dermatol. 119:166-173. 
Madison, K.C. 2003. Barrier function of the skin: "la raison d'etre" of the epidermis. J Invest Dermatol. 121:231-
241. 
Madison, K.C., P.W. Wertz, J.S. Strauss, and D.T. Downing. 1986. Lipid composition of cultured murine 
keratinocytes. J Invest Dermatol. 87:253-259. 
Marekov, L.N., and P.M. Steinert. 1998. Ceramides are bound to structural proteins of the human foreskin 
epidermal cornified cell envelope. J Biol Chem. 273:17763-17770. 
Markwell, M.A., L. Svennerholm, and J.C. Paulson. 1981. Specific gangliosides function as host cell receptors 
for Sendai virus. Proc Natl Acad Sci U S A. 78:5406-5410. 
Masukawa, Y., H. Narita, E. Shimizu, N. Kondo, Y. Sugai, T. Oba, R. Homma, J. Ishikawa, Y. Takagi, T. 
Kitahara, Y. Takema, and K. Kita. 2008. Characterization of overall ceramide species in human stratum 
corneum. J Lipid Res. 49:1466-1476. 
McGovern, M.M., and E.H. Schuchman. 1993. Acid Sphingomyelinase Deficiency. 
Melton, J.L., P.W. Wertz, D.C. Swartzendruber, and D.T. Downing. 1987. Effects of essential fatty acid 
deficiency on epidermal O-acylsphingolipids and transepidermal water loss in young pigs. Biochim 
Biophys Acta. 921:191-197. 
Mertens, A.E., T.P. Rygiel, C. Olivo, R. van der Kammen, and J.G. Collard. 2005. The Rac activator Tiam1 
controls tight junction biogenesis in keratinocytes through binding to and activation of the Par polarity 
complex. J Cell Biol. 170:1029-1037. 
Mizukoshi, K., K. Matsumoto, R. Hirose, T. Fujita, A. Ishida-Yamamoto, and H. Iizuka. 2011. Effects of serine 
palmitoyltransferase inhibitor ISP-I on the stratum corneum of intact mouse skin. Biol Pharm Bull. 
34:1383-1389. 
Morgan, E., P. Kannan-Thulasiraman, and N. Noy. 2010. Involvement of Fatty Acid Binding Protein 5 and 
PPARbeta/delta in Prostate Cancer Cell Growth. PPAR Res. 2010. 
Naruhn, S., W. Meissner, T. Adhikary, K. Kaddatz, T. Klein, B. Watzer, S. Muller-Brusselbach, and R. Muller. 
2010. 15-hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor 
beta/delta agonist. Molecular pharmacology. 77:171-184. 
Natoli, T.A., L.A. Smith, K.A. Rogers, B. Wang, S. Komarnitsky, Y. Budman, A. Belenky, N.O. Bukanov, W.R. 
Dackowski, H. Husson, R.J. Russo, J.A. Shayman, S.R. Ledbetter, J.P. Leonard, and O. Ibraghimov-
References 
 87 
Beskrovnaya. 2010. Inhibition of glucosylceramide accumulation results in effective blockade of 
polycystic kidney disease in mouse models. Nat Med. 16:788-792. 
Nemes, Z., L.N. Marekov, L. Fesus, and P.M. Steinert. 1999. A novel function for transglutaminase 1: 
attachment of long-chain omega-hydroxyceramides to involucrin by ester bond formation. Proc Natl 
Acad Sci U S A. 96:8402-8407. 
Nordström, V., M. Willershäuser, S. Herzer, J. Rozman, O. von Bohlen und Halbach, S. Meldner, U. Rothermel, 
S. Kaden, F.C. Roth, C. Waldeck, N. Gretz, M. Hrabeˇ de Angelis, A. Draguhn, M. Klingenspor, H.-J. 
Gröne, and R. Jennemann. 2013. Neuronal Expression of Glucosylceramide Synthase in Central Nervous 
System Regulates Body Weight and Energy Homeostasis. Plos Biology. 11. 
Ogawa, E., Y. Owada, S. Ikawa, Y. Adachi, T. Egawa, K. Nemoto, K. Suzuki, T. Hishinuma, H. Kawashima, H. 
Kondo, M. Muto, S. Aiba, and R. Okuyama. 2011. Epidermal FABP (FABP5) regulates keratinocyte 
differentiation by 13(S)-HODE-mediated activation of the NF-kappaB signaling pathway. J Invest 
Dermatol. 131:604-612. 
Ohman, H., and A. Vahlquist. 1998. The pH gradient over the stratum corneum differs in X-linked recessive and 
autosomal dominant ichthyosis: a clue to the molecular origin of the "acid skin mantle"? J Invest 
Dermatol. 111:674-677. 
Owens, D.M., M.R. Romero, C. Gardner, and F.M. Watt. 2003. Suprabasal alpha6beta4 integrin expression in 
epidermis results in enhanced tumourigenesis and disruption of TGFbeta signalling. J Cell Sci. 116:3783-
3791. 
Palmer, C.N., A.D. Irvine, A. Terron-Kwiatkowski, Y. Zhao, H. Liao, S.P. Lee, D.R. Goudie, A. Sandilands, 
L.E. Campbell, F.J. Smith, G.M. O'Regan, R.M. Watson, J.E. Cecil, S.J. Bale, J.G. Compton, J.J. 
DiGiovanna, P. Fleckman, S. Lewis-Jones, G. Arseculeratne, A. Sergeant, C.S. Munro, B. El Houate, K. 
McElreavey, L.B. Halkjaer, H. Bisgaard, S. Mukhopadhyay, and W.H. McLean. 2006. Common loss-of-
function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic 
dermatitis. Nat Genet. 38:441-446. 
Perry, D.K., and Y.A. Hannun. 1998. The role of ceramide in cell signaling. Biochim Biophys Acta. 1436:233-
243. 
Pewzner-Jung, Y., S. Ben-Dor, and A.H. Futerman. 2006. When do Lasses (longevity assurance genes) become 
CerS (ceramide synthases)?: Insights into the regulation of ceramide synthesis. J Biol Chem. 281:25001-
25005. 
Potten, C.S., R. Saffhill, and H.I. Maibach. 1987. Measurement of the transit time for cells through the epidermis 
and stratum corneum of the mouse and guinea-pig. Cell and tissue kinetics. 20:461-472. 
Pruett, S.T., A. Bushnev, K. Hagedorn, M. Adiga, C.A. Haynes, M.C. Sullards, D.C. Liotta, and A.H. Merrill, Jr. 
2008. Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols. J Lipid Res. 49:1621-
1639. 
Rabionet , M. 2011. Ceramide synthase 3 and its essential role in skin barrier function and male fertility. 
Dissertation. 
Raffaghello, L., D. Marimpietri, G. Pagnan, F. Pastorino, E. Cosimo, C. Brignole, M. Ponzoni, and P.G. 
Montaldo. 2003. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention 
of neuroblastoma relapse. Cancer Lett. 197:205-209. 
Raja, K. Sivamani, M.S. Garcia, and R.R. Isseroff. 2007. Wound re-epithelialization: modulating keratinocyte 
migration in wound healing. Front Biosci. 12:2849-2868. 
Rodriguez, C.I., F. Buchholz, J. Galloway, R. Sequerra, J. Kasper, R. Ayala, A.F. Stewart, and S.M. Dymecki. 
2000. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet. 25:139-140. 
Rosenwald, A.G., and R.E. Pagano. 1993. Intracellular transport of ceramide and its metabolites at the Golgi 
complex: insights from short-chain analogs. Adv Lipid Res. 26:101-118. 
Salic, A., and T.J. Mitchison. 2008. A chemical method for fast and sensitive detection of DNA synthesis in 
vivo. Proc Natl Acad Sci U S A. 105:2415-2420. 
Sandhoff, K. 1969. Variation of beta-N-acetylhexosaminidase-pattern in Tay-Sachs disease. FEBS Lett. 4:351-
354. 
Sandhoff, R. 2009. Very long chain sphingolipids: tissue expression, function and synthesis. FEBS Lett. 
584:1907-1913. 
References 
 88 
Sandilands, A., C. Sutherland, A.D. Irvine, and W.H. McLean. 2009. Filaggrin in the frontline: role in skin 
barrier function and disease. J Cell Sci. 122:1285-1294. 
Sato, J., M. Denda, J. Nakanishi, J. Nomura, and J. Koyama. 1998. Cholesterol sulfate inhibits proteases that are 
involved in desquamation of stratum corneum. J Invest Dermatol. 111:189-193. 
Schachtrup, C., T. Emmler, B. Bleck, A. Sandqvist, and F. Spener. 2004. Functional analysis of peroxisome-
proliferator-responsive element motifs in genes of fatty acid-binding proteins. The Biochemical journal. 
382:239-245. 
Schiffmann, S., J. Sandner, K. Birod, I. Wobst, C. Angioni, E. Ruckhaberle, M. Kaufmann, H. Ackermann, J. 
Lotsch, H. Schmidt, G. Geisslinger, and S. Grosch. 2009. Ceramide synthases and ceramide levels are 
increased in breast cancer tissue. Carcinogenesis. 30:745-752. 
Schmuth, M., C.M. Haqq, W.J. Cairns, J.C. Holder, S. Dorsam, S. Chang, P. Lau, A.J. Fowler, G. Chuang, A.H. 
Moser, B.E. Brown, M. Mao-Qiang, Y. Uchida, K. Schoonjans, J. Auwerx, P. Chambon, T.M. Willson, 
P.M. Elias, and K.R. Feingold. 2004. Peroxisome proliferator-activated receptor (PPAR)-beta/delta 
stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol. 122:971-983. 
Schmuth, M., M.Q. Man, F. Weber, W. Gao, K.R. Feingold, P. Fritsch, P.M. Elias, and W.M. Holleran. 2000. 
Permeability barrier disorder in Niemann-Pick disease: sphingomyelin-ceramide processing required for 
normal barrier homeostasis. J Invest Dermatol. 115:459-466. 
Schulz, T.J., and Y.H. Tseng. 2009. Emerging role of bone morphogenetic proteins in adipogenesis and energy 
metabolism. Cytokine & growth factor reviews. 20:523-531. 
Simpson, C.L., D.M. Patel, and K.J. Green. 2011. Deconstructing the skin: cytoarchitectural determinants of 
epidermal morphogenesis. Nat Rev Mol Cell Biol. 12:565-580. 
Soriano, P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 21:70-71. 
Sprong, H., B. Kruithof, R. Leijendekker, J.W. Slot, G. van Meer, and P. van der Sluijs. 1998. UDP-
galactose:ceramide galactosyltransferase is a class I integral membrane protein of the endoplasmic 
reticulum. J Biol Chem. 273:25880-25888. 
Tan, N.S., G. Icre, A. Montagner, B. Bordier-ten-Heggeler, W. Wahli, and L. Michalik. 2007. The nuclear 
hormone receptor peroxisome proliferator-activated receptor beta/delta potentiates cell chemotactism, 
polarization, and migration. Mol Cell Biol. 27:7161-7175. 
Tan, N.S., N.S. Shaw, N. Vinckenbosch, P. Liu, R. Yasmin, B. Desvergne, W. Wahli, and N. Noy. 2002. 
Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors 
in regulating transcription. Mol Cell Biol. 22:5114-5127. 
Thudichum, J.L.W. 1884. A treatise on the chemical constitution of the brain. 
Tobey, N.A. 1995. How does the esophageal epithelium maintain its integrity? Digestion. 56 Suppl 1:45-50. 
Uchida, Y., and S. Hamanaka. 2006. Stratum Corneum Ceramides: Function, Origins, and Therapeutic 
Applications. Skin Barrier:43-64. 
Uchida, Y., M. Hara, H. Nishio, E. Sidransky, S. Inoue, F. Otsuka, A. Suzuki, P.M. Elias, W.M. Holleran, and S. 
Hamanaka. 2000. Epidermal sphingomyelins are precursors for selected stratum corneum ceramides. J 
Lipid Res. 41:2071-2082. 
van Echten-Deckert, G., A. Klein, T. Linke, T. Heinemann, J. Weisgerber, and K. Sandhoff. 1997. Turnover of 
endogenous ceramide in cultured normal and Farber fibroblasts. J Lipid Res. 38:2569-2579. 
Van Kaer, L. 2005. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat 
Rev Immunol. 5:31-42. 
Vielhaber, G., S. Pfeiffer, L. Brade, B. Lindner, T. Goldmann, E. Vollmer, U. Hintze, K.P. Wittern, and R. 
Wepf. 2001. Localization of ceramide and glucosylceramide in human epidermis by immunogold electron 
microscopy. J Invest Dermatol. 117:1126-1136. 
Wang, D., H. Wang, Y. Guo, W. Ning, S. Katkuri, W. Wahli, B. Desvergne, S.K. Dey, and R.N. DuBois. 2006. 
Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer 
progression. Proc Natl Acad Sci U S A. 103:19069-19074. 
Wang, X.P., M. Schunck, K.J. Kallen, C. Neumann, C. Trautwein, S. Rose-John, and E. Proksch. 2004. The 
interleukin-6 cytokine system regulates epidermal permeability barrier homeostasis. J Invest Dermatol. 
123:124-131. 
References 
 89 
Watt, F.M. 2002a. Role of integrins in regulating epidermal adhesion, growth and differentiation. EMBO J. 
21:3919-3926. 
Watt, F.M. 2002b. The stem cell compartment in human interfollicular epidermis. J Dermatol Sci. 28:173-180. 
Weerheim, A., and M. Ponec. 2001. Determination of stratum corneum lipid profile by tape stripping in 
combination with high-performance thin-layer chromatography. Arch Dermatol Res. 293:191-199. 
Weidinger, S., T. Illig, H. Baurecht, A.D. Irvine, E. Rodriguez, A. Diaz-Lacava, N. Klopp, S. Wagenpfeil, Y. 
Zhao, H. Liao, S.P. Lee, C.N. Palmer, C. Jenneck, L. Maintz, T. Hagemann, H. Behrendt, J. Ring, M.M. 
Nothen, W.H. McLean, and N. Novak. 2006. Loss-of-function variations within the filaggrin gene 
predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol. 118:214-219. 
Werner, S., and R. Grose. 2003. Regulation of wound healing by growth factors and cytokines. Physiological 
reviews. 83:835-870. 
Wertz, P.W. 2006. Biochemistry of human stratum corneum lipids. Skin Barrier. 
Wertz, P.W., P.S. Cox, C.A. Squier, and D.T. Downing. 1986. Lipids of epidermis and keratinized and non-
keratinized oral epithelia. Comp Biochem Physiol B. 83:529-531. 
Westwick, J.K., A.E. Bielawska, G. Dbaibo, Y.A. Hannun, and D.A. Brenner. 1995. Ceramide activates the 
stress-activated protein kinases. J Biol Chem. 270:22689-22692. 
Wood, L.C., S.M. Jackson, P.M. Elias, C. Grunfeld, and K.R. Feingold. 1992. Cutaneous barrier perturbation 
stimulates cytokine production in the epidermis of mice. J Clin Invest. 90:482-487. 
Yamashita, T., A. Hashiramoto, M. Haluzik, H. Mizukami, S. Beck, A. Norton, M. Kono, S. Tsuji, J.L. Daniotti, 
N. Werth, R. Sandhoff, K. Sandhoff, and R.L. Proia. 2003. Enhanced insulin sensit ivity in mice lacking 
ganglioside GM3. Proc Natl Acad Sci U S A. 100:3445-3449. 
Yang, L., F. Francois, and Z. Pei. 2012. Molecular pathways: pathogenesis and clinical implications of 
microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res. 18:2138-2144. 
Yates, A.J. 1986. Gangliosides in the nervous system during development and regeneration. Neurochem Pathol. 
5:309-329. 
Zuo, Y., D.Z. Zhuang, R. Han, G. Isaac, J.J. Tobin, M. McKee, R. Welti, J.L. Brissette, M.L. Fitzgerald, and 
M.W. Freeman. 2008. ABCA12 maintains the epidermal lipid permeability barrier by facilitating 
formation of ceramide linoleic esters. J Biol Chem. 283:36624-36635. 
 
 
 
 
Appendix 
 90 
 
 
 
 
 
 
7. Appendix 
 
Appendix 
 91 
7.1 Supplementary Figures 
 
Figure A1. Epithelial alterations 
and hyperproliferation in 
esophageal tissue are observed 
already on day 10 after initiation of 
TAM induction. 
LM of H&E-stained cervical (A, B), 
thoracic (C, D) and abdominal (E, F) 
esophagus showed a less coherent 
morphology of the stratified epithelium 
in Ugcg mutants compared to controls 
in week 2 of TAM induction. (A’-F’) 
EdU staining of corresponding 
esophageal sections (cervical (A’, B’), 
thoracic (C’, D’), abdominal (E’, F’)) 24 
h after EdU injection (200 μg) revealed 
significantly more EdU-positive cells in 
Ugcg mutant samples. Due to 
dissociation of parts of the apical 
epithelium (B, B’, D, D’, F’), EdU-
positivity is observed in the 
esophageal lumen (B’, D’). Dashed 
line indicates epithelial basement 
membrane. Tissue types are 
(para)keratotic squamous epithelia 
(lamina propria, muscularis mucosae, 
(1); submucosa (2); muscularis 
externa (smooth and striated muscle, 
(3); scale bars = 100 μm. 
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Figure A2. Hyperstratifica-
tion of Ugcg mutant epidermis 
occurs first 3 weeks after TAM 
induction. 
LM of H&E-stained control (A, C, 
E, G) and mutant mouse skin 
sections (B, D, F, H) revealed 
the first significant alterations of 
epidermal morphology at day 21 
of TAM induction. UGCG-
deficient skin displayed a 
hyperstratified epidermis with a 
fivefold increase in epidermal 
layers (H) as compared to 
controls (G). Representative 
sections from four independent 
experiments with n = 4 each are 
shown (e = epidermis; d = 
dermis; inf = infundibulum; sc = 
stratum corneum; scale bars = 
50 μm). 
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Figure A3. MS analysis of OS-, EOS- and POS-SLs in epidermis of Ugcg
 f / f K14CreERT2
 mice. 
The epidermal composition of ωh-ULC-SLs was investigated by quantitative MS and revealed for all 
SL species (except for those denoted with n.s. (not significant)) significant differences between control 
and mutant epidermal extracts. (A) OS- and EOS-GlcCers were significantly reduced in mutant 
epidermis, the hydroxylated FA components hC32:0, hC34:1 and hC36:1 showed the largest decrease 
by weight for mutants vs. controls. (B) The largest decrease was observed for POS-SLs such as POS-
Cers containing hC32:0, hC34:1, hC34:2 and hC36:1 FAs. (C) Furthermore, Cers were significantly 
increased in mutant epidermis, and most species contained FAs similar to those found in the 
corresponding depleted GlcCer fraction (e.g., hC32:0, hC34:1, hC34:2, hC36:1). (D) ULC-SMs only 
occur to a minor extent in murine epidermis; those with a C32:0, C32:1 or C34:1 FA were significantly 
elevated. Mean values ± SD are shown for n = 4. 
Appendix 
 94 
 
Figure A4. MS 
analysis of epidermal 
NS- and AS-SLs in 
Ugcg
 f / f K14CreERT2
 mice.  
Significant differences in 
the SL pattern regarding 
nonhydroxylated (NS) 
and -hydroxylated (AS) 
species were observed 
for mutant vs. control 
epidermis. (A) For NS- 
and AS-GlcCers, those 
containing a C16, C24 
or C26 FA chain showed 
the most prominent 
decrease. (B) In gener-
al, the corresponding 
NS- and AS-Cers were 
significantly increased in 
mutants. In particular, 
FA-containing Cers with 
C18:0, C20:0, C22:0 
and C24:0 were ele-
vated. (C) The NS- and 
AS-SMs showed little 
differences between 
mutants and controls, 
except for C17:0 and 
hC16:0 species. Mean 
values ± SD are shown 
for n = 4; all differences 
were statistically signifi-
cant except those 
denoted with n.s. 
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Control     Ugcg
 f / f K14CreERT2
 
 
Figure A5. Infrared thermography of control and UGCG-deficient mice. 
The body surface temperature of mice was analyzed using an infrared camera. The thermal image 
shows that skin temperature decreased by a few °C for mutant vs. control.  
 
 
Figure A6. Investigation of apoptosis by TUNEL staining.  
Right Panel: TUNEL staining performed on paraffin sections of skins from 12 week-old mice showed 
apoptotic nuclei in the lower und upper stratum corneum layers of epidermis from Ugcg mutants 
(arrows), indicating a defect in corneocyte maturation rather than enhanced apoptosis. Left Panel: 
control epidermis was TUNEL-negative. Representative sections from three independent experiments 
with n = 3 each are shown (e = epidermis; d = dermis; inf = infundibulum; sc = stratum corneum; scale 
bars = 25 μm).  
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Figure A7. Relative expression of selected genes in microarray and qRT-PCR experiments. 
Differentially expressed genes involved in lipid metabolic pathways (A-C) and/or in epidermal 
differentiation (C, D) were additionally analyzed via qRT-PCR in order to corroborate the array data. 
White Bars show the relative fold changes of the corresponding genes normalized to GAPDH. Black 
bars show fold changes. For abbreviations see 7.3. 
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7.2 Supplementary Tables 
Table A1. Epidermal sphingolipids in control and mutant mice, as quantified by tandem mass 
spectrometry. 
a 
 Glucosylceramides 
[pmol/mg dw] ± SD 
Ceramides 
[pmol/mg dw] ± SD 
Sphingomyelins  
[pmol/mg dw] ± SD 
FA 
component
b Control Mutant 
 
Control Mutant
 
Control Mutant
 
NS  
(C16-C36) 
130.8  
± 17.6 
58.0  
± 10.3 
2263.1  
± 253.8 
5010.8  
± 265.3 
1425.9  
± 346.6 
1421.4  
± 618.0 
AS  
(C16-C26) 
102.3  
± 11.6 
12.5 
± 2 
1009.0  
± 125.7 
1415.5  
± 120.9 
664.5  
± 26.1 
177.0 
± 24.1 
OS  
(C28-C36) 
38.4  
± 3.8 
7.0 
± 1.4  
10.2  
± 1.1 
47.7  
± 3 
7.0  
± 1.1 
32.0 
± 4.3 
EOS  
(C28-C36) 
391.6  
± 64.2 
55.3  
± 11.8 
761.0  
± 107.8 
2057.6  
± 345.4 
5.4  
± 3.9 
34.0 
±15.9 
POS  
(C28-C36) 
6.9  
± 1.2 
1.0  
± 0.3 
544.6  
± 73.4 
99.1  
± 63.7 0 0 
a
 mutant = TAM-induced Ugcg 
 f / f K14CreERT2
 ; dw = dry wt. 
b
 NS, nonhydroxylated;
 
AS, α-hydroxylated; OS, ω-hydroxylated; EOS, ω-hydroxylated, esterified to an FA; 
POS, ω-hydroxylated, linked to protein. 
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Table A2. Gene ontology (GO) enrichment analysis. 
GO term description (biological process) p-value 
GO:0008152 metabolic process 3.09 E-16 
GO:0032502 developmental process 7.57 E-16 
GO:0048856 anatomical structure development 5.78 E-15 
GO:0007275 multicellular organismal development 7.91 E-15 
GO:0048731 system development 1.71 E-15 
GO:0010951 negative regulation of endopeptidase activity 1.96 E-13 
GO:0010466 negative regulation of peptidase activity 1.78 E-12 
GO:0009987 cellular process 3.09 E-12 
GO:0030154 cell differentiation 4.13 E-12 
GO:0009653 anatomical structure morphogenesis 6.65 E-12 
GO:0048869 cellular developmental process 1.31 E-11 
GO:0065007 biological regulation 1.36 E-11 
GO:0051346 negative regulation of hydrolase activity 4.36 E-11 
GO:0052547 regulation of peptidase activity 1.69 E-10 
GO:0052548 regulation of endopeptidase activity 3.40 E-10 
GO:0048513 organ development 1.11 E-9 
GO:0032501 multicellular organismal process 1.54 E-9 
GO:0044238 primary metabolic process 1.76 E-9 
GO:0051239 regulation of multicellular organismal process 1.98 E-9 
GO:0050790 regulation of catalytic activity 3.03 E-9 
GO:0009888 tissue development 3.09 E-9 
GO:0008544 epidermis development 5.55 E-9 
GO:0050789 regulation of biological process 5.90 E-9 
GO:0006629 lipid metabolic process 1.02 E-8 
GO:0008610 lipid biosynthetic process 1.24 E-8 
GO:0031424 keratinization 1.89 E-8 
GO:0044255 cellular lipid metabolic process 2.20 E-8 
GO:0065009 regulation of molecular function 2.98 E-8 
GO:0019222 regulation of metabolic process 4.43 E-8 
GO:0043086 negative regulation of catalytic activity 5.89 E-8 
GO:0048583 regulation of response to stimulus 5.94 E-8 
GO:0050896 response to stimulus 8.81 E-8 
GO:0009611 response to wounding 1.31 E–6 
GO:0050678 regulation of epithelial cell proliferation 4.4 E-4 
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Table A3. List of human diseases from the Medical Subject Headings database (MeSH) 
correlating to differentially expressed genes. 
MeSH Diseases p-value 
Head and Neck Neoplasms 1.46 E-13 
Psoriasis 1.64 E-13 
Skin Diseases, Papulosquamous 7.95 E-13 
Esophageal Neoplasms 2.10 E-11 
Esophageal Diseases 5.26 E-11 
Skin Diseases 8.08 E-11 
Inflammation 2.45 E-10 
Neoplastic Processes 2.68 E-10 
Skin and Connective Tissue Diseases 2.85 E-10 
Carcinomas, Squamous Cell 2.40 E-9 
Neoplasms, Squamous Cell 4.76 E-9 
Dermatitis 8.24 E-9 
Metaplasia 1.16 E-8 
Gastrointestinal Neoplasms 1.65 E-8 
Neoplasm Invasiveness 1.67 E-8 
Skin Neoplasms 1.69 E-8 
Skin Diseases, Genetic 1.86 E-8 
 
As expected from the observed phenotype of Ugcg mutants, the gene sets derived from expression 
analysis show the highest correlation to cancer, skin and esophageal diseases (lowest p values).  
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7.3 Catalog of Abbreviations, Terminology and Proteins 
For the following list of abbreviations IUPAC and IUBMB standards and the recommendations of the 
HGNC (genes, proteins) and BRENDA (enzymes) data bases have been used wherever possible. 
Where relevant, common synonyms for proteins or genes are given. The following conventions have 
been applied for symbolic names: human and mouse proteins are upper-case, roman type; human 
genes are upper-case, italics; mouse genes are italics, first character upper-case; greek letters (e.g., 
) are replaced by there roman equivalents as suffixes. For enzymes alternative names and EC 
numbers are given where available. In some cases only protein root symbols are given to designate a 
protein family or the symbol n is attached; for specific members the appropriate arabic numeral is 
attached. In general, when an abbreviation is used in a plural sense (families, classes), a lower-case s is 
attached. 
12R-LOX arachidonate 12-lipoxygenase (EC 1.13.11.31) 
AA amino acids 
ABCA12 ATP-binding cassette, sub-family A (ABC1), member 12  
AD atopic dermatitis 
aGSL acidic glycosphingolipid (carbohydrate headgroup with carboxyl, sulfate, or phosphate 
substituents) 
Alox12b gene encoding for 12R-LOX 
Alox12e gene encoding for eLOX-3 
AP alkaline phosphatase (EC 3.1.3.1) 
ARCI autosomal recessive congenital ichthyosis 
AS -hydroxylated FA
acid SMase, aSMase sphingomyelin phosphodiesterase (EC 3.1.4.12); acid sphingomyelinase 
AJ adherens junction 
AJAP1 adherens junctions associated protein 1 
B4GALT6 UDP-Gal:betaGlcNAc β-1,4-galactosyltransferase, polypeptide 6 
bFGF basic fibroblast growth factor 
BglII restriction endonuclease (Bacillus globigii), site II 
BM basement membrane 
BMP6 bone morphogenic protein 6 
bp base pair 
BSA bovine serum albumin 
CAPP ceramide-activated protein phosphatase (EC 3.1.3-) 
caspase-8 apototic cysteine protease 8 (EC 3.4.22.61) 
Appendix 
 101 
CD corneodesmosome  
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 
CDH3 cadherin 3, type 1, P-cadherin (placental) 
cDNA complementary DNA 
CDSN corneodesmosin 
CE cornified envelope 
Cer ceramide 
Cer-1-P ceramide 1-phosphate 
ceramidase N-acylsphingosine amidohydrolase (EC 3.5.1.23) 
CerS ceramide synthase family; sphingosine N-acyltransferase (EC 2.3.1.24) 
CERT ceramide transfer protein  
CGI-58 1-acylglycerol-3-phosphate O-acyltransferase (EC 2.3.1.51); also known as AGPAT  
Cho-P phosphocholine  
CI congenital ichthyosis 
ClaI restriction endonuclease (Caryophanon latum L), site I 
CLDN1 claudin 1 (tight junction protein) 
CLE cornified lipid envelope 
CoA Coenzyme A 
CRABP cellular retinoic acid binding protein 
Cre Cre-recombinase enzyme  (Cre = cyclization recombination), a tyrosine recombinase 
CreERT2 a genetic modification introducing tamoxifen-inducible Cre-recombinase activity 
CSPD Disodium 3-(4-methoxyspiro {1,2-dioxetane-3,2'-(5'-chloro)tricyclo [3.3.1.13,7]decan}-
4-yl)phenyl phosphate, a chemiluminescent substrate for alkaline phosphatase 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 
DAG diacylglycerol 
DAPI 4',6-diamidino-2-phenylindole, a fluorescent stain for A-T rich DNA regions 
DDC dermal dendritic cell 
dd H2O doubly distilled, autoclaved water 
DEAE diethylaminoethyl (Sephadex) 
DEGS2 sphingolipid delta(4)-desaturase/C4-hydroxylase 
delta-neo deleted neomycin cassette 
DETC dendritic epidermal T-cell 
DES1 dihydroceramide desaturase 1 
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DIG digoxigenin, a steroid hapten from Digitalis plants, used as immunohistochemical 
marker for in situ hybridization 
DNA deoxyribonucleic acid 
dNTP 2-deoxyribonucleoside-5-triphosphate 
DSCn desmocollin n (n = 1, 2, 3) 
DSGn desmoglein n (n = 1, 2); desmosomal cadherin proteins 
DSP desmoplakin (desmosomal catenin protein) 
dw dry weight 
ECL enhanced chemiluminescence 
ECM extracellular matrix 
EcoRV restriction endonuclease V (E. coli) 
type II, site-specific deoxyribonuclease (site V)  (EC 3.1.21.4) 
EDC epidermal differentiation complex  
EDTA ethylenediaminetetraacetic acid 
EdU 5-ethynyl-2-deoxyuridine 
EFAD essential fatty acid deficiency 
EGF epidermal growth factor 
ELOVL elongation of very-long-chain fatty acyl-CoA; fatty acid elongase; icosanoyl-CoA 
synthase (EC 2.3.1.119) 
eLOX3 hydroperoxide dehydratase (EC 4.2.1.92) 
EOS ω-hydroxylated FA esterified primarily to linoleic acid 
EPGN epigen growth factor 
ER endoplasmic reticulum 
ER-HR3 anti-hematopoiesis-related macrophage antibody  
ERT2 estrogen receptor T2 
ES embryonic stem cells 
EVPL envoplakin 
FA fatty acid 
FABP5 fatty acid binding protein 5 (epidermal) 
FAS Fas (TNF receptor superfamily, member 6); APO-1, CD95 
FATP4 solute carrier family 27 (fatty acid transporter), member 4;  SLC27A4 
FCS fetal calf serum 
FDR false discovery rate (chip statistics) 
F-granules filaggrin/profilaggrin-containing granules 
FGF fibroblast growth factor 
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FLG filaggrin (protein monomer) 
FLG2 filaggrin family member 2 (polymeric) 
floxed “flanked by LoxP”; a DNA sequence is sandwiched between to two loxP sites which are 
targeted by Cre recombinase 
FLP site-specific tyrosine recombinase (Saccharomyces cerevisiae), targets FRT site 
FLP-deleter a mouse strain used to remove Frt-flanked selection cassettes in vivo 
Frt FLP recombinase target site 
GalCer galactosylceramide; galactocerebroside 
e.g.,  galactosylceramide (d18:1/18:0)  =  N-(octadecanoyl)-1--D-galactosyl-
sphingosine 
GAPDH glyceraldehyde 3-phosphate dehydrogenase (EC 1.2.1.12/13/59) 
GERD gastroesophageal reflux disease 
Giemsa a stain prepared from a mixture of methylene blue, eosin, and Azure B 
GlcCer glucosylceramide;  glucocerebroside  
e.g., glucosylceramide (d18:1/18:0)  =  N-(octadecanoyl)-1--D-glucosyl-sphingosine;  
GlcCerase glucosylceramidase (EC 3.2.1.45), -glucocerebrosidase; 
D-glucosyl-N-acylsphingosine glucohydrolase 
GM3 NeuAc-Gal-Glc-Cer  (a ganglioside containing N-acetylneuraminic acid) 
GO gene ontology 
GRHL3 grainy head-like protein 3 
GSL glycosphingolipid 
HBEGF heparin-binding EGF-like growth factor 
H&E hematoxylin & eosin stain for DNA (pink) and protein (blue) 
HMG-CoA 3-hydroxy-3-methyl-glutaryl-CoA 
HI harlequin ichthyosis 
HPTLC high-performance thin-layer chromatography 
HRP horse radish peroxidase (EC 1.11.1.7) 
iCre codon-improved Cre recombinase gene 
IF immunofluorescence 
IL interleukin 
ITGA6B4 integrin-64, laminin receptor (adhesive protein in basal keratinocytes) 
IVL involucrin 
JNK janus kinase 
JUP junction plakoglobin; previously PKGB or CTNNG 
KAc potassium acetate 
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kb kilobases (in DNA) 
KDSR 3-ketodihydrosphingosine reductase (EC 1.1.1.102); 
3-dehydrosphinganine reductase (DSR) 
KG keratohyalin granule 
Ki-67 (MKI67) a nuclear protein associated with proliferation 
KLKn kallikrein protein family 
KpnI restriction endonuclease (Klebsiella pneumoniae) 
type II site-specific deoxyribonuclease (EC 3.1.21.4) 
KRTn keratin protein family 
LacZ β-galactosidase reporter gene 
LAMA5 laminin, alpha 5; laminin-5 (basement membrane protein) 
Lass the longevity assurance gene family; six LASS proteins function as ceramide synthases 
LB lamellar body 
LC long-chain, referring to FA chain length  
LC-ESI liquid chromatography electrospray ionization (for mass spectrometry) 
L-granules loricrin-containing granules 
LI1, LI2 lamellar ichthyosis type 1 and type 2 
LIN linoleic acid (C18:2, ω–6; cis,cis-9,12) 
LM light microscopy 
LOR loricrin 
LoxP, loxP “locus of X-over P1”; a DNA sequence derived from bacteriophage P1; a pair of LoxP 
sites flanking a gene are used as targets for Cre recombinase, e.g. for gene deletion. 
MS mass spectrometry 
MS/MS tandem mass spectrometry (fragmentation of selected parent ions) 
neo neomycin, an aminoglycoside antibiotic 
nGSL neutral glycosphingolipid (uncharged carbohydrate headgroup) 
NFB nuclear factor ‘kappa light chain enhancer’  (transcription factor) 
NheI restriction endonuclease (Neisseria mucosa heidelbergensis), site I 
NMF natural moisturizing factor 
NP-40 nonyl phenoxypolyethoxylethanol, a detergent 
NS nonhydroxylated FA 
nSMase neutral sphingomyelinase 
ωh ω-hydroxylated  
Ole oleic acid (C18:1, ω–9; cis-9) 
OS ω-hydroxylated FA 
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O/N overnight 
PacI restriction endonuclease (Pseudomonas alcaligenes), site I 
PAS periodic acid Schiff stain 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PFA paraformaldehyde 
PFU proof-reading polymerase 
PGK-DTA phosphoglycerate kinase I promoter from the diphtheria toxin gene 
PKC protein kinase C 
PLA2 phospholipase A2 
PLD phospholipase D 
PM plasma membrane 
PMNL polymorphonuclear leukocytes 
POS ω-hydroxylated FA esterified to a protein 
PPARβ/δ peroxisome proliferator-activated receptor β/δ 
PPL periplakin 
PPRE peroxisome proliferator responsive elements 
PSAP prosaposin; sphingolipid activator protein-1 
PtdCho phosphatidyl choline 
proFLG profilaggrin (polymeric FLG) 
proteinase K peptidase K  (EC 3.4.21.64) from Engyodontium album 
PUFA Polyunsaturated fatty acid 
qRT-PCR quantitative (real-time) reverse transcription polymerase chain reaction 
RBP2 retinol binding protein 2 
RNA ribonucleic acid 
RNAse A bovine pancreatic ribonuclease A (EC 3.1.27.5) 
RNaseOUT™ recombinant RNase inhibitor (Invitrogen) 
Rosa26 Rosaβgeo26 (gene locus in the mouse) 
RPTN repetin 
RT room temperature 
RXR retinoic X receptor 
S100A8 calgranulin A 
S100A9 calgranulin B 
SB stratum basale 
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SC stratum corneum 
SCD2 acyl-CoA desaturase 2 (EC 1.14.19.1); stearoyl-CoA desaturase 2 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SG stratum granulosum 
SGPP2 sphingosine-1-phosphate phosphatase 2 
SL sphingolipid 
SLC9A1 solute carrier family 9, subfamily A (NHE1, cation proton antiporter 1), member 1 
SM sphingomyelin 
SMase sphingomyelinase, sphingomyelin phosphodiesterase (EC 3.1.4.12) 
SMPD1 gene for sphingomyelin phosphodiesterase 1, acid lysosomal SMase 
SMPD2 gene for sphingomyelin phosphodiesterase 2, neutral SMase 
SM synthase sphingomyelin synthase (EC 2.7.8.27) 
SpeI restriction endonuclease (Sphaerotilus natans), site I 
Sph sphingosine = (4E)-sphingenine = (E,2S,3R)-2-aminooctadec-4-ene-1,3-diol 
Sph-1-P sphingosine-1-P 
sPLA2 secretory phospholipase A2 (EC 3.1.1.4) 
SPRRs small proline-rich proteins (family) 
SPT serine C-palmitoyltransferase (EC 2.3.1.50) 
SS  stratum spinosum 
Sst II  (SstII) restriction endonuclease (Streptomyces stanford), site II 
TAE TRIS-acetate-EDTA 
TAM tamoxifen, a selective estrogen receptor modulator with tissue-specific activity 
TE transesterification 
TEWL transepidermal water loss 
TJ tight junction 
TJ1 tight junction protein 1; zona occludens 1 
TLC thin-layer chromatography 
TG transglutaminase (EC 2.3.2.13) 
TG1 protein-glutamine gamma-glutamyltransferase 1 (EC 2.3.2.13) 
TGF transforming growth factor 
TJP1 tight junction protein 1 
TNF tumor necrosis factor  
TRIS tris(hydroxymethyl)-aminomethane 
Triton X-100 4-octylphenol polyethoxylate, a detergent 
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Tween® 20 nonionic detergent,  polyethylene glycol sorbitan monolaurate 
tUCA trans-urocanic acid 
UDP-Glc Uridine(5)diphospho(1)--D-glucose 
UGCG UDP-glucose:ceramide glucosyltransferase; glucosylceramide synthase (EC 2.4.1.80) 
ULC ultra-long-chain 
VEGF vascular endothelial growth factor 
VLC very-long-chain 
WPB water permeability barrier 
wt wild-type: natural or most common phenotype of a species; normal gene or allele 
ww wet weight 
XRI X-linked recessive ichthyosis 
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